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Resumo 
As exacerbações agudas da doença pulmonar obstrutiva crónica (EADPOC) 
são eventos frequentes e onerosos. Contudo, o conhecimento acerca da sua 
avaliação e curso de evolução é limitado. Este trabalho de investigação teve como 
objetivo compreender a avaliação e os padrões de recuperação das EADPOC 
geridas em contexto de ambulatório. Especificamente, pretendeu-se: i) aprofundar 
o conhecimento acerca das medidas de avaliação mais utilizadas na avaliação de
doentes com EADPOC e ii) explorar os padrões de recuperação durante as 
EADPOC utilizando diferentes medidas de avaliação. Foram realizados seis 
estudos. A Revisão Sistemática e os Estudos empíricos I e II responderam ao 
primeiro objetivo específico deste trabalho de investigação, sintetizando e 
explorando a fiabilidade, validade, capacidade de resposta e interpretabilidade de 
medidas de avaliação comummente utilizadas e de fácil acesso para a avaliação de 
doentes com EADPOC em contexto de ambulatório. Os resultados revelaram que 
apesar de existirem poucas medidas de avaliação com as suas propriedades 
métricas adequadamente estudadas, os seus valores de interpretabilidade parecem 
semelhantes aos estabelecidos em fases estáveis da DPOC. O segundo objetivo 
específico deste trabalho de investigação foi alcançado através de três Estudos 
empíricos (Estudos III, IV e V) que demonstraram que a recuperação de uma 
EADPOC é influenciada pelas características dos doentes no momento inicial da 
exacerbação. Estes Estudos mostraram ainda que as medidas reportadas pelos 
doentes e as medidas clínicas diferem nos seus padrões e tempos de recuperação 
durante as EADPOC. Os resultados deste trabalho de investigação constituem nova 
evidência acerca das medidas de avaliação e dos momentos mais adequados para 
avaliar, monitorizar e interpretar alterações no curso de EADPOC. É necessário 
realizar mais investigação com metodologias padrão, amostras maiores e desenhos 
de estudo longitudinais com avaliações pré e pós exacerbação de forma a consolidar 
estes resultados preliminares e aumentar o conhecimento acerca do curso de 
evolução das EADPOC geridas em contexto de ambulatório. 
Palavras-chave: DPOC, EXACERBAÇÕES, MEDIDAS DE RESULTADOS, 
PROPRIEDADES DE MEDIDA, RECUPERAÇÃO, EVOLUÇÃO. 
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Abstract 
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) 
are frequent and burdensome events. However, knowledge about their 
assessment and course of evolution is limited. This research work focused on 
understanding the assessment and recovery pattern of AECOPD managed on an 
outpatient setting. Specifically, it aimed to: i) gain more insight on the outcome 
measures most used to assess patients with AECOPD and their measurement 
properties and ii) explore patterns of recovery of different outcomes and outcome 
measures during these events. Six studies were conducted. The Systematic 
Review and empirical Studies I and II addressed the first specific aim of this 
research work by synthetising and exploring the reliability, validity, 
responsiveness and interpretability of outcome measures commonly used and 
easily available to assess outpatients with AECOPD. Findings showed that 
although few outcome measures exist which measurement properties have been 
properly studied in patients with AECOPD, their interpretability values seem to be 
similar to those in stable patients. The second specific aim of this research work 
was addressed with three empirical Studies (Studies III, IV and V) which showed 
that the recovery from AECOPD is influenced by patients’ characteristics 
assessed at the onset of the exacerbation. These Studies further evidenced 
different patterns and timings of recovery among patient-reported and clinical 
outcome measures. The findings of this research work constitute new evidence 
on the most adequate outcome measures and timings to assess, monitor and 
interpret changes during the course of AECOPD managed on an outpatient 
setting. Further research with standardised methodologies, larger samples and 
longitudinal pre-/post exacerbation designs is warranted to consolidate these 
preliminary findings and increase the scope of knowledge on the time course of 
AECOPD treated on an outpatient basis. 
Key words: COPD, EXACERBATIONS, OUTPATIENTS, OUTCOME 
MEASURES, MEASUREMENT PROPERTIES, RECOVERY, EVOLUTION.  
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3 
General Introduction 
Chronic respiratory diseases, defined as chronic conditions affecting the 
airways and the other structures of the lungs (World Health Organization, 2007), 
are rated by the World Health Organization as one of the four major chronic 
diseases of mankind (World Health Organization, 2008). Currently, more than 
one billion people suffer from chronic respiratory diseases worldwide (Forum of 
International Respiratory Societies, 2013) and, in Europe, the total annual cost of 
respiratory diseases amounts to more than €380 billion (European Respiratory 
Society, 2013). In Portugal, respiratory diseases are the 3rd leading cause of 
death and direct costs related to hospitalisations (in 2013 - €213 millions) 
(Direção-Geral da Saúde, 2016). These facts lead chronic respiratory diseases 
to represent a major health, societal and economic burden worldwide (World 
Health Organization, 2007). 
Chronic obstructive pulmonary disease (COPD) is defined as a “common, 
preventable and treatable disease that is characterised by persistent respiratory 
symptoms and airflow limitation that is due to airway and/or alveolar abnormalities 
usually caused by significant exposure to noxious particles or gases” (The Global 
Initiative for Chronic Obstructive Lung Disease, 2019). Currently, COPD is one of 
the five major respiratory diseases (Forum of International Respiratory Societies, 
2013), affecting 384 million people worldwide (Adeloye et al., 2015) and 800.000 
people in Portugal (Araújo, 2016). Attention to diagnosis and management of 
COPD has been growing, with an increase of 241% new diagnosed cases from 
2011 to 2016, in Portugal (Direção-Geral da Saúde, 2017). Nevertheless, 
according to the Portuguese national health regulator, COPD is still 
underdiagnosed (Direção-Geral da Saúde, 2017). Diagnosis of COPD should be 
considered in any patient who suffers from dyspnoea, chronic cough or sputum 
production, and/or has a history of exposure to risk factors for the disease, such 
as tobacco smoke, air pollution and occupational exposures (The Global Initiative 
for Chronic Obstructive Lung Disease, 2019). Although COPD prevalence is 
noted from the 40 decade of life onwards, it presents the highest prevalence 
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among those older than 60 years old (The Global Initiative for Chronic Obstructive 
Lung Disease, 2019). In these patients, COPD is currently the 3rd leading cause 
of Disability Adjusted Life Years (DALYs) lost worldwide (GBD 2015 DALYs and 
HALE Collaborators, 2016), being acute exacerbations of COPD (AECOPD) one 
of the events that most contribute to patients’ disability in the long term (Chabot 
et al., 2014; Kerkhof, Freeman, Jones, Chisholm, & Price, 2015). 
AECOPD, defined as an “acute worsening of respiratory symptoms that 
result in additional therapy” (The Global Initiative for Chronic Obstructive Lung 
Disease, 2019), are frequent events during the course of COPD (Wedzicha et al., 
2017) with mean rates from 0.85 to 4 per patient/year (Boer et al., 2018; Hurst et 
al., 2010). AECOPD may be triggered or potentiated by several risk factors, such 
as smoking, severe airflow limitation, bronchiectasis, bacterial and viral infections 
and comorbidities (Kim & Aaron, 2018) and result in significant personal, societal, 
clinical and economic impacts (Anzueto, 2010; Guarascio, Ray, Finch, & Self, 
2013; Kessler et al., 2006; Miravitlles, Anzueto, Legnani, Forstmeier, & Fargel, 
2007; Patel, Nagar, & Dalal, 2014; Toy, Gallagher, Stanley, Swensen, & Duh, 
2010). On an individual level, AECOPD are known to impair patients’ health-
related quality of life, psychological well-being and daily activities, with about 50% 
of patients being prevented from performing any activity during exacerbations 
(Kessler et al., 2006; Miravitlles et al., 2007). These effects have adverse 
consequences on patients’ personal and family relationships, leading to isolation 
and avoidance of social activities (Kessler et al., 2006). In addition, periodic 
AECOPD often require treatment on an outpatient or inpatient basis, resulting in 
absence from work (Patel et al., 2014). Clinically, patients with more frequent 
exacerbations present more pronounced decreases in their lung function and 
exercise performance and are associated with increased morbidity and mortality 
(Anzueto, 2010). The upper mentioned adverse effects culminate in a substantial 
economic burden with individual costs per patient/exacerbation varying from $88 
to $7.757 worldwide (Guarascio et al., 2013; Toy et al., 2010) and corresponding 
to 50% of all COPD-related costs (Celli & MacNee, 2004). 
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These epidemiologic and clinical data indicate that chronic respiratory 
diseases, namely COPD and its exacerbations, are posing tremendous 
challenges on health systems and societies (Price, Freeman, Cleland, Kaplan, & 
Cerasoli, 2011; Wilkinson, Donaldson, Hurst, Seemungal, & Wedzicha, 2004). 
Thus, their timely assessment and management have lately become a priority for 
researchers and health regulators (Direção-Geral da Saúde, 2015; Wilkinson et 
al., 2004), leading to several efforts to reach an in-depth understanding of the 
time course of AECOPD and the most effective interventions to accelerate 
recovery (Oliveira et al., 2017; Viniol & Vogelmeier, 2018; Wedzicha et al., 2017). 
Due to the significant contribution of AECOPD to the progression of the 
disease (Halpin, Miravitlles, Metzdorf, & Celli, 2017) and direct economic costs 
(Anzueto, 2010), the time course of AECOPD requiring patients’ hospitalisation 
has been widely studied. These studies have unravelled the behaviour of 
AECOPD treated at a hospital-basis and the response to treatment of relevant 
outcomes, such as dyspnoea, impact of the disease and patients’ respiratory and 
peripheral muscle strength (Feliz-Rodriguez et al., 2013; Koutsokera et al., 2009; 
Mesquita, Donaria, Genz, Pitta, & Probst, 2013; Nishimura et al., 2018; Parker, 
Voduc, Aaron, Webb, & O'Donnell, 2005; Seemungal, Donaldson, Bhowmik, 
Jeffries, & Wedzicha, 2000; Seemungal et al., 1998; Spruit et al., 2003; Zhou et 
al., 2018). Thus, contributing to better plan and manage these patients’ 
treatments on a hospital-basis. However, conflicting results have been reported 
on the behaviour of some outcomes, namely lung function (Mesquita et al., 2013; 
Parker et al., 2005; Seemungal et al., 2000), and on the effects of specific 
interventions with established evidence in the treatment of stable patients with 
COPD, such as pulmonary rehabilitation (Puhan, Gimeno-Santos, Cates, & 
Troosters, 2016; Wedzicha et al., 2017; Wilson et al., 2018). These 
inconsistencies among studies may occur due to the wide variety of outcomes 
and outcome measures used and/or due to the lack of appropriate measurement 
properties (i.e., reliability, validity and responsiveness) of these outcome 
measures used during exacerbation periods. Therefore, knowledge on the 
outcome measures used to assess a particular outcome and evidence on the 
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measurement properties of those instruments in patients with AECOPD is 
needed (research question I). 
Secondly, although most research has been conducted in hospitalised 
patients, according to the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), more than 80% of the AECOPD are managed on an outpatient basis 
(The Global Initiative for Chronic Obstructive Lung Disease, 2019), and failure in 
their treatment may lead to patients’ prolonged disability and hospitalisations 
(Adams, Melo, Luther, & Anzueto, 2000; Macfarlane, Colville, Guion, Macfarlane, 
& Rose, 1993; Miravitlles, Murio, & Guerrero, 2001). Hospitalised patients differ 
from outpatients not only in their management but also in the severity of their 
exacerbation (The Global Initiative for Chronic Obstructive Lung Disease, 2019), 
which may influence their pattern of recovery. Thus, understanding outpatients’ 
recovery during AECOPD seems crucial to timely manage and appropriately plan 
their follow-ups (research question II). 
This document is presented in five chapters. An introduction (Chapter I) is 
first provided with an overview of the two research questions and research 
objectives. This chapter is followed by Chapter II – background – which 
introduces research question I by presenting a Systematic review of the 
outcome measures used to assess the effects of pulmonary rehabilitation in 
patients with AECOPD and synthesising their measurement properties. Chapter 
III is composed of five empirical studies developed to address the two research 
questions within the timeframe of this research work.  
Research question I integrates two empirical studies – Studies I and II, 
that were built on the findings of the systematic review and explored the 
measurement properties of outcome measures to be used in patients with 
AECOPD. Study I explored the reliability, validity and minimal detectable 
difference (MDD) of computerised respiratory sounds in patients with COPD. 
Study II estimated the minimal important difference (MID) and MDD of the 
modified Borg scale (MBS), modified British Medical Research Council 
questionnaire (mMRC), peripheral oxygen saturation (SpO2), computerised 
7 
respiratory sounds and forced expiratory volume in one second (FEV1) in 
outpatients with AECOPD. 
Research question II started to be addressed in Study III, where the 
changes in computerised adventitious respiratory sounds of patients with 
AECOPD managed on an outpatient basis were explored. Considering the same 
time period (i.e., AECOPD), Study IV evaluated the changes in patient-reported 
symptoms and its relationships with the clinical outcome measures previously 
studied, whereas Study V evaluated the time course of different clinical, 
physiological and functional outcome measures, as well as the factors influencing 
patients’ recovery. An integrated discussion of the main findings, overall 
limitations and implications for future research and clinical practice follows in 
Chapter IV. Chapter V outlines the main conclusions of this research work and 
provides directions for further research in the field. Finally, Chapter VI presents 
the references used to support the General Introduction and General Discussion 
chapters. Figure 1 provides a graphic presentation of the rationale for this 
research work. 
Figure 1. Graphic representation of the rationale for this research work. 
StudiesResearch problems
Research 
questions
Research 
topic
Acute 
exacerbations 
of COPD
Outcome 
measures in 
outpatients with 
AECOPD
Outcome measures used in the 
management of patients with AECOPD 
and their measurement properties are 
not systematised
Systematic 
review I
Measurement properties of outcome 
measures used to assess patients with 
AECOPD are not established
Original 
studies I and 
II
Time course of 
AECOPD 
managed on an 
outpatient basis
Time course of AECOPD managed on 
an outpatient basis is unknown
Original 
studies III, IV 
and V
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Research question I 
AECOPD are highly heterogeneous, presenting an extensive range of 
clinical presentations (Oliveira et al., 2017). Thus, management of these events 
is challenging, and in the last decade strong research efforts have been 
conducted to increase the pharmacological and non-pharmacological 
approaches available to these patients (Evensen, 2010; National Clinical 
Guideline Centre, 2010; Puhan et al., 2016; Viniol & Vogelmeier, 2018; Wedzicha 
et al., 2017). The most recent European Respiratory Society/American Thoracic 
Society guideline aimed to provide the basis for rational decisions in the treatment 
of AECOPD, however, due to the sparse evidence and inconsistency among the 
results of studies, the majority of recommendations were of conditional strength 
and moderate to very low quality (Wedzicha et al., 2017). The consequences of 
this guideline are of particular importance for non-pharmacological interventions, 
such as pulmonary rehabilitation, a high-quality evidence-based intervention for 
stable patients with COPD, which implementation in acute exacerbations has 
been recommended against. However, this recommendation mainly focuses in 
AECOPD managed on inpatient settings and no recommendations were made 
regarding those managed on outpatient settings, which account for more than 
80% of all AECOPD (The Global Initiative for Chronic Obstructive Lung Disease, 
2019). Additionally, the recommendations made were largely based on outcomes 
related with future exacerbations, hospitalisations, treatment failure and adverse 
events. But, as recently stressed by Wilson et al. (2018), several outcomes of 
interest, such as patient-reported symptoms, muscle strength and exercise 
tolerance were not taken into account. Thus, as pointed out in a previous 
European Respiratory Society/American Thoracic Society statement of 2015 
(Celli et al., 2015), a question emerges on which outcomes and outcome 
measures are of relevance to assess the effects of treatments in patients with 
COPD, also during AECOPD. The selection of outcome measures in a clinical 
trial is of paramount importance as it can directly affect the success in capturing 
the impact of an intervention, or ultimately, mislead the true results (Coster, 2013; 
Ioannidis et al., 2014). Selecting unsuitable or poor-quality outcome measures 
9 
may lead to a waste of resources and even be unethical because participants 
contribute little to the body of knowledge but still suffer the burdens and risks of 
the study (Ioannidis et al., 2014). Thus, knowledge regarding new management 
strategies for outpatients with AECOPD should be built on sound evidence-based 
research using outcome measures that have demonstrated to be valid for the 
purpose and population in study, sensitive to small but clinically important 
changes and highly reproducible. These important psychometric properties of 
validity, reliability and responsiveness may also need to be balanced against 
some more practical considerations, such as costs and ease of use (Jerosch-
Herold, 2005). Aiming at contributing to increase the knowledge on the 
measurement properties of outcome measures used to assess patients with 
AECOPD, a Systematic review was conducted. This Systematic review 
identified patient-reported and clinical (non-patient-reported) outcome measures 
commonly used to assess the effects of pulmonary rehabilitation in patients with 
AECOPD and that can be easily applied in an outpatient setting (i.e., not 
expensive, not invasive, and quickly implemented). Additionally, it also 
synthesised the measurement properties of the identified outcome measures, if 
available in the literature. 
The Systematic review informed about some outcome measures which 
measurement properties have been tested in patients with AECOPD, such as 
computerised respiratory sounds. Computerised respiratory sounds are a simple, 
objective and non-invasive clinical measure (Bohadana, Izbicki, & Kraman, 2014) 
that can be acquired using electronic devices, such as digital stethoscopes and 
microphones, and classified/analysed using computerised technology based on 
specific signal characteristics of the respiratory sounds (Hadjileontiadis, 2018; 
Kahya, 2018; Pramono, Bowyer, & Rodriguez-Villegas, 2017). As its acquisition 
and analysis do not require significant resources, beyond those typical used in a 
patient-health professional encounter, computerised respiratory sounds have 
been indicated as an emergent measure to provide information on the function of 
the respiratory system (Bohadana et al., 2014). 
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Computerised respiratory sounds are generally classified as normal or 
adventitious (Sovijärvi et al., 2000). Normal respiratory sounds are nonmusical 
sounds produced from breathing and heard over the trachea (i.e., normal tracheal 
sounds) and chest wall (i.e., normal lung sounds) (Sovijärvi et al., 2000). These 
sounds are generated by the airflow in the respiratory tract and characterised by 
broad spectrum noise (Sovijärvi et al., 2000). Adventitious respiratory sounds are 
superimposed on normal respiratory sounds and can be discontinuous and 
explosive (crackles) or continuous and musical (wheezes) (Sovijärvi et al., 2000). 
Both normal and adventitious respiratory sounds have been found to be directly 
related to movement of air, changes within lung morphology and presence of 
secretions (Bohadana et al., 2014; Kiyokawa & Pasterkamp, 2002). Therefore, 
changes in airway and/or alveolar mechanisms may be primarily detected by 
changes in the frequency/intensity of normal respiratory sounds and by the 
presence of adventitious respiratory sounds (i.e., crackles and wheezes) 
(Gavriely, Nissan, Cugell, & Rubin, 1994). This theoretical potential of 
computerised respiratory sounds to be used as an outcome measure has been 
motivating research on their characteristics and measurement properties 
(Jácome & Marques, 2015).  
Jácome and Marques (2015) have found adequate within-day reliability of 
computerised respiratory sounds in patients with stable COPD. However, other 
measurement properties, such as between-days reliability and validity, need to 
be studied in stable patients with COPD before the use of these measures can 
be recommended for assessing respiratory function in both patients with stable 
and exacerbated COPD (Terwee et al., 2007). Thus, Study I explored 
computerised respiratory sounds repeatability during stable phases (i.e., 
between-day reliability) and its usefulness to assess lung function (validity) in 
stable patients with COPD.  
According to the COnsensus-based Standards for the selection of health 
Measurement INstruments (COSMIN), reliability, validity and responsiveness are 
the three main domains of measurement properties (Mokkink et al., 2010). 
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Nevertheless, to provide useful information about the effects of an intervention, 
the changes observed in a given outcome measure should also be easily 
interpreted (Cook, Paul, & Wyatt, 2014). Interpretability is defined as the degree 
to which one can assign qualitative meaning – that is, clinical or commonly 
understood connotations – to an instrument’s quantitative scores or change in 
scores, and although is not considered a measurement property (Mokkink, 
Prinsen, Bouter, Vet, & Terwee, 2016), it is recognised by the COSMIN as an 
important characteristic of a measurement instrument (Mokkink et al., 2016). A 
number of methods have been purposed to establish the interpretability of a 
measure, however the MID has been indicated has the most adequate method 
(Terwee et al., 2007). The MID has been defined as the smallest difference in 
score in the domain of interest which patients perceive as beneficial and would 
mandate, in the absence of troublesome side effects and excessive cost, a 
change in the patient’s management (Jaeschke, Singer, & Guyatt, 1989). In 
interventions involving patients with AECOPD, MIDs have mainly been 
established for patient-reported outcome measures (PROM), e.g., the COPD 
assessment test (CAT) and the chronic respiratory disease questionnaire (CRQ) 
(Weldam, Schuurmans, Liu, & Lammers, 2013), and in inpatients (Kon et al., 
2014; Tsai et al., 2008). This limited knowledge impairs the management of 
patients treated on an outpatient basis and the interpretation of changes in other 
important and widely used clinical respiratory measures, such as SpO2 and lung 
function. Study II estimated MIDs and MDDs, i.e., the minimal change in a 
specific measure that falls outside the measurement error (de Vet et al., 2006), 
for clinical respiratory measures in outpatients with AECOPD following 
pharmacological treatment.  
Research question II 
Early identification and timely management of AECOPD has been shown 
to reduce hospital admissions and recovery time, while improving patients’ 
health-related quality of life (Wilkinson et al., 2004). Nevertheless, most 
exacerbations are still not timely treated or adequately monitored, which may be 
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related with the symptom-based diagnosis and monitoring of AECOPD (The 
Global Initiative for Chronic Obstructive Lung Disease, 2019). Although this 
symptom-based approach of AECOPD presents some advantages, as it targets 
the primary concern of the patients and caregivers, it is highly subjective (Kim & 
Aaron, 2018). Patients’ recognition and management of their symptoms during 
AECOPD are influenced by their personal beliefs, perceptions regarding 
seriousness of the disease, knowledge of exacerbations and former experiences 
(Korpershoek, Vervoort, Nijssen, Trappenburg, & Schuurmans, 2016). This 
subjectivity poses difficulties for the patient and for the clinician to decide if a 
patient’s symptoms are “increased more than usual” and require additional 
management, leading to unreported exacerbations and, consequently, to an 
under-estimation of patient exacerbation rates (Kim & Aaron, 2018). Hence, a 
large amount of research has been dedicating to find objective, reliable, easy to 
obtain and simple markers of AECOPD (Guerra, Gaveikaite, Bianchi, & Puhan, 
2017). 
Physiologically, AECOPD are characterised by an increase in airway 
inflammation and obstruction, abnormal bronchial mucus production and marked 
air trapping (The Global Initiative for Chronic Obstructive Lung Disease, 2019), 
which results in changes in lung acoustics. As respiratory sounds are directly 
related to the movement of air within the tracheobronchial tree (Gavriely et al., 
1994), the changes in respiratory mechanics related with AECOPD may be 
primarily detected by changes in respiratory sounds, such as adventitious 
respiratory sounds. Recent studies have shown respiratory sounds ability to 
differentiate between groups of patients with stable and exacerbated COPD 
(Jácome, Oliveira, & Marques, 2017) and to characterise AECOPD into two 
phenotypes, based on computerised analysis (Fernandez-Granero, Sanchez-
Morillo, & Leon-Jimenez, 2018; Sanchez Morillo, Astorga Moreno, Fernandez 
Granero, & Leon Jimenez, 2013). Nevertheless, little information is available on 
respiratory sounds changes before, at the onset and during the recovery from an 
AECOPD within the same group of patients. This information may advance the 
diagnosis and monitoring of patients with COPD across all clinical and non-
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clinical settings, as respiratory sounds are non-invasive, population-specific and 
nearly universally available by simple means (Bohadana et al., 2014). Study III 
evaluated adventitious respiratory sounds changes during the course of an 
AECOPD. 
AECOPD result in significant short and long-term clinical, physiological 
and functional deteriorations (Anzueto, 2010; Spruit et al., 2003), being 
symptoms and lung function the parameters most studied, due to their key role in 
the diagnosis and monitoring of COPD (Feliz-Rodriguez et al., 2013; Koutsokera 
et al., 2009; Parker et al., 2005; Seemungal et al., 2000; Seemungal et al., 1998). 
Dyspnoea has been identified as the primary symptom in AECOPD, 
followed by increased cough, sputum production and fatigue (Miravitlles et al., 
2007; Parker et al., 2005; Seemungal et al., 2000; Seemungal et al., 1998). 
Regarding to lung function, modest but inconsistent reductions in peak expiratory 
flow, FEV1 and forced vital capacity, associated with lung hyperinflation (i.e., an 
elevated total lung capacity, functional residual capacity and residual capacity) 
have been reported at the onset of AECOPD (Aaron et al., 2002; Niewoehner, 
Collins, & Erbland, 2000; Parker et al., 2005; Seemungal et al., 2000). 
Nevertheless, the recovery period of these symptoms and signs is poorly 
understood and time intervals between 5 to 90 days have been reported (Feliz-
Rodriguez et al., 2013; Parker et al., 2005; Seemungal et al., 2000; Spencer, 
Calverley, Sherwood Burge, & Jones, 2001) with approximately 7 to 20% of 
patients never fully recovering to their baseline status (Seemungal et al., 2000; 
The Global Initiative for Chronic Obstructive Lung Disease, 2019).  
Additionally, although it is well-established that AECOPD in patients not 
admitted to the hospital may result in prolonged incapacity and hospitalisations 
(Adams et al., 2000; Macfarlane et al., 1993; Miravitlles et al., 2001), little 
information is still available on its effects on functional parameters, such as 
muscle strength, activities of daily living and impact of the disease, and their 
recovery process. Spruit et al. (2003) and Mesquita et al. (2013) reported 
decreases in quadriceps muscle strength and no improvements in respiratory 
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muscle strength during hospitalisations of AECOPD. However, it is known that 
hospitalised patients differ from outpatients not only in their management but also 
in the severity of their exacerbation (The Global Initiative for Chronic Obstructive 
Lung Disease, 2019), which may influence their pattern of recovery. Thus, 
understanding outpatients’ clinical, physiological and functional recovery seems 
crucial to timely manage and appropriately plan their follow-ups. Study IV and 
Study V characterised patients’ symptoms, lung function, SpO2, muscle strength, 
impact of the disease and functionality during the time course of AECOPD 
managed on an outpatient basis. 
Summary 
AECOPD are highly heterogeneous with an extensive range of clinical 
presentations and recovery patterns, thus significant research and clinical efforts 
are being conducted to improve the diagnosis, management and monitoring of 
these events. Noteworthy improvements have been achieved on the monitoring 
of inpatients with AECOPD, however studies are scarce on patients treated on 
an outpatient basis, which correspond to more than 80% of all exacerbations. In 
outpatients with AECOPD, uncertainty remains regarding to what are the most 
adequate outcome measures to use, the interpretability of those measures and 
how they evolve during these events. This chapter presents the most recent 
literature in the diagnosis, management and monitoring of AECOPD, the current 
challenges in these matters and the contribution of the studies developed within 
the scope of this research work to enhance knowledge on outcome measures 
and monitoring of outpatients with AECOPD. 
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Abstract 
Background: Conflicting results about the effects of community-based 
pulmonary rehabilitation in acute exacerbations of chronic obstructive pulmonary 
disease (AECOPD) exist, possibly because the variety of outcome measures 
used and the lack of appropriate measurement properties hinder the 
development of pulmonary rehabilitation guidelines. 
Purpose: The purpose of this study was to identify and review the 
measurement properties of patient-reported outcome measures (PROMs) and 
clinical outcome measures of AECOPD that are used in pulmonary rehabilitation 
and that can be easily applied in a community setting. 
Data Sources: PubMed, Web of Science, Scopus, and CINAHL were 
searched up to July 1, 2016. 
Study Selection: Phase 1 identified outcome measures used in 
pulmonary rehabilitation for AECOPD. Phase 2 reviewed the measurement 
properties of the identified outcome measures. 
Data Extraction: One reviewer extracted the data and 2 reviewers 
independently assessed the methodological quality of the studies and the 
measurement properties of the outcome measures by using the Consensus-
Based Standards for the Selection of Health Status Measurement Instruments 
(COSMIN) recommendations. 
Data Synthesis: Twenty-three PROMs and 18 clinical outcome measures 
were found. The outcome measures most used were the St George Respiratory 
Questionnaire (n=15/37 studies) and the 6-minute walk test (n=21/37 studies). 
Thirty-two studies described the measurement properties of 22 PROMs and 7 
clinical outcome measures. The methodological quality of the studies was mostly 
poor, and the measurement properties were mostly indeterminate. The outcome 
measure exhibiting more robust properties was the COPD Assessment Test. 
Limitations: A number of studies were not found with the validated search 
strategy used and were included a posteriori; the fact that 3 studies presented 
combined results— for patients who were stable and patients with exacerbation—
affected the conclusions that can be drawn. 
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Conclusions: A large variety of outcome measures have been used; 
however, studies on their measurement properties are needed to enhance the 
understanding of community pulmonary rehabilitation for AECOPD. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is frequently punctuated 
by acute exacerbations (AECOPD) (Anzueto, 2010). Currently, more than 80% 
of these events are recommended to be managed within the community since it 
can shorten the length of hospital stays and/or avoid hospital admittance (The 
Global Initiative for Chronic Obstructive Lung Disease, 2017) 
Pulmonary rehabilitation is a well-established, evidenced-based 
intervention, possible to be applied within the community (i.e., in nonspecialised 
community health services, in community centers, or at the patient’s home) 
(Cambach, Chadwick-Straver, Wagenaar, van Keimpema, & Kemper, 1997; 
Cecins, Landers, & Jenkins, 2017; Lacasse, Goldstein, Lasserson, & Martin, 
2006; Neves, Reis, & Goncalves, 2016) and with potential to prevent and 
decrease the harmful effects of acute exacerbations (Holland, 2014). Costs 
associated with AECOPD in the United States are estimated in $7100 per 
patient/per exacerbation (Guarascio, Ray, Finch, & Self, 2013) and recent 
economic studies have shown that, compared with usual care, community-based 
pulmonary rehabilitation provides cost savings of $1098 per patient (Xie, Schaink, 
Wang, & Krahn, 2015). 
Nevertheless, conflicting results regarding the clinical effects of pulmonary 
rehabilitation in AECOPD have been reported (Puhan, Gimeno-Santos, Cates, & 
Troosters, 2016; Wedzicha et al., 2017) and less than 10% of patients discharged 
from AECOPD are being referred for pulmonary rehabilitation thus, its 
implementation is not a common practice. This inconsistency among studies may 
occur due to the wide variety of outcomes and outcome measures used and/or 
due to the lack of appropriate measurement properties (i.e., reliability, validity and 
responsiveness) of the outcome measures used in exacerbation periods. It is 
known that the measurement properties of any outcome measure are population 
specific (De Vet, Terwee, Mokkink, & Knol, 2011) and that patients at distinct 
phases of their chronic disease (stable/exacerbation) differ in the physiologic and 
ventilatory mechanisms of their lungs (Papi, Luppi, Franco, & Fabbri, 2006). 
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Therefore, it can be hypothesised that instrument measurement properties will 
also vary in stable and exacerbation periods. 
Nevertheless, studies involving pulmonary rehabilitation in patients with 
AECOPD have been choosing their outcome measures based on the 
measurement properties established for stable patients with COPD (Borges & 
Carvalho, 2014; Puhan et al., 2012), which may hinder the development of 
pulmonary rehabilitation guidelines and lead instead to publication of 
recommendations which lack rigorous underpinning evidence in exacerbation 
periods. 
Additionally, attending to patient’s level of fragility during exacerbations, 
the specificities of implementing a pulmonary rehabilitation programme in a 
nonspecialised center and some practical issues, such as the need for specific 
equipment and sufficient space and time required to complete testing, especially 
when more than 1 test at baseline is required, may also influence the selection of 
the outcome measure (Holland, 2014). 
Thus, the 2 aims of this systematic review were to identify patient-reported 
outcome measures (PROMs) and clinical (non–patient-reported) outcome 
measures that are used to assess the effects of pulmonary rehabilitation 
interventions in patients with AECOPD and that can be easily applied in the 
community (i.e., not expensive, not invasive, and quickly implemented) and to 
synthesise/evaluate their measurement properties. 
Methods 
This systematic review (PROSPERO registration no. CRD42015023736) 
was conducted in 2 phases. Phase 1 identified outcome measures used to 
assess outcomes of pulmonary rehabilitation interventions in patients with 
AECOPD and that can be easily applied in community-based practice. Phase 2 
aimed to assess the measurement properties of the identified outcome 
measures. 
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Phase 1: Measures Used in Pulmonary Rehabilitation 
Data sources and searches. 
The effects of pulmonary rehabilitation interventions in patients with 
AECOPD have been largely reviewed (Hill, Patman, & Brooks, 2010; McCrory, 
Brown, Gelfand, & Bach, 2001; Osadnik, McDonald, Jones, & Holland, 2012; 
Puhan et al., 2016; Tang, Taylor, & Blackstock, 2010; Wedzicha et al., 2017), 
thus a first search limited to literature reviews was conducted from May to June 
2016 in PubMed, Web of Knowledge, Scopus, and CINAHL. The original papers 
included in these reviews were extracted and searched for the outcome 
measures. 
The latest available literature review on this theme was dated from 2012 
and thus, a second search using the same keywords and databases but limited 
to original studies published from 2010 to June 2016 was also performed to 
identify all outcome measures most recently used by physiotherapists. An interval 
of 2 years until the most recent review in the theme seemed appropriate, as 
studies indicate that time from submission to publication can go up to 2 years 
(Björk & Solomon, 2013). In both searches, the reference lists of the identified 
studies were scanned for other potential eligible studies. Additionally, a weekly 
update was conducted until July 2016. The full search strategy can be found in 
eAppendix 1 (available at: https://academic.oup.com/ptj). 
Study selection. 
Selection of studies was performed by 1 reviewer (A.L.O.) and checked by 
a second reviewer (A.S.M.). After removing duplicates, 1 reviewer (A.L.O.) 
performed the initial screening of articles based on type of publication and 
relevance for the scope of the review. Selection of studies was checked by a 
second reviewer (A.S.M.). 
First, title and abstract were screened, and if the articles were considered 
relevant, full text was analysed. Studies were included if they met the following 3 
criteria: aimed to assess pulmonary rehabilitation or one of its components; 
assessed patients with an AECOPD within 3 weeks of the onset as this is the 
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mean time needed for recovery (Seemungal, Donaldson, Bhowmik, Jeffries, & 
Wedzicha, 2000; Spruit et al., 2013; The Global Initiative for Chronic Obstructive 
Lung Disease, 2017); and were written in English, Spanish, French, or 
Portuguese. Studies were excluded if they were conducted in animals; patients 
requiring emergency intubation, intensive care unit management, and/or 
mechanical ventilation; patients with compromised neurological status or 
hemodynamic instability; patients performing self-management programmes 
only; and patients assessed only after discharge for AECOPD. Book chapters, 
abstracts of communications or meetings, letters to the editor, commentaries to 
studies, unpublished work and study protocols were excluded. 
Data extraction 
Data extraction focused on PROMs and clinical outcome measures used 
to assess pulmonary rehabilitation interventions and that can be easily applied in 
community-based practice. Thus, data regarding measures not suitable for this 
setting (e.g., arterial blood gases, cardiopulmonary exercise testing, body 
plethysmography studies, sputum weight and analysis; penetration index of 
inhaled radioparticles and hospital length of stay) were not extracted. Data 
extracted were: outcomes, outcome measures, patient characteristics (i.e., age 
and percentage of predicted forced expiratory volume in 1 second (FEV1) at 
stability or in acute exacerbation), treatment setting, time from AECOPD to 
intervention and duration of intervention). 
Phase 2: Properties of Measures 
Data sources and searches 
A systematic electronic literature search was conducted from June to July 
2016 on PubMed, Web of Science, Scopus, and CINAHL. A validated sensitive 
search filter (sensitivity=97.4%; precision=4.4%) for finding studies on 
measurement properties of outcome measures was used (Terwee, Jansma, 
Riphagen, & de Vet, 2009). Only outcome measures included in phase 1 were 
searched in phase 2, however, if new outcome measures feasible to be used in 
community practice emerged from the search, they were also included. 
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Reference lists of the identified studies were scanned for other potential eligible 
studies and a weekly update was conducted until September 2016. The full 
search strategy can be found in eAppendix 2 (available at: 
https://academic.oup.com/ptj). 
Study selection 
Selection of studies was performed by 1 reviewer (A.L.O.) and checked by 
a second reviewer (A.S.M.). Inclusion and exclusion criteria were as in phase 1. 
Additionally, studies were included if information was reported regarding 1 or 
more measurement properties (i.e., reliability – internal consistency, reliability, 
measurement error; validity – content validity, construct validity and criterion 
validity, responsiveness and interpretability). Studies were excluded if reported 
on measurement properties of outcome measures not feasible to use in 
community-based pulmonary rehabilitation programmes, separated items of an 
outcome measure and did not included the full measure. 
Data extraction and quality assessment 
Data was extracted by 1 reviewer (A.L.O.) using 2 standardised tables, 
one for PROMs and another for clinical outcome measures. Data extracted were: 
outcome, outcome measure, author and year of publication, measurement 
property assessed, quality of the study, quality of the measurement property and 
costs. 
Two independent reviewers (A.L.O. and A.S.M.) evaluated the quality of 
the included studies using the Consensus-Based Standards for the Selection of 
Health Status Measurement Instruments (COSMIN) checklist (i.e., poor, fair, 
good, excellent) (Terwee et al., 2012). A consensus method was used to solve 
disagreements between reviewers. 
The quality of the outcome measures reported was determined using the 
rating system for measurement properties proposed by Terwee et al. (2007). For 
each measurement property a criterion is defined for positive, negative and 
indeterminate rating. 
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Data synthesis and analysis 
Data on PROMs and clinical outcome measures were separately 
analysed. For each measurement property (i.e., reliability, validity, 
responsiveness and interpretability), a synthesis of the quality of the study, using 
the COSMIN criteria (Terwee et al., 2012), and of the quality outcome measure, 
using the system of Terwee et al. (2007) was performed. 
The consistency of the quality assessment performed by the 2 reviewers 
was explored with an interrater agreement analysis using the Cohen kappa for 
each box of the COSMIN criteria. The Cohen kappa value ranges from 0 to 1 and 
can be categorised as slight (<0.2), fair (0.21–0.4), moderate (0.41–0.6), 
substantial (0.61–0.8), or almost perfect (>0.81) agreement (Landis & Koch, 
1977). 
Results 
Phase 1: Measures Used in Pulmonary Rehabilitation 
Study selection 
A total of 220 literature reviews were found. After duplicates were removed 
(n=66) and exclusions were made on the basis of abstract and title screenings 
(n=22), 132 full texts were screened and 15 literature reviews that reported on 
pulmonary rehabilitation interventions in patients with AECOPD were included. 
Additionally, 24 original studies included in the 15 reviews were extracted and 
searched for outcome measures not reported in the reviews. 
The search conducted for original studies published after 2010 retrieved 
257 original studies. After duplicates were removed (n=134) and exclusions were 
made on the basis of abstract and title screenings (n=23), 100 full texts were 
screened and 13 original studies were included. Thus, a total of 37 original 
studies were searched for outcome measures. A flow diagram concerning the 
literature reviews and original studies search and reasons for studies exclusions 
can be found in the eFigure (available at: https://academic.oup.com/ptj). 
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Study characteristics 
The 37 studies included were conducted in 19 different countries. A steady 
increase in the number of studies investigating pulmonary rehabilitation in 
patients with AECOPD was observed, with only 7 papers published from 1964 to 
2000 and 37 by 2016. Most studies were randomised control trials (n=31) 
(Aggarwal, Shaphe, George, & Vats, 2010; Babu, Noone, Haneef, & Samuel, 
2010; Basoglu, Atasever, & Bacakoglu, 2005; Behnke, Jorres, Kirsten, & 
Magnussen, 2003; Behnke et al., 2000; Borges & Carvalho, 2014; Carr, Hill, 
Brooks, & Goldstein, 2009; Chaplin et al., 2013; Cross et al., 2012; Deepak, 
Mohapatra, Janmeja, Sood, & Gupta, 2014; Eaton et al., 2009; Giavedoni et al., 
2012; Goktalay et al., 2013; Greening et al., 2014; He, Yu, Wang, Lv, & Qiu, 2015; 
Kirsten, Taube, Lehnigk, Jorres, & Magnussen, 1998; Ko et al., 2011; Kodric et 
al., 2009; Liao, Chen, Chung, & Chien, 2015; Man, Polkey, Donaldson, Gray, & 
Moxham, 2004; Martín-Salvador et al., 2016; Murphy, Bell, & Costello, 2005; 
Osadnik et al., 2014; Petersen, Esmann, Honcke, & Munkner, 1967; Puhan et al., 
2012; Seymour et al., 2010; Sonia & Gupta, 2012; Tang, Blackstock, Clarence, 
& Taylor, 2012; Torres-Sanchez et al., 2016; Troosters et al., 2010; Yohannes & 
Connolly, 2003), conducted with inpatients (n=27) (Aggarwal et al., 2010; Babu 
et al., 2010; Basoglu et al., 2005; Borges & Carvalho, 2014; Carr et al., 2009; 
Chaplin et al., 2013; Clini et al., 2009; Cross et al., 2012; Eastwood, Jepsen, 
Coulter, Wong, & Zeng, 2016; Eaton et al., 2009; Giavedoni et al., 2012; Goktalay 
et al., 2013; He et al., 2015; Kirsten et al., 1998; Kodric et al., 2009; Liao et al., 
2015; Martín-Salvador et al., 2016; Meglic, Sorli, Kosnik, & Lainscak, 2011; Ngai, 
Jones, Hui-Chan, Ko, & Hui, 2013; Osadnik et al., 2014; Petersen et al., 1967; 
Puhan et al., 2012; Sonia & Gupta, 2012; Tang et al., 2012; Torres-Sanchez et 
al., 2016; Troosters et al., 2010; Yohannes & Connolly, 2003), followed by 
hospital outpatient departments (n=6) (Carr et al., 2009; Deepak et al., 2014; 
Eaton et al., 2009; Ko et al., 2011; Puhan et al., 2012; Seymour et al., 2010), 
community settings (n=3) (Man et al., 2004; Oliveira & Marques, 2016; Oliveira, 
Pinho, & Marques, 2017) and patients’ homes (n=1) (Murphy et al., 2005) (Tabs. 
1 and 2). 
 28 
Outcomes and outcome measures 
Twenty-three PROMs and 18 clinical outcome measures were identified. 
The most common patient-reported outcomes assessed were dyspnoea (n=24), 
using the modified Borg Scale (mBorg) (Behnke et al., 2003; Clini et al., 2009; 
Eaton et al., 2009; He et al., 2015; Kirsten et al., 1998; Ko et al., 2011; Kodric et 
al., 2009; Liao et al., 2015; Martín-Salvador et al., 2016; Oliveira & Marques, 
2016; Oliveira et al., 2017; Seymour et al., 2010; Sonia & Gupta, 2012; Torres-
Sanchez et al., 2016) (n=14), and health-related quality of life (n=23), using the 
St George Respiratory Questionnaire (SGRQ) (Basoglu et al., 2005; Borges & 
Carvalho, 2014; Carr et al., 2009; Clini et al., 2009; Cross et al., 2012; Deepak et 
al., 2014; Greening et al., 2014; Ko et al., 2011; Kodric et al., 2009; Man et al., 
2004; Martín-Salvador et al., 2016; Meglic et al., 2011; Murphy et al., 2005; 
Osadnik et al., 2014; Seymour et al., 2010) (n=15). The most common clinical 
outcomes assessed were functional exercise capacity (n=24), using the 6-minute 
walk test (Babu et al., 2010; Behnke et al., 2003; Behnke et al., 2000; Borges & 
Carvalho, 2014; Carr et al., 2009; Clini et al., 2009; Cross et al., 2012; Deepak et 
al., 2014; Eaton et al., 2009; Goktalay et al., 2013; He et al., 2015; Kirsten et al., 
1998; Ko et al., 2011; Liao et al., 2015; Oliveira & Marques, 2016; Osadnik et al., 
2014; Troosters et al., 2010) (n=21), and lung function (n=13), using the FEV1 
(Behnke et al., 2000; Borges & Carvalho, 2014; Eastwood et al., 2016; Kirsten et 
al., 1998; Ko et al., 2011; Kodric et al., 2009; Murphy et al., 2005; Ngai et al., 
2013; Tang et al., 2012; Torres-Sanchez et al., 2016) (n=10). Other outcomes 
assessed were anxiety and depression, fatigue, cough, physical activity, strength, 
activities of daily living, lung function, peripheral blood gases, subjective airway 
clearance, and body composition. 
Tables 1 and 2 show the patient-reported and clinical outcomes and 
outcome measures reported.
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Table 1. Patient-reported outcomes used in pulmonary rehabilitation of patients with acute exacerbation (AE) of chronic obstructive pulmonary disease 
(COPD). 
Outcome Outcome 
Measure 
Patient Characteristics Intervention Setting Intervention Timing Intervention 
Duration 
No. of 
Patients 
Age (y) FEV1pp 
(%) 
FEV1ppAE 
(%) 
FEV1ppST 
(%) 
Dyspnoea BDI/TDI 26–30 62.3–69 34.1–60 Inpatient and home 4–8 d after hospital 
presentation 
11 d–18 mo 
VAS 1–27 68.4–74 NS Inpatient At hospital presentation to 
2 d after hospital 
presentation 
45 min–2 mo 
Borg Scale 26–110 61–75 35–42 Inpatient and home At hospital presentation to 
hospital discharge 
Until hospital 
discharge to 6 wk 
mBorg 19–1826 45–78.8 34.1–69.4 50.5–56 Inpatient, hospital outpatient 
department, and community 
At hospital presentation to 
3 wk after discharge 
60 min–19 mo 
MRC 19–94 58.4–73.9 38–53.3 29–56 Inpatient, hospital outpatient 
department, and home 
At hospital presentation to 
2 wk after discharge 
Until hospital 
discharge to 12 wk 
mMRC 19–97 56.8–73.8 
(mean) 
35–69.4 37.3–44.4 Inpatient, hospital outpatient 
department, and community 
At hospital presentation to 
3 wk after discharge 
Until hospital 
discharge to 12 wk 
NYHA 38 61 NS Inpatient As soon as stable Until hospital 
discharge 
ADLDS 94 69.2–73.9 38–39 Inpatient 2 d after hospital 
presentation 
Until hospital 
discharge 
HRQL Diary 26 64–69 34.9–37.5 Inpatient and home 4–7 d after admission 19 mo 
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CRQ 19–97 64–73.9  34.1–52 36.7–42.7 Inpatient, hospital outpatient 
department, community, 
and home 
As soon as stable to 3.7 
wk after hospital 
presentation 
Until hospital 
discharge to 18 
mo 
SGRQ 19–1,826 58.4–78.8  35.6–56.1 29–56 Inpatient, hospital outpatient 
department, community, 
and home 
As soon as stable to 2 wk 
after hospital presentation 
Until hospital 
discharge to 12 wk 
SF-36 24–97 69.6–73.8  35–56.1 36.7–41.7 Inpatient, hospital outpatient 
department, and community 
After discharge to 3 wk 
after hospital presentation 
8 wk 
EQ-5D 16–526 65–73.7  52 38–42 Inpatient, hospital outpatient 
department, and home 
As soon as stable to 1 wk 
after hospital discharge 
Until hospital 
discharge to 8 wk 
CAT 11–94 69.2–78  34–39  Inpatient 1–2 days after hospital 
presentation 
2 d to until hospital 
discharge 
FACIT fatigue 19 71   29 Inpatient Immediately at hospital 
presentation 
6 wk 
Feeling 
thermometer 
19 67.5   42.7 Inpatient or hospital 
outpatient department 
2 wk after hospital 
presentation 
12 wk 
Anxiety and 
depression 
HADS 49–97 69.7–73.7 35–41   Inpatient and hospital 
outpatient department 
As soon as stable to 
immediately after 
discharge 
Until hospital 
discharge to 8 wk 
Fatigue mBorg 60 65–67 52   Hospital outpatient 
department 
1 wk after discharge 8 wk 
Sputum VAS sputum 11–61 68–78  34–39  Inpatient As soon as stable 2–4 d 
General 
symptoms 
BCSS 11–90 56.8–78  34–69.4 37.3–44.4 Inpatient and community At hospital presentation to 
72 h after hospital 
presentation 
60 min to until 
hospital discharge 
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ADL Barthel Index 21–110 68–75 45.1–46.1 35–38 Inpatient At hospital presentation to 
72 h after hospital 
presentation 
Until hospital 
discharge 
LCADL 44 77.4–78.8 41.8–41.4 Inpatient As soon as stable 8–9 d 
Composite 
measure 
BODE Index 50–97 65.1–73.9 35–39 37.3–44.4 Inpatient and hospital 
outpatient department 
At hospital presentation to 
2 d after hospital 
presentation 
Until hospital 
discharge to 8 wk 
ADL = activities of daily living; ADLDS = Activity of Daily Living Dyspnoea Scale; AE = acute exacerbation; BCSS = Breathlessness, Cough, and Sputum Scale; BDI/TDI = Baseline Dyspnoea Index and Transition Dyspnoea Index; BODE = body mass 
index, airflow obstruction, dyspnoea, and exercise capacity; CAT = COPD Assessment Test; CRQ = Chronic Respiratory Disease Questionnaire; EQ-5D = EuroQol 5D; FACIT = Functional Assessment of Chronic Illness Therapy; FEV1pp = percentage 
predicted forced expiratory volume in 1 s; HADS = Hospital Anxiety and Depression Scale; HRQL = Health-Related Quality of Life; LCADL = London Chest Activities of Daily Living Scale; mBorg = modified Borg Scale; MRC = Medical Research Council; 
mMRC = modified MRC; NS = not stated; NYHA = New York Heart Association Functional Classification; SF-36 = Short Form (36-Item) Health Survey; SGRQ = St George Respiratory Questionnaire; ST = stable; VAS = visual analog scale. 
Please note that for clarification purposes, references of the outcome measures were removed from the table and can be found in the original published article. 
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Table 2. Clinical outcomes used in pulmonary rehabilitation of patients with acute exacerbation (AE) of chronic obstructive pulmonary disease (COPD). 
Outcome Outcome 
Measure 
Patient Characteristics Intervention Setting Intervention Timing Intervention 
Duration 
No. of 
Patients 
Age (y) FEV1pp 
(%) 
FEV1ppAE 
(%) 
FEV1ppST 
(%) 
Functional 
exercise 
capacity 
6MWT 28–1826 61–73.9  34.1–69.4 50.5 Inpatient, hospital 
outpatient department, 
community, and home 
At hospital presentation to 
3 wk after discharge 
4 d–18 mo 
ISWT 26–196 65–71.1  52 36.7–51.9 Inpatient, hospital 
outpatient department, 
community, and home 
Immediately to 10 d after 
discharge 
6–8 wk 
ESWT 20–196 65–70.1  52 39.8–51.9 Inpatient, hospital 
outpatient department, and 
home 
At hospital presentation to 
1 wk after discharge 
Until hospital 
discharge to 8 wk 
3-min step test 26 65–67   38–42 Home Immediately after 
discharge 
6 wk 
3-min walk test 21 68–73.6  45.1–46.1  Inpatient 48 h after hospital 
presentation 
Until hospital 
discharge 
2-minute step-in-
place test 
49 72.4–73.7  39–41  Inpatient As soon as stable Until hospital 
discharge 
CAT 11–94 69.2–78  34–39  Inpatient 1–2 days after hospital 
presentation 
2 d to until 
hospital 
discharge 
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Oxygen 
saturation 
SpO2 1–526 56.8–73.9 35–69.4 52–56 Inpatient, hospital 
outpatient department, and 
community 
At hospital presentation to 
8 d after hospital 
presentation 
45 min–8 wk 
Lung function FEV1 1–60 62.3–78 34–56.1 38–56 Inpatient, hospital 
outpatient department, and 
home 
At hospital presentation to 
3 wk after hospital 
discharge 
45 min–18 mo 
FVC 11–59 62.3–78 34–39 38–56 Inpatient and home At hospital presentation to 
immediately after hospital 
discharge 
2 d–18 mo 
FEV1/FVC 59 70.2 57.9–64.4 Inpatient At hospital presentation 7 d 
PEF 38–45 61 NS Inpatient At hospital presentation Until hospital 
discharge 
CRS 19 56.8 69.4 Community Within 48 to 72 h after 
hospital presentation 
3 wk 
Body 
composition 
Fat-free mass 
index 
60 65–67 52 Hospital outpatient 
department 
1 wk after hospital 
discharge 
8 wk 
BMI 90 67.8–69.5 35.9–35.6 37.3–44.4 Inpatient 2 d after hospital 
presentation 
Until hospital 
discharge 
Physical activity Accelerometer 29 67.8–64.1 39.1–41.7 Inpatient 3 d after hospital 
presentation 
At least 3 
sessions 
Strength MVIC 11–196 65–78.8 39.1–52 38–51.9 Inpatient, hospital 
outpatient department, and 
home 
At hospital presentation to 
1 wk after hospital 
discharge 
7 d–8 wk 
TwQ 60 65–67 52 Hospital outpatient 
department 
1 wk after hospital 
discharge 
8 wk 
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MIP 28 62.3–65.6  38  Inpatient 6–8 d after hospital 
presentation 
11 d 
6MWT = 6-min walk test; AE = acute exacerbation; BMI = body mass index; CRS = computerised respiratory sounds; ESWT = endurance shuttle walk test; FEV1 = forced expiratory volume in 1 s; FEV1pp = percentage predicted FEV1; FVC = forced vital 
capacity; ISWT = incremental shuttle walk test; MIP = maximum inspiratory pressure; MVIC = maximal voluntary isometric contraction; NS = not stated; PEF = peak expiratory flow; SpO2 = peripheral oxygen saturation; ST = stable; TwQ = quadriceps twitch 
responses. 
Please note that for clarification purposes, references of the outcome measures were removed from the table and can be found in the original published article.
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Phase 2: Properties of Measures 
Study selection 
The search for measurement properties identified 82 studies. After the 
removal of duplicates, 41 studies were screened. During the title and abstract 
screening, 18 studies were excluded. The full text of 23 studies was assessed 
and another 15 studies were excluded. Therefore, 8 original studies were 
selected. The search for relevant studies within the reference lists retrieved 24 
additional studies. Therefore, a total of 32 studies were included in this review 
(Figure 1). 
Figure 1. Flow diagram of the measurement properties studies included. 
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Measurement properties 
The measurement properties of 22 PROMs used to assess 5 outcomes 
(i.e., dyspnoea [6 outcome measures], health-related quality of life [11 outcome 
measures], health status [2 outcome measures], activities of daily living [2 
outcome measures], and general symptoms [1 outcome measure]) were reported 
by 26 of 32 studies. The measurement properties of 7 clinical outcome measures 
used to assess 4 outcomes (i.e., oxygen saturation [1 outcome measure], lung 
function [4 outcome measures], body composition [1 outcome measure], and 
physical activity [1 outcome measure]) were reported in 8 of 32 studies. 
The methodological quality of each study and the quality of the 
measurement properties of each measure can be found in Tables 3 and 4. The 
agreement between the 2 independent reviewers using the COSMIN quality 
assessment was substantial (κ=0.688). 
The characteristics of the included studies and synthesis of the results per 
outcome and outcome measure can be found in eAppendix 3 (available at: 
https://academic.oup.com/ptj; eTab. 1a and eTab. 1b). 
Quality and properties of PROMs 
Reliability was studied for 5 PROMs in 5 studies of fair to excellent 
methodological quality (i.e., SGRQ, Chronic Respiratory Diseases Questionnaire 
[CRQ], Clinical COPD Questionnaire [CCQ], and COPD Assessment Test [CAT]) 
(Antoniu, Puiu, Zaharia, & Azoicai, 2014; Jones et al., 2009; Katsoulas et al., 
2010; Kocks et al., 2006; Tsai et al., 2008) and in 2 studies of poor methodological 
quality (i.e., CCQ and Exacerbations of Chronic Pulmonary Disease Tool–
Patient-Reported Outcome [EXACT-PRO]) (Antoniu et al., 2014; Leidy et al., 
2011). Studies were rated as poor mainly because an analysis of the 
unidimensionality of the scale was not preformed. 
Measurement properties presented positive results in all reliability 
categories assessed (i.e., internal consistency and test-retest; measurement 
error has not been assessed) and for all outcome measures (Tab. 3). 
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Validity was studied for most PROMs, except for the mBorg, visual analog 
scale, Short-Form 6D, and Nottingham Health Profile, in 21 studies (Aaron et al., 
2002; Antoniu et al., 2014; Bourbeau, Maltais, Rouleau, & Guimont, 2004; Doll, 
Duprat-Lomon, Ammerman, & Sagnier, 2003; Güryay et al., 2007; Hutchinson et 
al., 2010; Jones et al., 2011; Jones et al., 2009; Jones et al., 2012; Katsoulas et 
al., 2010; Kocks et al., 2006; Leidy, Murray, Jones, & Sethi, 2014; Leidy et al., 
2011; Miravitlles et al., 2011; Monz et al., 2010; Paterson et al., 2000; Steer, 
Norman, Afolabi, Gibson, & Bourke, 2012; Trappenburg et al., 2010; Tsai et al., 
2008; Tu, Zhang, & Fei, 2014; Yohannes, Baldwin, & Connolly, 2005). Overall, 
the methodological quality of the studies was rated from poor to fair, except for 
structural validity studied in the CRQ and the CAT, which were rated excellent 
(Jones et al., 2009; Tsai et al., 2008). For criterion validity, reasons for rating 
“poor” were related with the inadequacy of the gold standard used as comparator. 
Regarding to construct validity, weaknesses included lack of formulation of 
hypotheses and lack of description of the comparator instrument. 
Criterion validity was indeterminate in 5 studies (i.e., modified Medical 
Research Council [MRC], MRC, extended MRC, CCQ, COPD severity score, 
EuroQol 5D [EQ-5D], Breathing Problems Questionnaire, London Chest Activities 
of Daily Living Scale [LCADL], and Manchester Respiratory Activities of Daily 
Living Questionnaire) (Güryay et al., 2007; Miravitlles et al., 2011; Steer et al., 
2012; Trappenburg et al., 2010; Yohannes et al., 2005) and positive in 1 study 
(i.e., Global Initiative for Chronic Obstructive Lung Disease plus Symptom 
Severity Index [GOLD+SSI]) (Hutchinson et al., 2010). Structural validity 
presented positive results in 2 studies (i.e., CRQ and CAT) (Jones et al., 2009; 
Tsai et al., 2008). Construct validity, was indeterminate in 11 studies (i.e., 
Baseline Dyspnoea Index and Transition Dyspnoea Index [BDI/TDI], SGRQ, 
CRQ, CCQ, COPD severity score, EQ-5D, Short-Form 6D, Measure Your 
Medical Outcome Profile, and Medical Outcomes Study 6-Item General Health 
Survey, modified MRC, SGRQ, EXACT-PRO, and LCADL) (Aaron et al., 2002; 
Güryay et al., 2007; Jones et al., 2012; Katsoulas et al., 2010; Kocks et al., 2006; 
Leidy et al., 2014; Leidy et al., 2011; Miravitlles et al., 2011; Paterson et al., 2000; 
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Tu et al., 2014), negative in 2 studies (i.e., SGRQ and CRQ) (Doll et al., 2003; 
Tsai et al., 2008), and positive in 7 studies (i.e., SGRQ, CRQ, CCQ, CAT, and 
Cough and Sputum Assessment Questionnaire) (Antoniu et al., 2014; Bourbeau 
et al., 2004; Jones et al., 2011; Jones et al., 2009; Jones et al., 2012; Monz et 
al., 2010; Tu et al., 2014) (Tab. 3). 
Responsiveness was studied for most PROMs, except for the modified 
MRC, MRC, extended MRC, Breathing Problems Questionnaire, GOLD+SSI, 
Manchester Respiratory Activities of Daily Living Questionnaire, and LCADL, in 
19 studies of poor to fair methodological quality (Aaron et al., 2002; Antoniu et 
al., 2014; Bourbeau et al., 2004; Doll et al., 2003; Goossens, Nivens, Sachs, 
Monz, & Rutten-Van Mölken, 2011; Jones et al., 2012; Katsoulas et al., 2010; 
Kendrick, Baxi, & Smith, 2000; Kocks et al., 2006; Leidy et al., 2011; Lemasson 
et al., 2007; Mackay et al., 2012; Menn, Weber, & Holle, 2010; Miravitlles et al., 
2011; Monz et al., 2010; Paterson et al., 2000; Trappenburg et al., 2010; Tsai et 
al., 2008; Tu et al., 2014). Common weaknesses of studies included lack of 
description of the comparator instrument and inadequacy of design and statistical 
methods used. 
Responsiveness was indeterminate in 14 studies (i.e., SGRQ, CCQ, 
COPD severity score, EQ-5D, Short-Form 6D, Nottingham Health Profile, 
Measure Your Medical Outcome Profile, Medical Outcomes Study 6-Item 
General Health Survey, EXACT-PRO, Cough and Sputum Assessment 
Questionnaire, mBorg, visual analog scale, and CCQ) (Antoniu et al., 2014; Doll 
et al., 2003; Goossens et al., 2011; Jones et al., 2012; Katsoulas et al., 2010; 
Kendrick et al., 2000; Kocks et al., 2006; Leidy et al., 2011; Lemasson et al., 
2007; Menn et al., 2010; Miravitlles et al., 2011; Monz et al., 2010; Paterson et 
al., 2000; Trappenburg et al., 2010), negative in 5 studies (i.e., SGRQ, CRQ, 
CAT, and EQ-5D) (Aaron et al., 2002; Bourbeau et al., 2004; Jones et al., 2012; 
Miravitlles et al., 2011; Tsai et al., 2008) and positive in 3 studies (i.e., BDI/TDI 
and CAT) (Aaron et al., 2002; Mackay et al., 2012; Tu et al., 2014) (Tab. 3). 
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Interpretability was found in 2 studies which presented values of the 
minimal clinically important difference (MCID) for the CRQ (MCID=1.01) (Tsai et 
al., 2008) and the CCQ (MCID=0.44) (Kocks et al., 2006). 
Quality and properties of clinical measures 
Reliability was not studied for any of the clinical outcome measures found 
(Tab. 4). 
Validity was studied for all clinical outcome measures in 8 studies of fair to 
poor methodological quality (Aaron et al., 2002; Emerman & Cydulka, 1996; 
Güryay et al., 2007; Kelly, McAlpine, & Kyle, 2001; Pitta et al., 2006; Sanchez-
Morillo, Leon-Jimenez, & Moreno, 2013; Tsimogianni et al., 2009; White, O'Brien, 
Hill, & Stockley, 2005). For criterion validity, reasons for rating “poor” were related 
with the inadequacy of the gold standard used as comparator, whereas for 
construct validity reasons were related to the lack of formulation of hypotheses 
and the lack of description of the comparator instrument. 
Overall, measurement properties presented positive results for criterion 
validity assessed in 4 studies (i.e., peripheral oxygen saturation [SpO2], forced 
vital capacity, and computerised respiratory sounds) (Güryay et al., 2007; Kelly 
et al., 2001; Sanchez-Morillo et al., 2013; Tsimogianni et al., 2009); however, in 
1 study assessing the FEV1, criterion validity was indeterminate (Güryay et al., 
2007). Regarding to construct validity, indeterminate results were found in 2 
studies (i.e., SpO2, peak expiratory flow [PEF], FEV1, and forced vital capacity) 
(Güryay et al., 2007; White et al., 2005) and positive results in 3 studies (i.e., 
SpO2, PEF, and time spent in weight-bearing activities assessed with an 
accelerometer) (Emerman & Cydulka, 1996; Kelly et al., 2001; Pitta et al., 2006) 
(Tab. 4). 
Responsiveness was studied for the PEF and FEV1 in 2 studies (Aaron et 
al., 2002; Emerman & Cydulka, 1996) of fair and poor methodological quality, 
respectively. The study was rated as poor because it did not describe the 
measurement properties of the comparator instrument. 
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Responsiveness was rated positive for the PEF (Emerman & Cydulka, 
1996) and indeterminate for the FEV1 (Aaron et al., 2002) (Tab. 4). 
Interpretability was not studied for any of the clinical outcome measures 
found (Tab. 4).
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Table 3. Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) Evaluation, Quality of the Measurement 
Property, and Cost of Patient-Reported Outcomes. 
Outcome Outcome 
Measure 
Study Reliability Validity Responsiveness Cost 
Internal 
Consistency 
Test-
Retest 
Criterion 
Validity 
Structural 
Validity 
Construct Validity 
(Hypothesis 
Testing) 
Dyspnoea mBorg Kendrick et al. 
(2000) 
Poor/? Free 
VAS Lemasson et al. 
(2007) 
Poor/? Free 
mMRC Güryay et al. 
(2007) 
Poor/ ? Poor/? Free 
MRC Steer et al. 
(2012) 
Poor/ ? Free 
eMRC Steer et al. 
(2012) 
Poor/ ? No information 
BDI/TDI Aaron et al. 
(2002) 
Poor/? Fair/+ Not free for 
commercial use 
HRQL SGRQ Doll et al. (2003) Fair/− Poor/? Free 
Bourbeau et al. 
(2004) 
Fair/+ Fair/− 
Menn et al. 
(2010) 
Poor/? 
Katsoulas et al. 
(2010) 
Fair/+ Good/? Poor/? 
Jones et al. 
(2012) 
Poor/? Poor/? 
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Tu et al. (2014)     Poor/?  
CRQ Bourbeau et al. 
(2004) 
    Fair/+ Fair/− Not free 
Tsai et al. (2008) Excellent/+   Excellent/ + Poor/− Fair/− 
Aaron et al. 
(2002) 
    Poor/? Fair/− 
CCQ Trappenburg et 
al. (2010) 
  Fair/?   Poor/? Not free 
Antoniu et al. 
(2014) 
Poor/+ Fair/+   Fair/+ Poor/? 
Kocks et al. 
(2006) 
    Poor/? Poor/? 
CAT Jones et al. 
(2009) 
Excellent/+   Excellent/+ Fair/+  Not free for 
commercial use 
Jones et al. 
(2011) 
    Fair/+  
Jones et al. 
(2012) 
    Fair/+ Poor/− 
Mackay et al. 
(2012) 
     Fair/+ 
Tu et al. (2014)     Poor/+ Fair/+ 
COPDSS Miravitlles et al. 
(2011) 
  Fair/?  Poor/? Poor/? Free 
EQ-5D Menn et al. 
(2010) 
     Poor/? Not free for clinical 
and commercial use 
Goossens et al. 
(2011) 
     Poor/? 
Miravitlles et al. 
(2011) 
  Fair/?  Poor/? Fair/− 
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Paterson et al. 
(2000) 
Poor/? Poor/? 
SF-6D Menn et al. 
(2010) 
Poor/? Not free for 
commercial use 
BPQ Yohannes et al. 
(2005) 
Poor/? Not free for 
commercial use 
NHP Doll et al. (2003) Poor/? Not free; copyright 
held by Galen   
MYMOP Paterson et al. 
(2000) 
Poor/? Poor/? Free 
MOS-6A Paterson et al. 
(2000) 
Poor/? Poor/? Free 
Health status EXACT-
PRO 
Leidy et al. 
(2014) 
Poor/? Not free for 
commercial use 
Leidy et al. 
(2011) 
Poor/+ Poor/? Poor/? 
GOLD + SSI Hutchinson et al. 
(2010) 
Poor/+ Free 
ADL MRADL Yohannes et al. 
(2005) 
Poor/? Not free for 
commercial use 
LCADL Miravitlles et al. 
(2011) 
Fair/? Poor/? Free 
General 
symptoms 
CASA-Q Monz et al. 
(2010) 
Poor/+ Poor/? No information 
ADL = activities of daily living; BDI/TDI = Baseline Dyspnoea Index and Transition Dyspnoea Index; BPQ = Breathing Problems Questionnaire; CASA-Q = Cough and Sputum Assessment Questionnaire; CAT = COPD [Chronic Obstructive Pulmonary 
Disease] Assessment Test; CCQ = Clinical COPD Questionnaire; COPDSS = COPD severity score; CRQ = Chronic Respiratory Disease Questionnaire; eMRC = extended Medical Research Council (MRC); EQ-5D = EuroQol 5D; EXACT-PRO = 
Exacerbations of Chronic Pulmonary Disease Tool–Patient-Reported Outcome; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HRQL = Health-Related Quality of Life; LCADL = London Chest Activities of Daily Living Scale; mBorg = 
modified Borg Scale; mMRC = modified MRC; MOS-6A = Medical Outcomes Study 6-Item General Health Survey; MRADL = Manchester Respiratory Activities of Daily Living Questionnaire; MYMOP = Measure Your Medical Outcome Profile; NHP = 
Nottingham Health Profile; SF-6D = Short-Form 6D; SGRQ = St George Respiratory Questionnaire; SSI = Symptom Severity Index; VAS = visual analog scale; + = positive; − = negative; ? = indeterminate.
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Table 4. Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) Evaluation, Quality of the Measurement 
Property, and Cost of Clinical Outcomes. 
Outcome Outcome Measure Study Reliability Validity Responsiveness Cost 
Internal 
Consistency 
Test-
Retest 
Criterion 
Validity 
Construct Validity 
(Hypothesis Testing) 
Oxygen 
saturation 
SpO2 (%) Güryay et al. (2007)   Fair/+ Poor/?  Not 
free Kelly et al. (2001)   Fair/+ Poor/+  
Lung function PEF (pp) Emerman and 
Cydulka (1996) 
   Poor/+ Fair/+ Not 
free 
Güryay et al. (2007)    Poor/?  
FEV1 (pp or L) Güryay et al. (2007)   Poor/? Poor/?  Not 
free Aaron et al. (2002)     Poor/? 
White et al. (2005)    Poor/?  
FVC (pp) Güryay et al. (2007)    Poor/?  Not 
free 
CRS Sanchez-Morillo et al. 
(2013) 
  Fair/+   Not 
free 
Body 
composition 
BMI (kg/m2) Tsimogianni et al. 
(2009) 
  Poor/+   Free 
Physical 
activity 
Time spent in weight-bearing 
activities (min) 
Pitta et al. (2006)    Poor/+  Not 
free 
BMI = body mass index; CRS = computerised respiratory sounds; FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; PEF = peak expiratory flow; pp = percentage of predicted normal value; SpO2 = peripheral oxygen saturation; + = 
positive; − = negative; ? = indeterminate.
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Discussion 
To our knowledge, this is the first systematic review to provide a 
comprehensive overview of the measurement properties of the outcome 
measures most used in pulmonary rehabilitation programmes during AECOPD 
and that can be easily applied in a community setting. Twenty-three PROMs and 
18 clinical outcome measures were identified in intervention studies. The most 
used measures were the St George Respiratory Questionnaire (n=15/37) and the 
6-minute walk test (n=21/37). Several measures have been used only in isolated 
studies (i.e., New York Heart Association Functional Classification, Activities of 
Daily Living Dyspnoea Scale, diaries, Functional Assessment of Chronic Illness 
Therapy, feeling thermometer, mBorg fatigue, LCADL, 3-minute step test, 3-
minute walk test, 2-minute step-in-place test, FEV1/forced vital capacity, 
computerised respiratory sounds, fat-free mass index, body mass index, 
accelerometer, quadriceps twitch responses, and maximum inspiratory 
pressure). Measurement properties were only synthesised for 22 PROMs and 7 
clinical outcome measures. The methodological quality of most studies was poor, 
and the results obtained for the measurement properties were indeterminate. The 
PROMs and clinical outcome measures exhibiting the most appropriate 
measurement properties were the CAT and SpO2, respectively. 
The most used PROMs were the mBorg and the SGRQ. Dyspnoea and 
health-related quality of life have been reported as the outcomes that better 
reflect the overall impact of the disease (Janson et al., 2013) and, therefore their 
monitoring during AECOPD, with appropriate outcome measures, is essential to 
guide health professionals on the most effective interventions. Nevertheless, the 
measurement properties of the mBorg have been little reported and, when 
reported, in studies of poor methodological quality. The BDI/TDI, although not 
commonly used, was the only outcome measure which rated fair and positive for 
responsiveness on dyspnoea. The SGRQ has shown appropriate test retest 
reliability but inconclusive validity and responsiveness. Although, the SGRQ has 
strong measurement properties in stable patients with COPD (Spruit et al., 2013; 
Weldam, Schuurmans, Liu, & Lammers, 2013) it reports to the past month, 3 
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months and 1 year. These inappropriate timeframes to assess improvements 
from an AECOPD, which usually takes 1 to 3 weeks to be meaningful to patients 
(Seemungal et al., 2000; Woodhead et al., 2011) might explain some of the 
divergent results found. Measurement properties of CAT have been assessed in 
a reasonable number of studies of fair methodological quality (Jones et al., 2011; 
Jones et al., 2009; Jones et al., 2012; Mackay et al., 2012; Tu et al., 2014) and 
positive results have been found. Therefore, the BDI/TDI and CAT may be 
promising PROMs to assess the effectiveness of community-based pulmonary 
rehabilitation in patients with AECOPD. 
The most used clinical outcome measures were the FEV1 and the 6-minute 
walk test. However, the measurement properties of the FEV1 were found in 
studies of poor methodological quality and no studies were found reporting on 
the measurement properties of the 6-minute walk test in patients with AECOPD 
which impaired conclusions regarding its use. Similarly to exercise tolerance, no 
studies were found reporting on measurement properties of muscle strength. 
Currently, it is known that the inflammatory effects of AECOPD are not confined 
to the lungs but also impair peripheral muscle strength and exercise tolerance 
(Anzueto, 2010). Declines in these outcomes are independent predictors of 
hospitalisations and mortality (Maltais et al., 2014; Neder et al., 2016). Early 
rehabilitation may play a crucial role in preventing and reducing losses in exercise 
capacity, muscle strength and musculoskeletal dysfunction (Borges & Carvalho, 
2014; Troosters et al., 2010), thus possibly reverting this cascade of events. 
Nevertheless, there is the urgent need to establish the measurement properties 
of clinical outcome measures for AECOPD to assess patients’ dysfunctions, plan 
interventions, and verify their effectiveness. 
This systematic review evidenced that the conflicting results of pulmonary 
rehabilitation programmes in patients with AECOPD (Borges & Carvalho, 2014; 
Greening et al., 2014; Puhan et al., 2016; Puhan et al., 2012) may not be related 
to the quality of treatment but with the lack of appropriateness of measurement 
proprieties of the outcome measures used. Additionally, whilst the methodology 
of this review target only measures that could be implemented in community 
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settings (i.e., simple and accessible measures), our results can also be applicable 
to other clinical settings where these measures are available. Nevertheless, since 
most AECOPD are recommended to be managed in the community and 
community-based pulmonary rehabilitation might be a promising intervention for 
minimising a patient’s decline and prevent recurrence, robust studies on the 
validity, reliability and responsiveness, as well as on availability, cost and 
interpretability (i.e., by establishing the MCID), of outcome measures are urgently 
needed. These studies will contribute to clarify the role of community-based 
pulmonary rehabilitation in patients with AECOPD. 
Study Limitations 
This study has some limitations that need to be acknowledged. Several 
relevant studies for this systematic review (Aaron et al., 2002; Antoniu et al., 
2014; Doll et al., 2003; Emerman & Cydulka, 1996; Goossens et al., 2011; 
Hutchinson et al., 2010; Jones et al., 2011; Jones et al., 2012; Kelly et al., 2001; 
Kendrick et al., 2000; Kocks et al., 2006; Leidy et al., 2014; Leidy et al., 2011; 
Lemasson et al., 2007; Mackay et al., 2012; Miravitlles et al., 2011; Pitta et al., 
2006; Sanchez-Morillo et al., 2013; Steer et al., 2012; Trappenburg et al., 2010; 
Tsimogianni et al., 2009; White et al., 2005; Yohannes et al., 2005) were not 
found with the validated search strategy used and were only included after 
searching through the reference lists of the reviewed studies. Relevant studies 
may have fallen out of the search due the absence of keywords related to 
measurement properties in their title, abstract or keywords, which impaired the 
filter used to identify them. Adequate use of the Medical Subject Headings 
(MESH) terms is warranted to identify the purpose of the studies and improve the 
quality of the results found in future systematic reviews. 
This systematic review has followed the COSMIN recommendations to 
assess the quality of the included studies. The COSMIN was originally developed 
for health-related PROMs, such as questionnaires (Terwee et al., 2012), and thus 
its validity, reliability and adequacy for assessing the methodological quality of 
clinical studies and outcome measures, may be questioned. Nonetheless, in the 
absence of a measure specifically designed to evaluate such studies and 
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outcome measures, the COSMIN is indicated as an adequate alternative tool 
(Bartels, de Groot, & Terwee, 2013; Dobson et al., 2012). 
The selection of studies was performed by 1 reviewer which could have 
caused bias in the studies selection. This limitation has been mitigated by 
consulting a second reviewer when uncertainties were found and by defining strict 
inclusion and exclusion criteria prior to studies selection. 
Finally, 3 of the studies included presented combined results of stable and 
exacerbated patients with COPD (Bourbeau et al., 2004; Doll et al., 2003; Leidy 
et al., 2011) which could have affected some of the conclusions established. 
Nevertheless, the results of these studies have been considered within the 
universe of all studies included, and thus we believe that any potential bias that 
could have been introduced was diluted. Future studies should focus on patients 
with AECOPD only, so that recommendations regarding its measurement 
properties can be established with confidence. 
Conclusions 
Although a large number of outcome measures easy to implement in a 
community-based setting have been used to assess pulmonary rehabilitation in 
patients with AECOPD, their measurement properties have been poorly studied. 
Given the wide availability of measures it does not seem necessary to develop 
new outcome measures to be used in community-based pulmonary rehabilitation 
of patients with AECOPD. Instead, studies following the COSMIN standards to 
evaluate the measurement properties (i.e., reliability, validity and 
responsiveness) of the existing outcome measures are recommended. Such 
studies would contribute to clarify the role of community-based pulmonary 
rehabilitation in patients with AECOPD and guide the development of core 
outcome sets. 
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Abstract 
Introduction: Computerised respiratory Sounds (CRS) are closely related 
to the movement of air within the tracheobronchial tree and are promising 
outcome measures in patients with chronic obstructive pulmonary disease 
(COPD). However, CRS measurement properties have been poorly tested. 
Objective: The aim of this study was to assess the reliability, validity and 
the minimal detectable changes (MDC) of CRS in patients with stable COPD. 
Methods: Fifty patients (36♂, 67.26±9.31y, FEV1 
49.52±19.67%predicted) were enrolled. CRS were recorded simultaneously at 
seven anatomic locations (trachea; right and left anterior, lateral and posterior 
chest). The number of crackles, wheeze occupation rate, median frequency (F50) 
and maximum intensity (Imax) were processed using validated algorithms. 
Within-day and between-days reliability, criterion and construct validity, validity to 
predict exacerbations and MDC were established. 
Results: CRS presented moderate-to-excellent within-day reliability 
(ICC1,3≥0.51; p<0.05) and moderate-to-good between-days reliability 
(ICC1,2≥0.47; p<0.05) for most locations. Negligible-to-moderate correlations with 
FEV1%predicted were found (-0.53<rs<-0.28; p<0.05), and the inspiratory number 
of crackles were the best discriminator between mild-to-moderate and severe-to-
very severe airflow limitations (area under the curve >0.78). CRS correlated 
poorly with patient-reported outcomes (rs<0.48; p<0.05) and did not predict 
exacerbations. Inspiratory number of crackles at posterior right chest, inspiratory 
F50 at trachea and anterior left chest and expiratory Imax at anterior right chest 
were simultaneously reliable and valid, and their MDC were 2.41, 55.27, 29.55 
and 3.98, respectively. 
Conclusion: CRS are reliable and valid. Their use, integrated with other 
clinical and patient-reported measures, may fill the gap of assessing small 
airways and contribute toward a patient’s comprehensive evaluation. 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is characterised by 
persistent respiratory symptoms and airflow limitation due to smaller airway 
and/or alveolar abnormalities (The Global Initiative for Chronic Obstructive Lung 
Disease, 2017). Although diagnosis and monitoring of airflow limitation is usually 
performed by spirometry (gold standard test of lung function) (The Global 
Initiative for Chronic Obstructive Lung Disease, 2017), its usefulness to assess 
interventions has been questioned, as it mainly assesses large airways (McNulty 
& Usmani, 2014), changes in response to treatments are small (Calverley et al., 
2003; Zwick et al., 2009), and correlates poorly with patient-reported outcomes 
(Jones, 2001). Thus, international Respiratory Societies have been stressing the 
need to validate instruments that can express peripheral respiratory function, 
assess patient’s response to interventions and correlate with patient-reported 
outcomes (Celli et al., 2015). Computerised respiratory sounds are a simple, 
objective and noninvasive outcome measure that are directly related to the 
movement of air within the tracheobronchial tree (Gavriely, Nissan, Cugell, & 
Rubin, 1994). Therefore, changes in airway and/or alveolar mechanisms may be 
primarily detected by changes in the frequency/intensity of normal respiratory 
sounds and by the presence of adventitious respiratory sounds (i.e., crackles and 
wheezes) (Gavriely et al., 1994). This theoretical potential of computerised 
respiratory sounds to be used as an outcome measure has been motivating 
research of their characteristics and measurement properties (Jácome & 
Marques, 2015a; Jácome, Oliveira, & Marques, 2017; Oliveira, Pinho, & 
Marques, 2017). A recent study in stable patients with COPD has shown that 
respiratory sounds have adequate within-day reliability (Jácome & Marques, 
2015a). However, other measurement properties need to be studied before 
computerised respiratory sounds utilisation can be recommended for clinical 
practice (Terwee et al., 2007). Between-days reliability and validity are crucial 
measurement properties of an outcome measure which, according to the authors’ 
best knowledge, have never been explored in computerised respiratory sounds, 
hindering the interpretation of its actual usefulness to assess lung function 
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(validity) and its repeatability during prolonged stable phases (reliability). This 
study aimed to evaluate the between-days reliability, criterion, construct and 
predictive validity of computerised respiratory sounds in patients with COPD. The 
authors hypothesised that computerised respiratory sounds would present (a) 
significant and moderate between-days reliability; (b) significant, negative and 
low-to-moderate correlations with lung function; (c) significant, negative and 
moderate correlations with patient-reported outcome measures and (d) 
significant ability to predict acute exacerbations of COPD up to 1 year. 
Materials and methods 
Study design 
A cross-sectional study was conducted. Reliability and validity were 
explored, described and interpreted following the COnsensus-based Standards 
for the selection of health status Measurement Instruments (COSMIN) guidelines 
(Terwee et al., 2007; Terwee et al., 2012). 
Sample size 
The sample size was determined according to the COSMIN guidelines, 
which have established that a study with good methodological quality should 
enroll a minimum of 50cparticipants (Terwee et al., 2012). 
Participants 
Outpatients with stable COPD were recruited from a central hospital 
between January 2016 and 2017. Inclusion criteria were diagnosis of COPD 
according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
criteria (The Global Initiative for Chronic Obstructive Lung Disease, 2017) and 
clinical stability for one month prior to the study (i.e., no hospital admissions, 
exacerbations as defined by GOLD, or changes in respiratory system 
medication). Patients were excluded if they had severe co-existing respiratory, 
neurological, cardiac, musculoskeletal, or psychiatric impairments. Approvals for 
this study were obtained from the ethics committee of the Central Hospital 
(13NOV’1514:40065682) and National Data Protection Committee (8828/2016). 
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Eligible patients were identified by clinicians and then contacted by the 
researchers, who explained the purpose of the study and asked about their 
willingness to participate. When patients agreed to participate, an appointment 
with the researchers was scheduled and written informed consent was obtained. 
Data collection 
Participants were asked to attend to two testing sessions with a 5–7 days 
interval. In the first session, patients completed a questionnaire with 
sociodemographic (age and gender) and health-related (smoking status, 
exacerbations in the previous year, symptoms and impact of the disease) 
information. Height and weight were recorded to calculate the body mass index 
(BMI). Smoking status was evaluated with a two-question survey on current and 
previous smoking habits. Cough and wheezing were assessed through a 
standardised numeric rating scale (NRS) in which the patient reported the 
severity of the symptoms in the previous 24 hours. The NRS is reliable (Intraclass 
correlation coefficient, ICC=0.54 to 0.86) and valid to assess symptoms in 
patients with respiratory diseases (Boulet et al., 2015; Morris et al., 2007). 
Dyspnoea was collected using the modified Medical Research Council (mMRC) 
dyspnoea scale (Doherty et al., 2006). The patients read the 5-point mMRC scale 
and pointed the grade (0–4) that most closely matched his or her breathlessness. 
Higher scores represent more breathlessness. The mMRC has shown to be a 
reliable (ICC=0.82) (Mahler et al., 2009) and valid measure of disability related 
with dyspnoea (Bestall et al., 1999). Impact of the disease was collected with the 
COPD Assessment Test (CAT). The CAT is a reliable (Cronbach α=0.88) and 
valid self-administered eight-question questionnaire, which allows the 
assessment of the impact of COPD on health status within only a few minutes 
(Jones et al., 2009). Higher scores represent higher impact of COPD. Then, three 
respiratory sounds recordings were performed with air-coupled electret 
microphones (C 417 PP; AKG Acoustics GmbH, Vienna, Austria) (Vannuccini et 
al., 2000) following the computerised respiratory sound analysis (CORSA) 
guidelines for short-term acquisitions (Rossi et al., 2000). Finally, lung function 
was assessed with a portable spirometer (MicroLab 3535; CareFusion, Kent, UK) 
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according to the guidelines (Miller et al., 2005). In the second session, only 
respiratory sounds were recorded. Effort was made to keep all factors associated 
with the testing sessions consistent, specifically the time of day, location of the 
sessions, chest locations of the microphones and order of testing. Additionally, 
participants were telephoned every 3 months, up to 1 year of their initial 
assessment, to gather information about the occurrence of an exacerbation (The 
Global Initiative for Chronic Obstructive Lung Disease, 2017). 
Respiratory sound recordings 
Recordings were performed simultaneously at seven anatomic locations 
(trachea and right and left anterior upper, lateral middle and posterior lower chest) 
(Rossi et al., 2000). The recording system included eight air-coupled electret 
microphones, a multi-channel audio interface (AudioBox 1818 VSL; PreSonus, 
Baton Rouge, LA) and a laptop computer running LungSounds@UA interface 
(Pinho, Oliveira, Oliveira, Dinis, & Marques, 2014). Seven microphones, mounted 
in couplers made Teflon (Kraman, Wodicka, Oh, & Pasterkamp, 1995), were 
attached on the participant’s skin with double-faced adhesive tapes (Double Stick 
Discs; 3M Littmann, Cheshire, UK), and one microphone was placed closed to 
the patient to record the background noise. The analog sound signals acquired 
were amplified and converted to digital by the audio interface with a 24-bit 
resolution and a sampling rate of 44.1 kHz. Each data acquisition session lasted 
for 20 seconds (Vyshedskiy & Murphy, 2012), and the recorded data were later 
converted to.wav format. 
Signal processing 
Respiratory sound files were processed by automatic algorithms 
implemented in Matlab R2009a (MathWorks, Natick, Massachusetts). Data were 
obtained for number of crackles, occupation rate of wheezes (%Wh), median 
frequency (F50) and maximum intensity (Imax) per respiratory phase (i.e., 
inspiration and expiration) and per chest location.  
Number of crackles per respiratory phase was calculated using the 
following equation: 
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𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑟𝑎𝑐𝑘𝑙𝑒𝑠 =
sum of crackles per respiratory phase
total number of respiratory phases
  (1) 
 
%Wh was calculated through the following equations:  
𝑟𝑎𝑡𝑒 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑤ℎ𝑒𝑒𝑧𝑒 =
duration of wheeze in the respiratory phase
total duration of the respiratory phase
 X 100 (2) 
 
%Wh = ∑(rate of each wheeze in the respiratory phase) (3) 
 
F50 and Imax were calculated following the methodology proposed by 
(Pasterkamp, Powell, & Sanchez, 1996) after excluding adventitious respiratory 
sounds in each file. F50 and Imax were analysed within a frequency band of 300–
600 Hz, as this has been indicated as the most representative frequency band 
for patients with respiratory diseases (Hossain & Moussavi, 2004; Sulzer, 
Schüttler, Penzel, & Wichert, 1997). All analyses were checked by two respiratory 
experts and the average respiratory sound spectra and background noise were 
plotted to ensure the quality of sound recordings. Background noise was closely 
superimposed to respiratory sound intensity at lateral chest; hence, these 
locations were excluded from further analyses. The average spectra of normal 
respiratory sounds at trachea, anterior, lateral and posterior chest can be found 
in the Supporting Information and a detailed description of the signal processing 
is provided elsewhere (Oliveira, Sen, Kahya, Afreixo, & Marques, 2017). 
Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics version 
24.0 (IBM Corporation, Armonk, New York) and plots were created using 
GraphPad Prism version 5.01 (GraphPad Software, Inc., La Jolla, California). The 
level of significance was set at 0.05. Descriptive statistics were used to describe 
the sample. Characteristics were compared between patients at stages I-II and 
III-IV of airflow limitation (The Global Initiative for Chronic Obstructive Lung 
Disease, 2017), using independent t-tests for normally distributed data (age, BMI 
and lung function), Mann-Whitney U-tests for ordinal data (mMRC, CAT and 
NRS) and Chi-squared tests for categorical data (gender, smoking status and 
number of exacerbations/year). 
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Reliability 
Within-day reliability and between-days reliability were determined. 
Relative and absolute reliability were calculated with the ICC and the Bland and 
Altman method, respectively (Rankin & Stokes, 1998). Within-day reliability was 
computed using the ICC equation1, k), where k=3 corresponds to the three 
recordings performed in session 1. The Bland and Altman method assesses the 
agreement between two sets of measures (Bland & Altman, 1986); thus, random 
numbers were generated in MATLAB to delete one recording. Between-days 
reliability was computed using the ICC equation (Equation 1, k), where k=2 
corresponds to the two recordings used (one from session 1 and one from 
session 2). Bland and Altman plots were also created to analyse the distribution 
of results from session 1 and 2. ICC was interpreted as excellent (>0.75), 
moderate-to-good (0.4-0.75) or poor (<0.4) (Fleiss, 1986). 
Validity 
Criterion validity was assessed by analysing the degree to which 
respiratory sounds correlated with lung function (i.e., percent predicted forced 
expiratory volume in 1 second, FEV1%predicted) using Spearman’s rank 
correlation coefficient. The strength of the correlations was interpreted as 
negligible (i.e., 0-0.30), low (0.31-0.50), moderate (0.51-0.70), high (0.71-0.90) or 
very high (0.91-1) (Mukaka, 2012). Receiver operating characteristic (ROC) 
analysis was used to assess the ability of respiratory sounds to differentiate 
between patients’ airflow limitation severity. The ROC analysis only allows to plot 
the performance of a binary classification, thus, patients classified in the GOLD 
criteria as I and II were labelled as mild-to-moderate airflow limitation and patients 
classified as III and IV were labelled as severe-to very severe airflow limitation. 
The cut-off for each respiratory sound parameter was chosen as the point where 
the sensitivity and specificity were simultaneously maximised. Area under the 
curves (AUC) and the 95% confidence interval were determined. AUC was 
interpreted as: AUC=0.5 no discrimination; 0.7≤AUC<0.8 acceptable 
discrimination; 0.8≤AUC<0.9 excellent discrimination and AUC≥0.9 outstanding 
discrimination (Hosmer Jr, Lemeshow, & Sturdivant, 2013). Construct validity 
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was assessed by examining the relationship between adventitious respiratory 
sounds, NRS, mMRC and CAT using Spearman’s rank correlation coefficient. 
Predictive validity up to 12 months exacerbations were explored with ROC 
analysis and the influence of independent predictors (i.e., number of crackles, 
%Wh, F50 and Imax) on the time until the first exacerbation was analysed by 
univariate and multivariate Cox regression analyses. 
Minimal detectable changes (MDC) 
MDC were only computed for respiratory sound parameters and locations 
that have simultaneously shown adequate between-days reliability (significant 
ICC>0.75) and validity (significant correlations with FEV1%predicted). To 
determine the MDC, first, the standard error of measurement (SEM) was 
calculated using the following equation: 
𝑆𝐸𝑀 = 𝑆𝐷 √(1 − 𝐼𝐶𝐶1,2 ) (4) 
where SD is the standard deviation of the scores obtained from all participants 
and ICC is the between-days reliability coefficient. The MDC at the 95% level of 
confidence (MDC95) was calculated as follows: 
𝑀𝐷𝐶95 = 𝑆𝐸𝑀 × 1.96 × √2 (5) 
The MDC was also expressed as a percentage (MDC%), defined as 
𝑀𝐷𝐶% = (𝑀𝐷𝐶95 𝑚𝑒𝑎𝑛) × 100⁄  (6) 
where “mean” is the mean of the scores obtained in the two testing sessions. A 
MDC% below 30% was considered acceptable (Portney & Watkins, 2000). 
Results 
Participants 
Fifty-eight patients were contacted and invited to participate in the study. 
However, seven refused to participate, as they did not perceive the study as 
relevant (n=5) or had family constrains to their participation (n=2), and one did 
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not complete the assessment. Therefore, 50 participants (36 males) were 
enrolled in the study. Participants’ characteristics are summarised in Table 1. 
Table 1. Sample characterisation. 
Characteristics Total 
(n=50) 
GOLD stages 
I-II (n=21) 
GOLD stages 
III-IV (n=29) 
p-value 
Age, years 67.26±9.31 67.29±11.22 67.24±7.87 0.987 
Gender (male), n(%) 36 (72) 13 (62) 23 (79) 0.213 
BMI, kg/m2 27.26±8.22 29.93±11.26 25.32±4.28 0.049* 
Smoking status, n(%) 
Current 
Former 
Never 
 
7 (14) 
26 (52) 
17 (34) 
 
5 (24) 
7 (33) 
9 (43) 
 
2 (7) 
19 (66) 
8 (28) 
0.056 
Packs/year, M[IQR] 50 [32-77] 48 [24-54] 50 [33-90] 0.294 
Exacerbations/year, n(%) 
0 
1 
≥2 
 
18 (36) 
9 (18) 
23 (46) 
 
6 (29) 
4 (19) 
11 (52) 
 
12 (41) 
5 (18) 
12 (41) 
0.638 
FEV1, L 1.24±0.53 1.65±0.53 0.95±0.28 <0.001* 
FEV1, %predicted 49.52±19.67 69.10±10.65 35.34±10.04 <0.001* 
FEV1/FVC, % 49.76±13.24 58.71±8.65 43.28±12.24 <0.001* 
GOLD stages, n(%)     
I 3 (6)    
II 18 (36)    
III 21 (42)    
IV 8 (16)    
CAT, M[IQR] 13 [8-21] 12 [9-18] 14 [7-23] 0.582 
mMRC, M[IQR] 2 [1-2] 1 [1-2] 2 [1-3] 0.004* 
NRS, M[IQR]     
Cough 1 [0-3] 2 [0-5] 1 [0-3] 0.233 
Wheezing 2 [0-4] 2 [0-3] 3 [0-5] 0.236 
Abbreviations: BMI, body mass index; CAT, COPD Assessment Test; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; IQR, interquartile range; M, median; mMRC, Modified British Medical Research Council questionnaire; SD, 
standard deviation; NRS, numeric rating scale. Values are presented as mean±standard deviation, unless otherwise stated. *P<.05. 
Reliability 
Adventitious respiratory sounds presented excellent within-day reliability 
(ICC1,3>0.75); except at trachea in both respiratory phases (0.57<ICC1,3<0.74) 
and moderate-to-good reliability at anterior chest during expiration 
(0.65<ICC1,3<0.73) for the number of crackles and at anterior right chest during 
both phases (0.51<ICC1,3<0.68) for %Wh. F50 and Imax also presented excellent 
reliability, except at anterior right chest during inspiration (0.51<ICC1,3<0.73). 
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Absolute reliability showed no systematic bias for any location and/or respiratory 
phase according to the Bland and Altman plots. Further information of within-day 
reliability is in the Supporting Information. 
Table 2 presents the relative between-days reliability. During inspiration, 
crackles and wheezes showed moderate-to-good or excellent reliability 
(0.48≤ICC1,2≤0.96; P<.05) at anterior and posterior chest. F50 and Imax showed 
moderate-to-good or excellent reliability (ICC1,2>0.47 and ICC1,2≥0.60, 
respectively; P<.05), except at posterior left chest (ICC1,2<0.41; P>.05). During 
expiration, %Wh and normal respiratory sounds were reliable at trachea and at 
the anterior chest (ICC1,2>0.54; P<.05) and the number of crackles was only 
reliable at trachea (ICC1,2=0.79; P<.05). 
Table 2. Between-days reliability (ICC1,2) for normal and adventitious respiratory sounds. 
 Inspiration Expiration 
 No. 
crackles 
%Wh F50 Imax No. 
crackles 
%Wh F50 Imax 
Trachea 0.38 
[-0.12-
0.69] 
0.62* 
[0.31; 
0.79] 
0.79* 
[0.62-
0.83] 
0.62* 
[0.32-
0.79] 
0.79* 
[0.62-0.88] 
0.69* 
[0.44-
0.83] 
0.71* 
[0.47-
0.84] 
0.84* 
[0.72-
0.91] 
Anterior 
right  
0.63* 
[0.33-
0.796] 
0.92* 
[0.86-
0.96] 
0.51* 
[0.12-
0.73] 
0.60* 
[0.27-
0.78] 
0.44 
[-0.02-
0.69] 
0.54* 
[0.16-
0.74] 
0.54* 
[0.16-
0.75] 
0.78* 
[0.60-
0.88] 
Anterior 
left 
0.88* 
[0.78-0.94] 
0.96* 
[0.92-
0.96] 
0.86* 
[0.73-
0.93] 
0.73* 
[0.48-
0.86] 
0.36 
[-0.22-
0.66] 
0.70* 
[0.43-
0.85] 
0.75* 
[0.52-
0.87] 
0.60* 
[0.24-
0.79] 
Posterior 
right  
0.79* 
[0.62-0.89] 
0.57* 
[0.21-
0.76] 
0.47* 
[0.03-
0.71] 
0.65* 
[0.35-
0.81] 
0.42 
[-0.05-
0.68] 
-0.01 
[-0.85-
0.45] 
0.39 
[-0.11-
0.66] 
0.43 
[-0.03-
0.69] 
Posterior 
left  
0.74* 
[0.52-0.86] 
0.48* 
[0.04-
0.72] 
0.41 
[-0.10-
0.68] 
0.15 
[-0.58-
0.54] 
0.25 
[-0.39-
0.59] 
0.07 
[-0.73-
0.50] 
0.31 
[-0.29-
0.63] 
0.07 
[-0.72-
0.50] 
Abbreviations: %Wh, wheeze occupation rate; F50, median frequency; Imax, maximum intensity. Values are presented as ICC1,2 (95% confidence interval). 
*P<.05. 
Good absolute between-days reliability with no systematic bias was found 
in the Bland and Altman plots for number of crackles and normal respiratory 
sounds. However, large limits of agreement were found at trachea for all 
respiratory sound parameters and for %Wh in all locations, especially during 
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expiration. Figures 1 and 2 show the Bland-Altman plots obtained at posterior 
right and left chest, respectively. The remaining plots are found in the Supporting 
Information. 
Figure 1. Bland and Altman plots of number of crackles and wheeze occupation rate (%Wh) 
collected at session 1 (S1) and session 2 (S2) at posterior right and left chest. Solid lines represent 
the zero value, and dashed lines show the associated bias and 95% upper limit of agreement 
(ULA) and lower limit of agreement (LLA). 
Figure 2. Bland and Altman plots of median frequency (F50) and maximum intensity (Imax) 
collected at session 1 (S1) and session 2 (S2) at posterior right and left chest. Solid lines represent 
the zero value, and dashed lines show the associated bias and 95% upper limit of agreement 
(ULA) and lower limit of agreement (LLA). 
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Validity 
Concerning criterion validity, significant negligible-to-moderate negative 
correlations (–0.53<rs<–0.28; P<.05) between FEV1%predicted and adventitious 
respiratory sounds were found, especially for the number of crackles during 
inspiration. Significant correlations were also found for normal respiratory 
sounds, being negative for inspiratory F50 and positive for Imax, especially during 
inspiration. Table 3 presents the correlations between FEV1%predicted and 
computerised respiratory sounds. 
Table 3. Correlations between lung function (FEV1%predicted) and computerised respiratory 
sounds. 
 Inspiration Expiration 
             F
E
V
1  %
p
re
d
ic
te
d
 
 
No. 
crackles 
%wh F50 Imax 
No. 
crackles 
%wh F50 Imax 
Trachea rs=-0.07 rs=-0.09 rs=-0.35* rs=0.28* rs=-0.20 rs=-0.37* rs=-0.18 rs=0.26 
Anterior 
right  
rs=-0.11 rs=-0.09 rs=-0.18 rs=0.32* rs=-0.16 rs=-0.20 rs=0.04 rs=0.32* 
Anterior 
left  
rs=-0.42* rs=-0.13 rs=-0.37* rs=0.36* rs=-0.53* rs=-0.18 rs=0.04 rs=0.03 
Posterior 
right  
rs=-0.44* rs=-0.23 rs=0.06 rs=0.23 rs=-0.11 rs=-0.21 rs=0.02 rs=0.28 
Posterior 
Left  
rs=-0.42* rs=-0.22 rs=0.02 rs=0.07 rs=-0.16 rs=-0.12 rs=0.14 rs=-0.08 
Abbreviations: %Wh, wheeze occupation rate; F50, median frequency; Imax, maximum intensity. Values are presented as Spearman’s correlations. *P<.05. 
AUCs of all variables analysed ranged from 0.27 to 0.81, indicating ‘no 
discrimination’ to ‘acceptable discrimination’. Higher AUCs were found for 
inspiratory number of crackles recorded at posterior right (AUC=0.78; 95% 
CI=0.51-1.00; P<.001) and left (AUC=0.81; 95% CI=0.68-0.93; P<.001) chest 
(Figure 3). To differentiate between participants with mild-to-moderate from 
participants with severe-to-very severe airflow limitation, cut-off points of 0.1 
(sensitivity=81%; specificity=71%) and of 0.5 (sensitivity= 74%; specificity= 80%) 
for the mean number of crackles at posterior right and left chest, respectively, 
were identified. Results from the ROC analysis of all computerised respiratory 
sounds are shown in the Supporting Information. 
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Figure 3. Receiver operator characteristics (ROC) of the inspiratory number of crackles at 
posterior right and left chest to differentiate between participants with mild-to-moderate airflow 
limitation and participants with severe-to-very severe airflow limitation. 
Concerning construct validity, significant low positive (rs<0.48; P<.05) 
correlations were found between patient-reported outcome measures and 
computerised respiratory sounds. Values for all correlations are shown in the 
Supporting Information. Concerning predictive validity, both adventitious and 
normal respiratory sounds showed no ability to predict exacerbations up to 1 year, 
with AUCs ranging from 0.00 to 0.58 (P>.05). None of the computerised 
respiratory sound parameters were predictors of the time until the first 
exacerbation (P>.05; hazard ratios between 0.95 and 1.04). 
MDC 
The respiratory sounds parameters presenting adequate reliability and 
validity were inspiratory number of crackles at posterior right chest, inspiratory 
F50 at trachea and anterior left chest and expiratory Imax at anterior right chest. 
The MDC95 was 2.41 (SEM=0.87; MDC%=175.38%), 55.27 (SEM=19.94; 
MDC%=41.22%), 29.55 (SEM=10.66; MDC%=31.86%) and 3.98 (SEM=1.43; 
MDC%=35.47%) for number of crackles, F50 at trachea, F50 at anterior left chest 
and Imax, respectively. 
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Discussion 
To the authors’ best knowledge, this is the first study describing 
computerised respiratory sounds reliability and validity according to the COSMIM 
guidelines. The main findings indicate that respiratory sounds (a) present 
moderate-to-excellent within-day reliability and moderate-to-good between-days 
reliability; (b) are valid to express lung function, especially inspiratory number of 
crackles at posterior chest; (c) correlate poorly with patient-reported outcome 
measures; (d) do not predict COPD exacerbations and (e) present high values of 
MDC. 
Moderate-to-excellent within-day reliability was found for all respiratory 
sound parameters, which is in line with data previously reported (ICC1,3 from 0.66 
to 0.89) (Jácome & Marques, 2015a). Regarding to between-days reliability, 
slightly lower values were found. This was expected, as it is known that better 
reliability is achieved when repeated tests are performed within short periods of 
time (Shin, Ro du, Lee, Oh, & Kim, 2012). The number of inspiratory crackles, 
recorded at posterior chest, and inspiratory and expiratory %Wh, recorded at 
anterior chest, were the most reliable parameters. It is known that COPD is 
characterised by changes in airflow mechanics targeting mainly the smaller 
airways (The Global Initiative for Chronic Obstructive Lung Disease, 2017); thus, 
inspiratory crackles at posterior regions have been indicated as the most common 
and persistent finding in these patients (Jácome & Marques, 2015a, 2015b). 
Wheezes are also a usual characteristic of patients with bronchial obstruction 
(Meslier, Charbonneau, & Racineux, 1995). In the present study, inspiratory 
wheezes were slightly more reliable than expiratory wheezes, which may be 
explained by their genesis. Patients with COPD usually experience expiratory low 
frequency wheezes (also known as rhonchi) in upper airways that are generally 
produced by increased sputum and are easily removed by cough (Bohadana, 
Izbicki, & Kraman, 2014; Jácome & Marques, 2015b). In contrast, inspiratory 
wheezes are more related with severe airway obstruction (Meslier et al., 1995), 
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which characterises most of our sample, and thus are more difficult to change 
with respiratory manoeuvres. 
Regarding construct validity, significant and positive, although low, 
correlations were found between respiratory sounds and patient-reported 
outcome measures. Similar results have been found for FEV1 (0.14<r<0.41) 
(Jones, 2001) and for respiratory sounds (0.33<r< 0.57) (Jácome & Marques, 
2017) in previous studies and further confirms that clinical outcome measures 
significantly differ from the individuals’ experience of the disease effects on health 
status and hence, should not be used isolated (Westwood et al., 2011). 
Respiratory sounds presented no ability to predict exacerbations up to 1 
year after the baseline assessment. Although changes in the tracheobronchial 
tree are closely related with changes in respiratory acoustics (Pasterkamp, 
Kraman, & Wodicka, 1997), such associations are likely to be unravelled in time 
periods close to exacerbations, when the beginning of the inflammatory and/or 
infectious process has occurred. Additionally, although COPD is mainly 
characterised by changes in smaller airways, COPD exacerbations are frequently 
triggered by upper respiratory tract infections (Wedzicha & Donaldson, 2003); 
thus, it is reasonable that predictions of these events are better detected by 
changes in larger airways. Indeed, recent studies have shown that computerised 
respiratory sounds, recorded at trachea, have potential to predict exacerbations 
in the short term (i.e., 5 days ahead of medical attention); however, such 
predictions have been determined based on complex analysis (principal 
component analysis) that cannot be easily understood and applicable by 
clinicians in clinical practice (Fernandez-Granero, Sanchez-Morillo, & Leon-
Jimenez, 2015). Our results have shown that F50 and Imax recorded at upper 
anatomical locations are valid and reliable parameters and can be more easily 
determined or even perceived by clinicians during auscultation. Thus, we 
recommend future studies on COPD telemonitoring to explore the efficacy of 
these normal respiratory parameters to early detect exacerbations. 
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High MDC values were found for all respiratory sound parameters which 
might be related with patients’ high inter-subject variability, as reported in 
previous studies (Jácome & Marques, 2015a). These results highlight the 
importance of supporting health care professionals’ clinical decisions in the 
interpretation of respiratory sound changes at an individual level and in 
combination with other patient-reported outcome measures. Nevertheless, this 
was the first study to calculate MDC for respiratory sounds and provides a 
valuable cut-off point to represent minimum detectable change in repeated 
measures beyond the threshold of error. 
Limitations 
This study has some potential limitations that need to be discussed. Flows 
and/or volumes were not controlled during respiratory sounds recordings and it 
is known that respiratory sound acoustics depends on volume and rate of 
respiratory manoeuvres (Pasterkamp et al., 1997). However, this can be arguable 
for the purposes of this study as it has been previously demonstrated that even 
without airflow control, respiratory sounds present adequate reliability (ICC>0.70) 
and are almost as reliable as during recordings at controlled flows (Jácome & 
Marques, 2015a). Moreover, this study was designed to be as close to clinical 
practice as possible and, currently, equipment for airflow monitoring is expensive, 
little portable and requires trained professionals for its interpretation, which 
hinders its use in such settings. This study followed the COSMIN methodological 
recommendations to test the suitability of an outcome measure to be 
implemented in the clinical practice. The COSMIN was originally developed for 
health-related, patient-reported outcome measures, such as questionnaires 
(Terwee et al., 2007). Therefore, the application of the COSMIN as a tool for 
guiding methodology of studies testing clinical outcome measures can be 
questioned. Nonetheless, in the absence of guidelines specifically designed to 
conduct such studies, the COSMIN is indicated as an adequate alternative tool 
(Bartels, de Groot, & Terwee, 2013). 
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Conclusions 
The number of crackles recorded at posterior locations and the normal 
respiratory sounds recorded at trachea and anterior regions are reliable and valid 
parameters to assess and monitor patients with stable COPD. Nonetheless, 
results from criterion and construct validity showed that computerised respiratory 
sounds should not be used isolated, but rather integrated with other clinical and 
patient reported outcome measures, as they may fill the gap of assessing small 
airways and contribute toward a patient’s comprehensive evaluation. 
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Abstract 
Interpreting clinical changes during acute exacerbations of chronic 
obstructive pulmonary disease (AECOPD) is challenging due to the absence of 
established minimal detectable (MDD) and important (MID) differences for most 
respiratory measures. This study established MDD and MID for respiratory 
measures in outpatients with AECOPD following pharmacological treatment. 
COPD assessment test (CAT), modified Borg scale (MBS), modified 
British Medical Research Council questionnaire (mMRC), peripheral oxygen 
saturation (SpO2), computerised respiratory sounds and forced expiratory volume 
in one second (FEV1) were collected within 24-48h of an AECOPD and after 45 
days of pharmacological treatment. MID and MDD were calculated using anchor- 
(ROC and linear regression analysis) and distribution-based methods (effect size, 
SEM, 0.5*SD and MDC95) and pooled using Meta XL.  
Forty-four outpatients with AECOPD (31♂; 68.2±9.1yrs; FEV1 
51.1±20.3%predicted) participated. Significant correlations with CAT were found 
for the MBS (r=0.34), mMRC (r=0.39) and FEV1 (r=0.33), resulting in MIDs of 0.8, 
0.5-0.6 and 0.03L, respectively. MDD of 0.5-1.4 (MBS), 0.4-1.2 (mMRC), 0.10-
0.28L (FEV1), 3.6-10.1% (FEV1%predicted), 0.9-2.4% (SpO2), 0.7-1.9 (number of 
inspiratory crackles), 1.1-4.5 (number of expiratory crackles), 7.1-25.8% 
(inspiratory wheeze rate) and 11.8-63.0% (expiratory wheeze rate) were found. 
Pooled data of MID/MDD showed that improvements of 0.9 for the MBS, 
0.6 for the mMRC, 0.15L for the FEV1, 7.6% for the FEV1%predicted, 1.5% for 
the SpO2, 1.1 for the inspiratory and 2.4 for the number of expiratory number of 
crackles, 14.1% for the inspiratory and 32.5% for the expiratory wheeze rate are 
meaningful following an AECOPD managed with pharmacological treatment on 
an outpatient basis. 
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Introduction 
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) 
are frequent events during the course of COPD (Boer et al., 2018). Recovery 
from AECOPD can take up to 91 days, and it is known that some patients may 
never fully recover to their baseline status (Seemungal et al., 1998). Additionally, 
costs associated with the management of AECOPD are estimated in $7.100 per 
patient, per exacerbation (Guarascio, Ray, Finch, & Self, 2013). These facts 
place AECOPD as the main responsible for patients’ clinical deterioration and 
increased healthcare costs in COPD (Anzueto, 2010). 
The health and economic burden of AECOPD demand timely and 
appropriate management of these events (Viniol & Vogelmeier, 2018), and a 
significant amount of research is currently being conducted with this purpose 
(Viniol & Vogelmeier, 2018; Wedzicha et al., 2017). Nevertheless, the 
interpretation of improvements seen during the recovery from AECOPD remains 
difficult, due to the absence of minimal important differences (MID) for most 
respiratory measures used in the assessment and monitoring of these patients 
(Oliveira & Marques, 2018). 
MID, defined as a meaningful important change for patients, which would 
lead to consider a change in the patients’ management (Brożek, Guyatt, & 
Schünemann, 2006), is currently the standard to interpret results obtained, guide 
changes in patient’s treatments and to calculate sample sizes in clinical research. 
According to the authors best knowledge, MIDs for patients with AECOPD have 
been established mainly in inpatients (Kon et al., 2014; Tsai et al., 2008) and for 
patient-reported measures, such as the Clinical COPD Questionnaire (Oliveira & 
Marques, 2018), the Chronic Respiratory Disease Questionnaire (Oliveira & 
Marques, 2018) and the COPD Assessment Test (CAT) (Kon et al., 2014). This 
limits the management of patients treated on an outpatient basis, which 
correspond to more than 80% of AECOPD (The Global Initiative for Chronic 
Obstructive Lung Disease, 2018), and the interpretation of changes in other 
important and widely used clinical respiratory measures, such as peripheral 
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oxygen saturation (SpO2), auscultation and lung function (Fernandez-Villar et al., 
2018; Oliveira & Marques, 2018). Additionally, the interpretability of specific 
measures of dyspnoea, the most representative and valued symptom in patients 
presenting an AECOPD (Parker, Voduc, Aaron, Webb, & O'Donnell, 2005; 
Seemungal et al., 1998), is yet to be established. Incorrect interpretations of 
patients’ improvements in these outcomes may lead to the development of 
suboptimal therapies and ultimately increase the rate of patients’ deterioration. 
Thus, this study aimed to estimate the MID in outpatients with AECOPD 
for the following respiratory measures: modified Borg scale (MBS), modified 
British Medical Research Council (mMRC) questionnaire, SpO2, computerised 
respiratory sounds, namely crackles and wheezes, and forced expiratory volume 
in one second (FEV1). Additionally, the minimal detectable difference (MDD), i.e., 
the minimal change in a specific measure that fall outside the measurement error 
(de Vet et al., 2006), was also calculated for each outcome measure. 
Methods 
Study design and participants 
An observational study, part of a longitudinal study conducted in 
outpatients with AECOPD recruited from the urgent care of a Central hospital 
(Oliveira, Rodrigues, & Marques, 2018), was conducted. Inclusion criteria were 
diagnosis of an AECOPD according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria (The Global Initiative for Chronic 
Obstructive Lung Disease, 2018). Exclusion criteria were hospitalisation (defined 
as the need to be admitted as an inpatient at the respiratory or intensive care unit 
for further assessment/treatment after consultation with the urgency physician), 
patients requiring emergency intubation, and/or mechanical ventilation; patients 
with compromised neurological status or hemodynamic instability or presence of 
severe co-existing respiratory, neurological (e.g., Parkinson disease), cardiac 
(e.g., uncontrolled symptomatic heart failure), musculoskeletal (e.g., 
kyphoscoliosis), or signs of psychiatric impairments. Eligible patients were 
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identified by physicians and contacted by the researchers, who explained the 
purpose of the study and asked about their willingness to participate. An 
appointment with the researchers was scheduled within 48 hours of the hospital 
visit with those interested to participate. 
Approval for this study was obtained from the ethics committee of the 
Centro Hospitalar do Baixo Vouga (13NOV’1514:40065682) and from the 
National Data Protection Committee (8828/2016). Written informed consent, 
following the guidelines of the Declaration of Helsinki, was obtained from patients 
before any data collection. 
Data collection 
Patients were asked to attend to 4 assessment sessions: within 48 hours 
of the urgent care visit (T1 – exacerbation onset) and approximately 8 days (T2 
– during exacerbation), 15 days (T3 – following exacerbation) (Seemungal, 
Donaldson, Bhowmik, Jeffries, & Wedzicha, 2000) and 45 days after the hospital 
visit (T4 – at stability post exacerbation). Data collection occurred at the urgent 
care, in the facilities of the Respiratory Research and Rehabilitation Laboratory 
(Lab3R) of the School of Health Sciences, University of Aveiro (Portugal) or at 
patients’ home.  
According to the time interval used in previous studies to establish minimal 
important differences for clinical measures in AECOPD (i.e., 14 days to 3 months) 
(Jones, Harding, et al., 2012; Kocks et al., 2006; Kon et al., 2014; Tsai et al., 
2008), and to ensure patients’ stability after the AECOPD (defined according to 
patient’s reports of symptoms stability - i.e., no changes beyond their day-to-day 
variability, no visits to health care units and no changes in their medication in the 
month preceding the evaluation) (Soler-Cataluna, Alcazar-Navarrete, & 
Miravitlles, 2014), only data from T1 and T4 were explored.  
Sociodemographic (age, sex), anthropometric (height, weight and body 
mass index - BMI) and general clinical data (smoking habits, number of 
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exacerbations in the past year, medication and activities related dyspnoea) were 
first collected.  
In each data collection moment, impact of the disease, dyspnoea at rest 
and during activities, SpO2, computerised respiratory sounds and lung function 
were collected by a trained physiotherapist following the described standardised 
order. 
Impact of the disease was measured with the CAT, a disease-specific 
questionnaire consisting of eight items (i.e., cough, sputum, chest tightness, 
breathlessness going up hills/stairs, activity limitations at home, confidence 
leaving home, sleep, and energy) scored from 0 to 5 (Jones et al., 2009). Each 
item individual score is added to provide a total CAT score that can range from 0 
to 40 (Jones et al., 2009). Higher scores indicate more impact of the disease on 
patients’ life. CAT was chosen as the anchor to determine the MID of the 
respiratory measures since it reflects a global rating of impact in health, is 
responsive to change, and has a MID established for patients with AECOPD (Kon 
et al., 2014). 
Dyspnoea at rest was assessed with the MBS (Sulzer, Schüttler, Penzel, 
& Wichert, 1997), and activity limitation due to dyspnoea was assessed using the 
mMRC questionnaire (Doherty et al., 2006). The MBS is a categorical scale with 
a score from 0 to 10, where 0 corresponds to the sensation of normal breathing 
and 10 corresponds to the patients’ maximum possible sensation of dyspnoea 
(Crisafulli & Clini, 2010). The mMRC questionnaire is a 5-point scale where level 
0 represents the lowest level of dyspnoea impairment perceived and level 4 the 
greatest dyspnoea impairment (Crisafulli & Clini, 2010). Both scales have been 
shown to be valid and reliable in patients with COPD (Crisafulli & Clini, 2010; 
Meek & Lareau, 2003). 
Peripheral oxygen saturation was collected at rest with a pulse oximeter 
(Pulsox 300i, Konica Minolta, Tokyo, Japan). This measure has been widely used 
to assess effectiveness of interventions in patients with AECOPD and has shown 
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fair validity against arterial oxygen saturation (bias in the Bland and Altman of -
0.78; 95% confidence interval – CI of 8.2 to 6.7) in this population (Oliveira & 
Marques, 2018). 
Computerised respiratory sounds, specifically the inspiratory and 
expiratory mean number of crackles and wheeze occupation rate, acquired at the 
posterior chest, were analysed. Respiratory sounds were acquired with air-
coupled electret microphones (C 417PP, AKG Acoustics GmbH, Vienna, Austria) 
and a multi-channel audio interface (AudioBox 1818 VSL, PreSonus, Florida, 
USA) and were analysed with previous validated algorithms (Huq & Moussavi, 
2010; Pinho, Oliveira, Jácome, Rodrigues, & Marques, 2016; Taplidou & 
Hadjileontiadis, 2007). Number of crackles and wheeze occupation rate acquired 
in posterior locations have been shown to be valid against lung function (-
0.11<rs<-0.44) (Oliveira, Lage, Rodrigues, & Marques, 2018), reliable 
(0.25<ICC1,2<0.86) (Jácome & Marques, 2015; Oliveira, Lage, et al., 2018) and 
sensitive to changes in patients with stable and exacerbated COPD (Jácome, 
Oliveira, & Marques, 2017; Oliveira, Rodrigues, et al., 2018). Further details on 
respiratory sound acquisition and analysis have been provided elsewhere 
(Oliveira, Sen, Kahya, Afreixo, & Marques, 2017). 
Lung function was assessed with a portable spirometer (MicroLab 3535, 
CareFusion, Kent, UK) (Miller et al., 2005) according to international guidelines 
(American Thoracic Society, & European Respiratory Society, 2002). FEV1 in 
litres and as percentage of predicted (FEV1 percentage predicted) were extracted 
for each patient. These parameters have been shown to be feasible, valid and 
reliable (ICC=0.89) to assess in patients with AECOPD (Fernandez-Villar et al., 
2018). 
Statistical analysis 
All statistical analyses were performed using IBM SPSS Statistics version 
25.0 (IBM Corporation, Armonk, NY, USA) or Meta XL 5.3 (EpiGear International, 
Queensland, Australia). Plots were created using GraphPad Prism version 5.01 
(GraphPad Software, Inc., La Jolla, CA, USA) or Meta XL 5.3. The level of 
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significance was set at 0.05. Descriptive statistics were used to describe the 
sample, and participants’ characteristics were expressed as relative frequencies, 
mean (standard deviation) or median (interquartile range) as appropriate. 
Outlier’s analysis was performed by plotting the studied variables (i.e. MBS, 
mMRC, SpO2, computerised respiratory sounds, FEV1 and FEV1 percentage 
predicted) against the CAT (i.e., the anchor used to compute the MID) on a graph 
and visually inspecting the graph for wayward (extreme) points (Aggarwal & 
Ranganathan, 2016). The outliers found were removed for both MID and MDD 
analysis. Significance of changes between T1 and T4 was calculated with paired 
t-tests or Wilcoxon signed-rank tests depending on normality. 
Minimal important difference 
MIDs were calculated through questionnaire referencing methods using 
CAT as an anchor. Then, changes in CAT were correlated with changes in MBS, 
mMRC, SpO2, inspiratory and expiratory mean number of crackles and wheeze 
occupation rate, FEV1 and FEV1 percentage predicted, using Pearson correlation 
coefficient, to determine suitability for its use as an anchor. Significant 
correlations equal or superior to 0.3 were considered suitable and used in further 
analysis to establish the MID (Revicki, Hays, Cella, & Sloan, 2008). To 
discriminate patients who improved from those who did not improve their health 
status, the established MID in the CAT total score for patients with AECOPD (two 
points improvement) was used (Jones, Harding, et al., 2012; Kon et al., 2014). 
MIDs were calculated using receiver operating characteristic (ROC) curves and 
linear regression analysis. For each ROC curve, the area under the curve (AUC) 
and 95% confidence intervals were obtained and the MID for each respiratory 
measure was chosen as the point where the sensitivity (SN) and specificity (SP) 
were simultaneously maximised (i.e., the data point closest to the upper left 
corner of the ROC curve) (Table 1). For linear regression analysis, the equations 
developed which reached statistical significance were used to estimate change 
in respiratory scores corresponding to the MID improvement for the CAT (Table 
1). 
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Minimal detectable difference 
Distribution-based methods used to calculate MDD were (1) effect sizes 
(34), interpreted as small (dz>0.2), medium (dz>0.5) or large (dz≥0.8) (Portney & 
Watkins, 2000); (2) 0.5 times the standard deviation (SD) of the baseline session 
(33); (3) standard error of measurement (SEM) (Hosmer Jr, Lemeshow, & 
Sturdivant, 2013) and (4) minimal detectable change (MDC) at the 95% level of 
confidence (Shin, Ro du, Lee, Oh, & Kim, 2012) (Table 1). The intraclass 
correlation coefficient (ICC1,2) used for the SEM calculation was established 
based on the between-days reliability previously published by Sant'Anna et al. 
(2017) for SpO2 (ICC3,1=0.89) and MBS (ICC3,1=0.95), Mahler et al. (2009) for 
mMRC (ICC=0.82) and FEV1 (ICC=0.96), and by Oliveira, Lage, et al. (2018) for 
number of crackles (inspiratory crackles ICC1,2=0.79; expiratory crackles 
ICC1,2=0.42) and wheeze occupation rate (inspiratory wheezes ICC1,2=0.57; 
expiratory wheezes ICC1,2=0.07). The pooling of data was performed based on 
what has been previously described by Alma et al. (2006, 2008). MIDs and MDD 
estimated with each of the anchor- and distribution-based methods for the MBS, 
mMRC, SpO2, inspiratory and expiratory mean number of crackles and wheeze 
occupation rate, FEV1, and FEV1 percentage predicted were pooled using Meta 
XL 5.3. The input data were the estimated MID/MDD with each method and 
respective confidence interval, when appropriated, being the output the same as 
the input. Given that anchor- are preferred over distribution-based methods for 
the establishment of clinically significance (Angst, Aeschlimann, & Angst, 2017; 
Revicki et al., 2008), a quality effects model (Doi & Thalib, 2008) was used to 
incorporate the weight of each method in the pooled estimate, where anchor 
methods weighted more than distribution methods (Alma et al., 2018). 
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Table 1. Anchor and distribution-based methods to estimate the minimal important and detectable 
differences. 
Method Approach Statistics 
Anchor-based method ROC curve - 
Linear regression 
analysis 
- 
Distribution-based 
method 
ES 
(𝑚𝑒𝑎𝑛𝑇4 − 𝑚𝑒𝑎𝑛𝑇1)/√(𝑆𝐷𝑇1
2 + 𝑆𝐷𝑇4
2 )/2
0.5 times SD 0.5 × SDT1 
SEM SDT1 √(1 − ICC1,2 ) 
MDC95 MDC95 = SEM × 1.96 × √2 
ES, effect size; MDC95, minimal detectable change at the 95% level of confidence; ROC, receiver operator characteristics; 
SD, standard deviation; SEM, standard error of measurement. 
Results 
Participants 
Seventy-eight non-hospitalised patients with AECOPD were referred for 
possible inclusion in the study. Of these, 34 were excluded because, at T1, 
presented lung function tests and clinical history incompatible with a diagnosis of 
COPD (n=22), did not meet the definition for AECOPD (n=1), presented lung 
neoplasia (n= 2), severe heart failure (n=1), were unable to comply with testing 
(n=3), or decline to participate in the study (n=5). Forty-four non-hospitalised 
patients with AECOPD (31 males; 68.2±9.1 years; 51.1±20.3 FEV1 percentage 
predicted) were invited and agreed to participate in the study. Nineteen patients 
were excluded from the respiratory sound analysis because the respiratory sound 
data collection was not completed (n=6) and their respiratory sounds (collected 
at the urgent care) had a significant amount of background noise hindering the 
use of the algorithms described in the Data collection section (n=13). Participants’ 
characteristics are summarised in Table 2. 
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Table 2. Sample characterisation. 
Characteristics Patients with  
AECOPD 
(n=44) 
Patients included 
for RS analysis 
(n=25) 
Age, years,  68.2±9.1 70.0±9.8 
Sex (male), n(%) 31 (70.5) 16 (47.1) 
BMI, kg/m2 25.9±4.8 26.7±4.9 
Smoking status, n(%) 
Current 
Former 
Never 
 
8 (18.2) 
22 (50.0) 
14 (31.8) 
 
4 (16.0) 
11 (44.0) 
10 (40.0) 
Packs/year  45.0 [22.0-67.3] 30.0 [15.0-70.0] 
Exacerbations/year, n(%) 
0 
1 
≥2 
 
8 (18.2) 
11 (25.0) 
25 (56.8) 
 
5 (20.0) 
5 (20.0) 
15 (60.0) 
FEV1, L 1.22±0.51 1.25±0.54 
FEV1, %predicted 51.1±20.3 54.2±20.6 
FEV1/FVC, % 50.5±13.6 51.7±13.8 
GOLD stages, n(%)   
A 6 (13.6) 4 (6.8) 
B 5 (11.4) 3 (5.1) 
C 5 (11.4) 5 (8.5) 
D 26 (59.1) 13 (22.0) 
Medication, n(%)   
Antibiotics 28 (65.1) 17 (70.8) 
Bronchodilators   
SABA 9 (20.9) 3 (12.5) 
SAMA 6 (14.0) 3 (12.5) 
SABA/SAMA combination 6 (14.0) 6 (25.0) 
LABA 5 (11.6) 3 (12.5) 
LAMA 22 (51.2) 13 (54.2) 
LABA/LAMA combination 5 (11.6) 2 (8.3) 
ICS 7 (16.3) 5 (20.8) 
ICS/LABA combination 27 (62.8) 16 (66.7) 
Xanthines 16 (37.2) 8 (33.3) 
LTRA 4 (9.3) 3 (12.5) 
Expectorants 20 (46.5) 12 (50) 
Oral Corticosteroids 9 (20.9) 5 (20.8) 
mMRC 1.0 [0.5-2.0] 1.0 [0.5-2.0] 
Values are presented as mean±standard deviation or median [interquartile range], unless otherwise stated. BMI, body mass index; FEV1, forced expiratory volume 
in one second (at stability); FVC, forced vital capacity (at stability); GOLD, global initiative for chronic obstructive lung disease; ICS, inhaled corticosteroids; LABA, 
long-acting beta-agonists; LAMA, long-acting muscarinic antagonists; LTRA, leukotriene receptor antagonist; mMRC, modified British Medical Research Council 
questionnaire; SD, standard deviation; SABA, short-acting beta agonists; SAMA, short-acting muscarinic-antagonist. 
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Minimal important difference 
Following the AECOPD, 31 patients improved beyond the MID of the CAT 
(mean difference of -10.7±5.3), 6 patients did not improve beyond the MID (mean 
difference of 6.2±3.2) and 7 failed to complete the post-AECOPD assessment. 
Outlier’s examination leads to the removal of three participants. No differences 
were found between included participants and outliers for their baseline 
characteristics (p>0.05). Distribution of scores in SpO2, MBS, mMRC, respiratory 
sounds, FEV1 and FEV1 percentage predicted for all participants and according 
to differences in CAT are presented in Table 3. 
Table 3. Mean scores at the onset of AECOPD (T1), after 45 days of AECOPD (T4) and mean 
change for the respiratory measurement by the COPD Assessment Score. 
Exacerbation 
onset 
Stability  
post exacerbation 
Mean difference p-value 
ΔSpO2 92.6±2.6 94.0±2.7 1.3±2.5 0.004 
≥2 CAT 92.7±2.6 94.0±2.8 1.5±2.7 
<2 CAT 92.2±2.6 94.0±2.4 2.0±2.1 
ΔMBS 2.3±2.2 1.0±1.9 -1.3±2.1 0.001 
≥2 CAT 2.2±2.2 0.7±1.2 -1.5±2.1 
<2 CAT 2.8±2.6 2.4±3.9 -0.4±1.8 
ΔmMRC 2.6±1.0 1.4±1.0 -0.9±1.1 <0.001 
≥2 CAT 2.3±1.1 1.3±0.9 -1.1±0.9 
<2 CAT 1.8±0.8 2.4±2.0 0.4±0.6 
ΔInspiratory CR 1.4±1.6 0.7±1.0 -0.7±1.1 0.013 
≥2 CAT 1.4±1.7 0.6±0.8 -0.6±1.1 
<2 CAT 1.4±1.7 1.5±1.8 -1.0±1.1 
ΔExpiratory CR 1.3±2.0 0.3±6.5 -0.1±2.2 0.026 
≥2 CAT 1.1±1.7 0.3±0.7 -0.8±1.8 
<2 CAT 3.5±4.9 0.4±0.7 -3.5±4.9 
ΔInspiratory %Wh 8.1±13.7 2.0±5.8 -6.3±16.3 0.096 
≥2 CAT 7.6±14.3 2.3±6.2 -5.6±16.9 
<2 CAT 13.7±1.9 0.0±0.0 -13.7±1.9 
ΔExpiratory %Wh 16.2±8.4 8.4±17.0 -5.6±30.7 0.307 
≥2 CAT 17.6±23.6 6.9±15.9 -9.8±29.9 
<2 CAT 2.1±3.0 18.7±24.1 25.5±23.1 
FEV1 1.09±0.51 1.23±0.50 0.12±0.33 0.037 
≥2 CAT 1.11±0.53 1.30±0.50 0.16±0.34 
<2 CAT 0.98±0.43 0.86±0.28 -0.07±0.26 
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FEV1% predicted 46.2±18.2 52.8±20.0 5.6±14.3 0.049 
≥2 CAT 48.2±18.8 56.5±19.2 6.9±14.9  
<2 CAT 36.3±10.7 32.4±10.2 -1.2±8.0  
Values are presented as mean± standard deviation. %Wh, wheeze occupation rate; CAT, COPD assessment test; CR, crackle; FEV1 (L), forced expiratory volume 
in one second; MBS, modified Borg scale; mMRC, Modified British Medical Research Council questionnaire; SpO2 (%), peripheral oxygen saturation. 
Correlations with changes in CAT equal or superior to 0.3 were found for 
changes in MBS (r=0.34; p=0.05), mMRC (r=0.39; p=0.025) and FEV1 (r=-0.33; 
p=0.048) (Figure 1). No significant correlations were observed with changes in 
SpO2 (r=-0.02; p=0.894), FEV1 percentage predicted (r=-0.29; p=0.102), 
inspiratory (r=-0.21; p=0.356) and expiratory (r=-0.22; p=0.324) number of 
crackles, and inspiratory (r=0.24; p=0.291) and expiratory (r=0.36; p=0.102) 
wheeze occupation rate. Therefore, MID could only be calculated for MBS, 
mMRC and FEV1. 
 
Figure 1. Correlations between changes in the CAT and changes in the (A) modified Borg scale, 
(b) modified British Medical Research Council questionnaire (mMRC) and (C) forced expiratory 
volume in one second (FEV1). 
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Using ROC statistics, the AUCs generated for the mMRC showed 
(AUC=0.92; 95%CI=0.82–1.00; p=0.003) adequate discrimination between those 
improving above and below the MID for CAT (Figure 2). No significant results 
were observed for the discrimination ability of the MBS (AUC=0.63; 95%CI=0.37–
0.89; p=0.366) and for the FEV1 (AUC=0.67; 95%CI=0.43–0.90; p=0.243). Using 
ROC, a MID of -0.5 (SN=79%; SP=100%) was obtained for mMRC. Since 
significance was not reached for the MBS and FEV1, MID were not established.  
Figure 2. ROCs to discriminate between patients improving above and below the MID in CAT (i.e. 
two points) for the modified British Medical Research Council questionnaire (mMRC). 
Using linear regression, the estimated minimum important improvement 
for the MBS, mMRC and FEV1 was -0.8 (95% CI -1.65 to 0.00; p=0.05), -0.6 (95% 
CI -1.00 to -0.22; p=0.025) and 0.03L (95% CI -0.11 to 0.17; p=0.049), 
respectively (Figure 3). 
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Figure 3. Linear regression between the CAT and the (A) modified Borg scale, (b) modified British 
Medical Research Council questionnaire (mMRC) and (C) FEV1. 
Minimal detectable difference 
Small effect sizes were found for the MBS (dz=0.37), FEV1 (dz=0.28), FEV1 
percentage predicted (dz=0.34), inspiratory number of crackles (dz=0.48) and 
expiratory wheeze rate (dz=0.39), medium effect sizes were found for the 
inspiratory wheeze rate (dz=0.58), expiratory number of crackles (dz=0.65) and 
SpO2 (dz=0.52) and large effect sizes were found for the mMRC (dz=0.80) (Table 
4). Values of the 0.5*SD, SEM and MDC95 can be found in the summary of Table 
4. 
Pooled MID and MDD 
Pooled MID and MDD for the MBS, mMRC, FEV1, FEV1 percentage 
predicted, SpO2, inspiratory number of crackles, expiratory number of crackles, 
inspiratory wheeze rate and expiratory wheeze rate were of 0.9, 0.6, 0.15L, 7.6%, 
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1.5%, 1.1, 2.4, 14.1% and 32.5%, respectively. Individual and pooled values can 
be found in Table 4 and plots of pooled MID and MDD for MBS, mMRC, FEV1 
can be found in Figure 4. 
Table 4. Anchor-based and distribution-based estimates of the minimal important and detectable 
differences of the respiratory measures. 
Anchor-based methods Distribution-based method Pooled 
value 
Measures ROC 
curve 
Linear 
regression 
analysis 
ES 0.5*SD SEM MDC95 
MBS - 0.8 0.37 1.1 0.5 1.4 0.9 
mMRC 0.5 0.6 0.80 0.5 0.4 1.2 0.6 
FEV1 0.03 0.28 0.3 0.1 0.3 0.15 
FEV1% 
predicted 
- - 0.34 9.1 3.6 10.1 7.6 
SpO2 - - 0.52 1.3 0.9 2.4 1.5 
Insp. CR - - 0.48 0.8 0.7 1.9 1.1 
Exp CR - - 0.65 1.1 1.6 4.5 2.4 
Insp. %Wh - - 0.58 7.1 9.3 25.8 14.1 
Exp. %Wh - - 0.39 11.8 22.7 63.0 32.5 
%Wh, wheeze occupation rate; CR, crackle; ES, effect size; FEV1, forced expiratory volume in one second; MBS, modified Borg scale; MDC95, minimal detectable 
change at the 95% level of confidence; mMRC, Modified British Medical Research Council questionnaire; ROC, receiver operating characteristic; SD, standard 
deviation; SEM, standard error of measurement; SpO2, peripheral oxygen saturation. Results are presented as absolute values. 
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Figure 4. Summary plots of the pooled values of the MID and MDD for the (A) modified Borg 
scale; (B) modified British Medical Research Council (mMRC) questionnaire and (C) forced 
expiratory volume in one second (FEV1). The horizontal plots represent the minimal clinically 
important difference estimates derived in this study, classified per method. Where appropriate the 
estimates include the 95% confidence interval. The bold dotted vertical line resembles the MID 
estimate as obtained from the literature for stable patients with COPD. 
Discussion 
This study showed a pooled MID and MDD of 0.9 for the MBS, 0.6 for the 
mMRC, 0.15L for the FEV1, 7.6% for the FEV1 percentage predicted, 1.5% for 
the SpO2, 1.1 for inspiratory and 2.4 for the expiratory number of crackles, 14.1% 
for the inspiratory and 32.5% for the expiratory wheeze occupation rate.  
The pooled MID and MDD for dyspnoea scales were similar to those 
reported in pharmacological trials (approximately 1 point in the MBS) (Jones et 
al., 2014; Ries, 2005) and slightly lower than those reported for pulmonary 
rehabilitation and surgical intervention (approximately two points in the MBS and 
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one point in the mMRC) (Crisafulli & Clini, 2010) in stable patients with COPD. 
Large benefits of these last two interventions are quickly perceived and reported 
by patients, since they either target specifically dyspnoea (i.e., pulmonary 
rehabilitation) or are invasive and affect directly the mechanics of breathing (i.e., 
surgery), contrary to the effects of pharmacological treatments, which mainly 
target inflammation and/or infection (Ries, 2005). Attention to patients’ baseline 
dyspnoea and to the ability to change of the outcome measure is also needed 
when interpreting these data. MBS is not strictly linear, and having a sample with 
higher scores of dyspnoea (previous studies ranged from 1.8 to 8.5) than those 
reported in our study, will lead to larger changes, as at the higher end of the scale 
there are larger numerical intervals between word anchors for symptom severity 
(Ries, 2005). The mMRC presented large effect sizes following the recovery 
period of the AECOPD than in previous studies with stable patients, showing to 
be more sensitive to changes with interventions during AECOPD than in stable 
stages of the disease (Crisafulli & Clini, 2010; Jones et al., 2014).  
Although the values of the MID and MDD are similar between disease 
stages, which facilitates their used interchangeably during stable and 
exacerbation periods, health professionals should be aware that the time needed 
to achieve these MID/MDD was shorter in patients with AECOPD (approximately 
45 days), than the three months of treatments commonly used in stable patients 
(Crisafulli & Clini, 2010; Jones et al., 2009; Ries, 2005).  
Therefore, the nature of the interventions, patients’ baseline dyspnoea, the 
sensitivity to change of the measure used and the time until treatment effects are 
main aspects to consider when interpreting MID and MDD for dyspnoea scales. 
These novel results not only attribute meaning to patients’ improvements during 
AECOPD but will also aid health professionals to establish specific timings to 
follow-up dyspnoea symptoms in these patients.  
Similar to dyspnoea scales, the MID achieved for the FEV1 matched those 
reported in the literature for stable patients (0.10–0.18 litres) (Donohue, 2005). 
Nevertheless, few studies have determined MID for the FEV1, mainly due to the 
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lack of correlation between lung function and patient-reported outcomes 
(Donohue et al., 2018; Jones, Miravitlles, van der Molen, & Kulich, 2012) and 
because lung function is commonly not a goal in the management of COPD (The 
Global Initiative for Chronic Obstructive Lung Disease, 2018). Conversely, lung 
function is still the primary endpoint most frequently used by regulatory authorities 
to interpret drug efficacy in COPD trials (Cazzola et al., 2008) and spirometry has 
been found to be reliable and valid during AECOPD (Fernandez-Villar et al., 
2018). Thus, our findings may be used in future clinical trials to establish 
therapies effectiveness during AECOPD, further contributing to the current health 
and research priority of finding the most appropriate management for AECOPD 
(Wedzicha et al., 2017).  
Due to the lack of correlation with the anchor chosen, only MDD could be 
established for the FEV1 percentage predicted, SpO2 and respiratory sounds. 
These outcome measures have been extensively used to assess the effects of 
interventions in patients with AECOPD, however little is known about their 
measurement properties and interpretability (Oliveira & Marques, 2018). There is 
only one recommendation from the European Respiratory Society to consider an 
increment of 9% in FEV1 percentage predicted for bronchodilator responsiveness 
in stable patients, which is identical to our results (Quanjer et al., 1993). 
A medium effect size was found for SpO2, after the intervention, meaning 
that SpO2 may be little sensitive to changes in outpatients with AECOPD. 
Although a MID could not be obtained, according to the oxyhaemoglobin 
dissociation curve, it would not be expected that a difference of 1.5% would be 
clinically significant for patients already presenting baseline SpO2 higher than 
92%. Nevertheless, such difference might be meaningful in more hypoxemic 
patients, as it will make a difference in their ability to perform activities of daily 
living (Saglam et al., 2015). Future studies including patients with different levels 
of baseline SpO2 are needed to further explore this hypothesis and establish 
recommendations for clinical practice. 
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Minimal detectable differences found for computerised respiratory sounds 
were lower than those previously published in stable patients (i.e., MDD of 2.4 for 
inspiratory crackles) (Oliveira, Lage, et al., 2018), but significantly higher than the 
differences found before and after a pulmonary rehabilitation programme in 
stable patients (i.e., mean difference of 0.8 for expiratory crackles and median 
difference of less than 10% in inspiratory and expiratory %Wh) (Jácome & 
Marques, 2017) and during the course of an AECOPD (mean difference of less 
than 1 crackle and less than 10% in inspiratory and expiratory number of crackles 
and %Wh, respectively) (Oliveira, Rodrigues, et al., 2018). These results imply 
that although statistically significant, the changes being observed in the literature 
may be within the error of the measure. Nevertheless, these interpretations need 
caution, as it is known that respiratory sounds present high intersubject variability 
(Jácome & Marques, 2015), which have probably influenced the MDD obtained 
using distribution methods. 
Limitations and future work 
This study has some limitations that need to be acknowledged. Treatment 
of exacerbations was not standardised, but optimised according to the physician 
best judgement, using pharmacology as the standard treatment. Although the 
effects of therapies were not of interest in this study, it must be acknowledged 
that different combination of treatments might influence patient’s recovery. 
Additionally, MID could not be established for FEV1 percentage predicted, SpO2 
and computerised respiratory sounds, which may reduce their usefulness to 
interpret clinical changes. These outcome measures have great potential to be 
used at bedside of patients with AECOPD, as they are simple non-invasive and 
widely available. Thus, it is important that future studies build knowledge from our 
results and find relevant anchors to establish MID for FEV1 percentage predicted, 
SpO2 and computerised respiratory sounds. Also, patient’s stable state prior to 
the exacerbation was not assessed, and thus it cannot be firmly stated that all 
patients have returned to their baseline symptoms as reported by themselves. 
However, as only outpatients, which present less severe exacerbations (The 
Global Initiative for Chronic Obstructive Lung Disease, 2018), were included, and 
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no reports of relapses and changes in treatment occurred, we strongly believe 
that patients were in a stable state of their disease during the last data collection 
moment and that the established MID/MDD can be used with confidence. 
Although the most recommended anchor and distribution methods have been 
used to establish the MID and MDD, other important anchor methods (Alma et 
al., 2016; Angst et al., 2017), such as patient and health professional referencing, 
using global rate of change scales and criterion-referencing, through correlation 
with key health-related events in COPD were not implemented. Thus, further 
examination of the interpretability of these respiratory measures is 
recommended, including using additional anchor methods but also establishing 
MID for different relevant interventions and patients with different levels of 
severity of their AECOPD. Finally, the sample included in this study is part of a 
primary research aiming at exploring the time course of AECOPD in outpatients 
(Oliveira, Afreixo, & Marques, 2018; Oliveira, Rodrigues, et al., 2018), thus a 
sample size calculation was not computed specifically to address the 
establishment of MID and MDD. This limitation may have caused our study to be 
underpowered for this aim. Nevertheless, according to the authors’ best 
knowledge, this is the first study to contribute to establish MID and MDD of 
several respiratory outcome measures used in the monitoring of patients with 
AECOPD, and thus it has potential to be used, not only in clinical practice, to aid 
clinical interpretations of responses to interventions, but also as a booster for 
future research in the area, by providing data to compute appropriate sample 
sizes. 
Conclusion 
Pooled data of MID and MDD showed that improvements of 0.9 for the 
MBS, 0.6 for the mMRC, 0.15L for the FEV1, 7.6% for the FEV1 percentage 
predicted, 1.5% for the SpO2, 1.1 for the inspiratory and 2.4 for the expiratory 
number of crackles, 14.1% for the inspiratory and 32.5% for the expiratory 
wheeze occupation rate are meaningful following an AECOPD managed with 
pharmacological treatment on an outpatient basis. These estimates might be 
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useful in clinical practice to aid clinical interpretations of responses to 
interventions and to monitor recovery of outpatients with AECOPD. 
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Abstract 
Background: Timely diagnosis of acute exacerbations of COPD 
(AECOPD) is challenging as it depends on patients' reports. AECOPD are 
characterised by increased airway obstruction, mucus and air trapping, which 
results in changes in lung acoustics. Thus, adventitious respiratory sounds (ARS) 
may be useful to detect/monitor AECOPD. 
Objective: To evaluate computerised ARS changes during AECOPD. 
Methods: 25 non-hospitalised patients with AECOPD (16♂, 70 [62.5–
77.0] yrs, FEV1 59 [31.5–73.0] %predicted) and 34 healthy volunteers (17♂, 63.5 
[57.7–72.3] yrs, FEV1 103.0 [88.8–125.3] %predicted) were enrolled. ARS at 
anterior and posterior right and left chest were recorded at hospital presentation 
(T1), 15 days (T2) and 45 days (T3) after hospital presentation from patients with 
AECOPD and only once from healthy participants. A subsample of 9 patients (7♂; 
66 [60.0–76.0] yrs; FEV1 62 [26.5–74.0] %predicted) was also included to study 
ARS pre-AECOPD (T0). Number of crackles and wheeze occupation rate (%Wh) 
were processed using validated algorithms.  
Results: During AECOPD, patients presented more inspiratory crackles 
at T1 than T3 (p=0.013) and more inspiratory %Wh at T1 than T2 (p=0.006), at 
posterior chest. Patients with stable COPD presented more inspiratory crackles 
(p=0.012), at posterior chest, and more expiratory %Wh, both at anterior 
(p<0.001) and posterior (p=0.001) chest, than healthy participants. No 
differences were observed for the remaining ARS parameters or subsamples 
(p>0.05). 
Conclusions: Inspiratory crackles seem to persist until 15 days post 
exacerbation whilst inspiratory %Wh decreased after this period. ARS seem to 
be sensitive to monitor AECOPD. This information may allow advances in 
monitoring the recovery time of patients with AECOPD across all clinical and non-
clinical settings. 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is a progressive 
respiratory disease frequently punctuated by acute exacerbations (AECOPD) 
(Wedzicha & Wilkinson, 2006), i.e., “acute worsening of respiratory symptoms 
that result in additional therapy” (The Global Initiative for Chronic Obstructive 
Lung Disease, 2018). These events account for half of the total respiratory 
admissions for COPD (Gibson, Loddenkemper, Lundback, & Sibille, 2013) and 
are closely related with increases in healthcare costs (AECOPD related costs 
vary approximately from $88 to $7.757 per exacerbation worldwide) (Toy, 
Gallagher, Stanley, Swensen, & Duh, 2010). Furthermore, AECOPD are 
responsible for accelerating lung function decline, decrease quality of life and 
increase mortality (Anzueto, 2010).  
The early identification and timely management of AECOPD has been 
shown to reduce hospital admissions and recovery time, while improving quality 
of life (Wilkinson, Donaldson, Hurst, Seemungal, & Wedzicha, 2004). 
Nevertheless, most exacerbations are still not timely treated as the 
diagnosis/monitoring relies exclusively on patients' reports of symptoms 
worsening (The Global Initiative for Chronic Obstructive Lung Disease, 2018). 
Such reports require patients' collaboration and judgment, which are frequently 
affected by their pronounced dyspnoea and anxiety associated with these events 
(Bailey, 2004; Parker, Voduc, Aaron, Webb, & O'Donnell, 2005). 
Physiologically, AECOPD are characterised by an increase in airway 
inflammation and obstruction, abnormal bronchial mucus production and marked 
air trapping (The Global Initiative for Chronic Obstructive Lung Disease, 2018), 
which results in changes in lung acoustics. As respiratory sounds are directly 
related to the movement of air within the tracheobronchial tree (Gavriely, Nissan, 
Cugell, & Rubin, 1994), the changes in respiratory mechanics related with 
AECOPD may be primarily detected by changes in respiratory sounds, namely 
adventitious respiratory sounds (ARS, crackles and wheezes). Recent studies 
have shown respiratory sounds ability to differentiate between groups of patients 
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with stable and exacerbated COPD (Jácome, Oliveira, & Marques, 2017) and to 
characterise AECOPD into two phenotypes, based on computerised analysis 
(Sanchez Morillo, Astorga Moreno, Fernandez Granero, & Leon Jimenez, 2013). 
Nevertheless, there is little information available on the time course of 
respiratory sounds changes during recovery from AECOPD, within the same 
group of patients. This information may advance the monitoring of patients with 
COPD across all clinical and non-clinical settings, as respiratory sounds are non-
invasive, population-specific and nearly universally available by simple means 
(Bohadana, Izbicki, & Kraman, 2014). Additionally, improved knowledge on ARS 
behaviour preceding, during and after an exacerbation may aid to standardise 
and optimise the length of treatment, and to plan appropriate follow-up and 
clinical studies involving AECOPD. 
This study aimed to evaluate ARS changes during the course of AECOPD. 
A secondary aim was to explore prospectively the influence of exacerbations in 
ARS in a subsample of patients with stable COPD followed by an AECOPD. 
Materials and methods 
Study design and participants 
A longitudinal observational study was conducted in non-hospitalised 
patients with AECOPD recruited from the urgent care of a Central hospital 
between January 2016 and February 2017. Inclusion criteria were diagnosis of 
AECOPD according to the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) criteria (The Global Initiative for Chronic Obstructive Lung Disease, 
2018). A subsample of stable patients with COPD was recruited from routine 
pulmonology appointments of a Central hospital and asked to contact the 
researchers if an episode of exacerbation requiring hospital visit occurred. 
Patients were included if they were diagnosed with COPD according to the GOLD 
criteria and were clinically stable for 1 month prior to the study (no hospital 
admissions, exacerbations or changes in medication for the respiratory system) 
(The Global Initiative for Chronic Obstructive Lung Disease, 2018). Exclusion 
 122 
criteria for both samples were hospitalisation or presence of severe co-existing 
respiratory, neurological, cardiac, musculoskeletal (e.g., kyphoscoliosis), or signs 
of psychiatric impairments. Eligible patients were identified by clinicians and 
contacted by the researchers, who explained the purpose of the study and asked 
about their willingness to participate. When subjects agreed to participate, an 
appointment with the researchers was scheduled. 
A group of healthy non-smokers, matched for gender, age and body mass 
index (BMI), were also recruited to serve as control, as currently there are no 
established reference values for ARS (Oliveira & Marques, 2014). Healthy 
nonsmokers were recruited from the university campus and surrounding 
community and excluded if they presented one or more of the following 
conditions: acute (within the past month) or chronic respiratory disease, cardiac 
disease, musculoskeletal or signs of psychiatric impairments. 
Approval for this study was obtained from the ethics committee of the 
Central Hospital (13NOV′1514:40065682) and of the University of Aveiro 
(8/2015) and from the National Data Protection Committee (8828/2016). Written 
informed consent was obtained before data collection. 
Sample size 
A sample size estimation with 95% power at 5% significance determined 
that a significant difference in the inspiratory mean number of crackles obtained 
through repeated measures from patients with COPD at exacerbated (2.97±1.98) 
and stable (1.20±0.80) phases of their disease would be detected with a minimum 
of 23 participants (Jácome et al., 2017). A high statistical power was chosen due 
to the great amount of inter and intra subject variability presented by ARS 
(Jácome & Marques, 2015a; Oliveira, Lage, Rodrigues, & Marques, 2018), which 
could potentially cause type II errors if the study was underpowered (Biau, 
Kernéis, & Porcher, 2008). In health-related longitudinal studies, dropout rates 
are of approximately 20–45% (Bildt et al., 2001; Soyseth, Johnsen, & Kongerud, 
2008) thus, 36 participants with AECOPD were aimed to be recruited. Sample 
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size estimation was performed using the G*Power 3.1 software (University 
Düsseldorf, Germany). 
Data collection 
Participants with AECOPD recruited from the urgent care were asked to 
attend to 3 assessment sessions: at the exacerbation onset (T1 – 24–48 h of the 
hospital visit), 15 days (T2 – following exacerbation) (Aaron et al., 2012; 
Seemungal, Donaldson, Bhowmik, Jeffries, & Wedzicha, 2000) and 45 days after 
the hospital visit (T3 – at stability post exacerbation). The subsample of patients 
recruited from routine pulmonology appointments were asked to attend to 4 
assessment sessions: 24–48 h after the pulmonology routine appointment (T0 – 
at stability pre exacerbation), at the exacerbation onset (T1 – 24–48 h of the 
hospital visit), 15 days (T2 – following exacerbation) (Aaron et al., 2012; 
Seemungal et al., 2000) and 45 days after the hospital visit (T3 – at stability post 
exacerbation). Data from healthy non-smokers was only collected once (T0) (Fig. 
1). Data collection occurred at the urgent care, in the facilities of the University of 
Aveiro or at patients' home. 
Figure 1. Time points of data collection. 
Sociodemographic (age, gender), anthropometric (height, weight and BMI) 
and general clinical data (smoking habits, number of exacerbations in the past 
year, medication and dyspnoea) were first collected. Dyspnoea was assessed 
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with the modified British Medical Research Council questionnaire (Doherty et al., 
2006). The questionnaire comprises five grades in a scale from 0 to 4, with higher 
grades indicating greater perceived dyspnoea. Then, computerised respiratory 
sounds (recorded as described below) and lung function, assessed with a 
portable spirometer (MicroLab 3535, CareFusion, Kent, UK) according to 
standardised guidelines were collected (Miller et al., 2005). Respiratory sounds 
were collected in all data collection moments and spirometry was also performed 
at T3, during the stable phase, post exacerbation. 
All assessments were performed by a physiotherapist following the 
described standardised order. 
Respiratory sound recordings 
Respiratory sound recordings followed computerised respiratory sound 
analysis guidelines for short-term acquisitions (Rossi et al., 2000) (i.e., 
participants were in a seated-upright position, wearing a nose clip and were 
asked to breathe deeper than normal through the mouth). Recordings were 
performed simultaneously at 7 anatomic locations (trachea and right and left 
anterior, lateral, and posterior chest). The system for respiratory sound 
recordings included eight air-coupled electret microphones with 20–20000Hz 
frequency bandwidth (C 417 PP, AKG Acoustics GmbH, Vienna, Austria) 
(Vannuccini et al., 2000), a multi-channel audio interface (AudioBox 1818 VSL, 
PreSonus, Florida, USA), and a laptop computer running LungSounds@UA 
software (Pinho, Oliveira, Oliveira, Dinis, & Marques, 2014). Seven microphones, 
mounted in capsules made of Teflon (Kraman, Wodicka, Oh, & Pasterkamp, 
1995; Wodicka, Kraman, Zenk, & Pasterkamp, 1994), were attached on the 
participant's skin with double-faced adhesive tapes (Double Stick Discs, 3M 
Littmann, Cheshire, UK). The eighth microphone was placed close to the patient 
to record background noise. The analog sound signals acquired were amplified 
and converted to digital by the audio interface with a 24-bit resolution and a 
sampling rate of 44.1 kHz. Each data acquisition session lasted for 20-s 
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(Vyshedskiy & Murphy, 2012) and the recorded data were later converted to WAV 
format. 
Signal processing 
All sound files were analysed using automatic algorithms implemented in 
Matlab R2009a (MathWorks, Natick, Massachusetts).  
Breathing cycles were semi-automatically detected using the algorithm 
developed by Huq and Moussavi (95.5% sensitivity and 95.6% specificity) (Huq 
& Moussavi, 2010). Crackles were detected using a validated algorithm based on 
the combination of fractal dimension and box filtering techniques (Pinho, Oliveira, 
Jácome, Rodrigues, & Marques, 2016). Wheezes were detected using an 
algorithm based on timefrequency analysis (Taplidou & Hadjileontiadis, 2007). 
The mean number of crackles (total, fine and coarse) and wheeze occupation 
rate (%Wh – total, monophonic and polyphonic), per breathing phase (inspiration 
and expiration) and per chest location was extracted. Normal respiratory sounds 
were also analysed but were only slightly louder than the superimposed 
background sound so these data were excluded from further analyses (please 
see supplementary material 1). The average spectra of normal respiratory 
sounds at trachea, anterior and posterior chest can be found in the 
supplementary material 1 and a detailed description of the signal processing is 
provided elsewhere (Oliveira, Sen, Kahya, Afreixo, & Marques, 2017). Lateral 
locations were also excluded from the analysis, as previous literature has shown 
that this anatomical location presents a great number of artefacts and is poorly 
reliable (Oliveira et al., 2018). All analyses were checked by two respiratory 
experts to ensure the quality of the sound recordings. 
Statistical analysis 
All statistical analyses were performed using IBM SPSS Statistics version 
24.0 (IBM Corporation, Armonk, NY, USA) and plots created using GraphPad 
Prism version 5.01 (GraphPad Software, Inc., La Jolla, CA, USA). The level of 
significance was set at 0.05. 
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Descriptive statistics were used to describe the sample. Characteristics 
were compared between healthy non-smokers and patients with COPD at stable 
phases (T3) using independent t-tests for normally distributed data (i.e., BMI), 
Mann-Whitney U-tests for nonnormally distributed data (i.e., age, lung function, 
packs-year) and ordinal data (i.e., mMRC), and Chi-square tests for categorical 
data (i.e., gender, smoking status and exacerbations/year). 
Computerised ARS data were explored for each of the five analysed 
locations; however, no significant differences were found between right and left 
chest of the same region (i.e., anterior, lateral or posterior), thus, to simplify the 
interpretability of the findings, data from right and left were pooled for each chest 
region (Oliveira, Sen, et al., 2017). Then, the number of participants with crackles 
and wheezes in each chest region was calculated and the Cochran test with 
Bonferroni corrections was used to compare number of participants presenting 
crackles and wheezes among T1, T2 and T3. Fisher's exact test was used to 
investigate differences between healthy non-smokers and patients with COPD at 
stable phases (T3) on the number of participants presenting crackles and 
wheezes. Comparisons of number of crackles and %Wh among T1, T2 and T3 in 
patients with COPD were performed with the Friedman test, and multiple 
comparisons with the Wilcoxon sign-rank test. Multiple comparisons were 
corrected for number of comparisons using Bonferroni corrections. Comparisons 
between healthy non-smokers and patients with COPD at stable phases 
regarding mean number of crackles and %Wh was performed with Mann–
Whitney U test. When statistically significant differences were found for the 
number of crackles or %Wh, a comparison of the type of crackles or wheezes 
was also performed. 
An additional analysis, similar to the described previously for patients 
recruited at the onset of the AECOPD, was conducted with the subsample of 
patients presenting data collected prior to the exacerbation. 
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Results 
Participants 
Seventy-four non-hospitalised patients with AECOPD were referred for 
possible inclusion in the study. Of these, 34 patients refereed with AECOPD were 
excluded because at T1 they had pulmonary function test not compatible with a 
diagnosis of COPD (n=22), did not meet the definition for AECOPD (n=1), 
presented lung neoplasia (n=2), severe heart failure (n=1), were unable to comply 
with data collection (n=3), or declined to participate in the study (n=5). Fifteen 
patients were further excluded from the analysis because failed to complete all 
time points of data collection (i.e., T1, T2 and T3) (n=6) and their respiratory 
sounds (collected at the urgent care) had a significant amount of background 
noise hindering the use of the algorithms described in the Signal processing 
section (n=9). Thirty-four healthy nonsmokers were also contacted and invited to 
participate. Thus, twenty-five participants with AECOPD (16 males; 70 [62.5–
77.0] years old; FEV1 59 [31.5–73.0] % predicted) and thirty-four healthy non-
smokers (17 male; 63.5 [57.7–72.3] years old; FEV1 103.0 [88.8–125.3] % 
predicted) were enrolled in the study. Participants' characteristics are 
summarised in Table 1. 
Table 1. Sample characterisation. 
Characteristics Patients with 
AECOPD 
(n=25) 
Healthy 
non-smokers 
(n=34) 
p-value 
Age, years 70 [62.5-77.0] 63.5 [57.7-72.3] 0.061 
Gender (male), n(%) 16 (47.1) 17 (68.0) 0.090 
BMI, kg/m2, mean±SD 26.7±4.9 27.4±4.7 0.568 
Smoking status, n(%) 
Current 
Former 
Never 
4 (16.0) 
11 (44.0) 
10 (40.0) 
- 
6 (17.6) 
28 (82.4) 
0.002* 
Packs/year 30.0 [15.0-70.0] 6.5 [1.8-18.8] 0.010* 
Exacerbations/year, n(%) 
0 
1 
≥2 
5 (20) 
5 (20) 
15 (60) 
34 (100) 
- 
- 
<0.001* 
FEV1, L 1.2 [0.8-1.7] 2.6 [2.1-3.0] <0.001* 
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FEV1, %predicted 59 [31.5-73.0] 103.0 [88.8-125.3] <0.001* 
FEV1/FVC, % 52 [40.0-62.0] 83 [79.5-88.3] <0.001* 
GOLD stages, n(%)    
A 4 (6.8) -  
B 3 (5.1) -  
C 5 (8.5) -  
D 13 (22.0) -  
Medication use, n(%) Stability AECOPD (extra)   
Antibiotics 1 (4) 15 (60) -  
Bronchodilators   -  
Beta-adrenergic agonists 7 (28) 0 (0) 0  
Cholinergic antagonists 15 (60) 3 (12) 0  
Anti-inflammatory 4 (16) 1 (4) 0  
Xanthines 8 (32) 0 0  
Associations of bronchodilators 
with cholinergic antagonists 
17 (68) 5 (20) 0  
Expectorants 4 (16) 6 (24) 0  
mMRC 1 [0.5-2.0] 0.0 [0.0-1.0] <0.001* 
*p<0.05. Values are presented as median [interquartile range], unless otherwise stated. Legend: BMI, body mass index; FEV1, forced expiratory volume in one 
second (at stability); FVC, forced vital capacity (at stability); GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, Modified British Medical 
Research Council questionnaire; SD, standard deviation. 
A subsample of 9 participants with stable COPD a priori was also included 
and followed up until an AECOPD occurred and during its recovery. This sub-
group of participants (7 males; 66 [60.0–76.0] years old; FEV1 62 [26.5–74.0] % 
predicted) was slightly overweight (27.9±4.46 kg/m2), presented a median 
number of packs/year of 21.2 [10.0–30.0] and were mainly former smokers (n=5; 
55.6%; current smokers: n=2; 22.2%; never smokers: n=2; 22.2%). Most 
participants were classified as being in a stage D of the GOLD classification (n=5; 
55.6%; GOLD B: n=2; 22.2%; GOLD C: n=2; 22.2%), presented more than 2 
AECOPD in the past year (n=6; 66.7%; 1 AECOPD: n=2; 22.2%; 0 AECOPD: 
n=1; 11.1%) and were treated for their AECOPD with antibiotics (n=5; 56%), 
cholinergic antagonist bronchodilators (n=2; 22%), anti-inflammatory 
bronchodilators (n=1; 11%) and expectorants (n=3; 33%). Patients presented a 
median mMRC of 2 [1–3]. Median time to exacerbation was 23 [18–146] days. 
Computerised respiratory sounds 
Crackles 
Significant differences were found in the total number of inspiratory 
(p=0.008) and coarse (p=0.003) crackles within patients with AECOPD at T1, T2 
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and T3 at the posterior chest. Patients presented significantly more inspiratory 
(p=0.013) and coarse (p=0.013) crackles at T1 than at T3. Fig. 2 presents the 
number of crackles at each chest region in healthy participants and patients with 
AECOPD. A detailed characterisation of crackles can be found in the 
supplementary material 2.  
Figure 2. Number of inspiratory and expiratory crackles in healthy participants and participants 
with COPD (T1, T2, T3) at A) trachea, B) anterior and C) posterior chest regions. * significantly 
different from T3. 
Patients with stable COPD presented significantly more inspiratory 
crackles (p=0.012), both fine (p=0.003) and coarse (p=0.013) crackles, at the 
posterior chest than healthy participants. No significant differences were found 
regarding the remaining variables, locations or respiratory phases (p>0.05). 
Wheezes 
Significant differences were found in the inspiratory %Wh (p=0.019) and 
inspiratory monophonic %Wh (p=0.012), within patients with AECOPD at T1, T2 
and T3 at posterior chest. Namely, patients presented significantly more 
inspiratory %Wh (p=0.006) and monophonic %Wh (p=0.045) at T1 than at T2. A 
higher number of patients presenting inspiratory wheezes and monophonic 
wheezes were found at T1 than at T2 at trachea (p=0.037) and anterior chest 
region (p=0.014). The number of patients with expiratory monophonic wheezes 
was also higher at T1 than at T3 at the anterior chest (p=0.029). No significant 
differences were found regarding the remaining variables, locations and 
respiratory phases (p>0.05). Fig. 3 presents the %Wh at each chest region in 
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healthy participants and patients with AECOPD. A detailed characterisation of 
wheezes can be found in the supplementary material 3. 
 
Figure 3. Inspiratory and expiratory wheeze occupation rate in healthy participants and 
participants with COPD (T1, T2, T3) at A) trachea, B) anterior and C) posterior chest regions. * 
significantly different from T3. † significantly different from T2. 
Patients with stable COPD presented significantly more expiratory and 
monophonic %Wh, both at anterior (total %Wh: p<0.001; monophonic %Wh: 
p=0.007) and posterior (total %Wh: p=0.001; monophonic %Wh: p<0.001) chest 
regions than healthy participants. No differences were found regarding the 
number of healthy participants and stable patients with wheezes (p>0.05). 
Sub-analysis 
No differences were found among the four-time points of data collection 
for inspiratory and expiratory crackles and wheezes at all anatomical locations 
(p>0.05), in the subsample of patients with stable COPD a priori. A detailed 
characterisation of the respiratory sounds of this subsample can be found in the 
supporting information 4 and 5. 
Discussion 
The main findings of this study were that inspiratory crackles and wheezes 
change significantly during the course of AECOPD and patients with stable 
COPD presented significantly more inspiratory crackles and expiratory wheezes 
than healthy peers. 
131 
Differences in ARS found during the course of AECOPD and between 
stable patients with COPD and healthy peers were mainly observed at posterior 
and more peripheral chest locations, both for crackles and wheezes. In previous 
studies, the posterior region has been indicated as the most reliable and valid 
chest location for auscultation in patients with COPD (Jácome & Marques, 2015a; 
Oliveira et al., 2018). These findings, added to physiological and epidemiological 
data showing that COPD is primarily targeted by smaller airway and/or alveolar 
abnormalities (The Global Initiative for Chronic Obstructive Lung Disease, 2018) 
and that approximately 70–80% of AECOPD are due to infections, especially of 
the small airways (Sethi & Murphy, 2008), might lead us to confidently identify the 
posterior chest region as the preferred location of auscultation to monitor patients 
with COPD. 
Coarse crackles and monophonic wheezes during inspiration were the 
respiratory sounds parameters presenting significant degrees of change. 
Previous research, conducted in independent samples of stable and exacerbated 
patients with COPD, has shown equivalent results for the number of coarse 
crackles (Jácome et al., 2017), despite acknowledging that respiratory tract 
infections, the main cause of AECOPD, are mainly characterised by fine crackles. 
Such results have been attributed to the frequency response of stethoscopes 
used which might be cutting high frequencies of interest, and consequently 
affecting fine crackles detection (Murphy et al., 2004). Thus, a deeper 
understanding of this matter is yet needed. Respiratory tract infections define a 
wide range of infectious diseases, including pneumonia, acute bronchitis, 
AECOPD and acute infective exacerbations of asthma (Greene et al., 2011). 
Pneumonia is the respiratory infection most studied for ARS (Alcon, Fabregas, & 
Torres, 2005). It should be emphasised that AECOPD and pneumonia differ 
greatly in their pathophysiology (Alcon et al., 2005; The Global Initiative for 
Chronic Obstructive Lung Disease, 2018). AECOPD are characterised by an 
increase in airway inflammation and obstruction, abnormal bronchial mucus and 
marked air trapping (The Global Initiative for Chronic Obstructive Lung Disease, 
2018), whilst pneumonia usually presents lung consolidation and a filling of the 
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alveolar air spaces with exudate, inflammatory cells, and fibrin (Alcon et al., 
2005). Accordingly, AECOPD are more prompt to develop hypersecretions than 
pneumonia and thus, generate more coarse crackles, which “indicates 
intermittent airway opening related to secretions”, than fine crackles that are 
“unrelated to secretions” (Bohadana et al., 2014). 
Contrary to what has been reported in previous literature (Jácome et al., 
2017), only inspiratory wheezes presented significant changes during the course 
of AECOPD. Compared to crackles, wheezes usually present higher inter subject 
variability (Jácome & Marques, 2015a) and, in patients with more severe airway 
obstruction, expiratory wheezes have been indicated as a poorly reliable 
parameter, as they are strongly influenced by air-flow and respiratory 
manoeuvres (Oliveira et al., 2018). Because previous research has been 
conducted using independent samples of patients with stable and AECOPD, 
variability might be increased, explaining the differences found. Also, previous 
studies have included mainly mild to moderate patients with COPD (Jácome et 
al., 2017; Oliveira, Pinho, & Marques, 2017), whilst our sample included mostly 
severe patients, where inspiratory wheezes might be more representative. 
Considering the changes in ARS during the course of AECOPD, %Wh, 
specifically monophonic, significantly decreased after 15 days of treatment (i.e., 
approximate time needed to resolve an AECOPD (Seemungal et al., 2000)), 
whilst crackles, specifically coarse crackles, only decreased significantly after 45 
days post-exacerbation. Previous studies conducted during an AECOPD have 
shown an improvement in air-flow limitation (assessed by FEV1 and peak 
expiratory flow - PEF) approximately 15-days post exacerbation (Parker et al., 
2005; Seemungal et al., 2000). Knowing that %Wh is highly associated with the 
degree of bronchial obstruction (Bentur et al., 2004; Fiz et al., 2002), this was an 
expected result and enhances the role of wheezes auscultation to monitor 
AECOPD. Crackles are more related to changes (i.e., inflammation and/or 
infection) in more peripheral airways which usually take longer to resolve (Piirila 
& Sovijarvi, 1995; Woodhead et al., 2011). 
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No differences were observed in the subsample of patients with stable 
COPD studied a priori and during AECOPD across any time points. Thus, it was 
not possible to demonstrate if ARS recovered to baseline characteristics after an 
exacerbation, or if AECOPD have a cumulative effect in ARS similar to other 
outcomes, such as muscle strength and lung function (Anzueto, 2010). It is known 
that ARS present high inter and intra subject variability (Jácome & Marques, 
2015a) and thus, the sample size included in this sub-analysis might have been 
insufficient to detect significant changes. Nevertheless, if ARS are to be used 
clinically, knowing their evolution before and after exacerbations is essential to 
better interpret and manage treatment. This sub-analysis was therefore a needed 
first step towards ARS use in the monitoring of AECOPD and can be used as a 
pilot study to compute sample sizes in future studies (data are in supporting 
information 4 and 5). 
Patients with COPD presented significantly more inspiratory crackles and 
expiratory wheezes than healthy peers. It is known that COPD is mainly 
characterised by inspiratory and coarse crackles and expiratory wheezes 
(Jácome & Marques, 2015b), when compared with other chronic diseases, such 
as fibrosis, asthma, pneumonia, bronchiectasis and heart failure. Thus, this was 
an expected result. However, few studies have compared ARS in healthy people 
and patients with COPD, even though the presence of ARS has been recognised 
in healthy people (Oliveira & Marques, 2014). Although differences in ARS were 
found between patients with COPD and healthy people, the number of people 
with ARS in both groups was not significantly different. Therefore, our results 
further enhance the recommendation of not using the presence of ARS as an 
indicator of pathology (Oliveira et al., 2018), but instead investigate ARS 
characteristics (i.e., number, type, position in the respiratory cycle) and place it 
together with other clinical findings. 
Comparing to previous studies, a small number of crackles and low %Wh 
were found in patients with COPD (median no. of crackles per respiratory phase 
between 0.3 in stable patients to 0.6 in AECOPD; median %Wh of approximately 
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0) and healthy people (median no. of crackles and %Wh of approximately 0). 
Studies have been indicating a mean number of crackles between 0.8 and 5 per 
respiratory phase and a mean %Wh of 0.79% to approximately 10% in patients 
with COPD (Jácome & Marques, 2015b, 2017; Jácome et al., 2017) and 
approximately 1.5 crackles and 35% %Wh in healthy people (Oliveira, Sen, et al., 
2017). Reasons for these differences might be explained by the different 
protocols used to collect and analyse ARS. In this study, ARS were collected 
using AKG air-coupled electret microphones (response rate 20–20000Hz) 
mounted in capsules made of Teflon to minimise noise and increase sound 
transmission (Kraman et al., 1995; Wodicka et al., 1994). Additionally, all 
participants, independently of having ARS or not, were included in the analysis 
to potentiate the comprehensiveness and generalisation of our findings. Previous 
studies have used sensors with different frequency responses (e.g., 40–15000Hz 
(Oliveira, Sen, et al., 2017); 50–1800Hz; 4–20000Hz; 65–20000Hz (Jácome & 
Marques, 2015b)), diverse set ups of data collection (e.g., electret microphones 
imbedded in a soft foam mat and electret condenser microphones connected to 
the diaphragm or main tube of conventional stethoscopes (Jácome & Marques, 
2015b, 2017; Jácome et al., 2017)) and analysis (have only included in their 
analysis people presenting ARS (Oliveira, Sen, et al., 2017)). Such variety of 
procedures may produce recordings of different quality and range of sound 
spectrum, influencing the results achieved and thus impairing comparisons 
among studies. 
Limitations 
This study has some limitations that need to be acknowledged. Firstly, 
treatment of exacerbations during this study was not standardised, but rather 
prescribed according to the physician best judgment and clinical indication. 
Although for the purpose of this study the effects of therapies used were not of 
interest, it has to be acknowledged that different combination of drugs might have 
influenced the recovery times and outcomes of individual patients. Secondly, 
flows and/or volumes were not controlled during ARS recordings, which might 
have affected the results, since ARS characteristics depend on the rate and 
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volume of the respiratory manoeuvres (Pasterkamp, Kraman, & Wodicka, 1997). 
However, patients with AECOPD often present severe dyspnoea and anxiety 
(Bailey, 2004; Parker et al., 2005) which causes the use of a mouthpiece or 
facemask (necessary to assess flows and/or volumes) to be highly uncomfortable 
or even not tolerated. Furthermore, the primary purpose of this study was to 
assess computerised ARS utility in a community-based clinical setting, where 
control of airflow is often not practical. Thirdly, the complex set up used to record 
ARS may be perceived as a limitation to the use of computerised respiratory 
sounds in the clinical practice. Future research should focus in developing 
technologies for acquiring high quality data at bedside with minimal setup. Finally, 
although statistically significant differences were found for inspiratory number of 
crackles and %Wh at posterior regions, the absolute differences among data 
collection times were small and possibly not detected by health professionals with 
standard auscultation. Thus, it is imperative that future studies explore the 
minimal clinical important difference of ARS to enhance the clinical meaning of 
this measure and potentiate the development and implementation of friendly used 
computerised auscultation systems that can be translated into clinical practice. 
Conclusion 
Inspiratory crackles and wheezes changed significantly during the course 
of AECOPD, and patients with stable COPD presented significantly more 
inspiratory crackles and expiratory wheezes than healthy peers. Inspiratory 
crackles seem to persist until 15 days after the exacerbations (i.e., approximate 
time needed to resolve AECOPD) whilst inspiratory %Wh significantly decreased 
after this period. Crackles and wheezes seem to be sensitive to monitor the 
course of AECOPD. This information may allow further advances in the 
monitoring of patients with COPD across all clinical and non-clinical settings, as 
respiratory sounds are non-invasive, population-specific and nearly universally 
available by simple means. Further studies with larger samples and including 
data collected before the AECOPD are needed to confirm these findings. 
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Letter to the editor 
Symptoms are the cornerstone for diagnosing acute exacerbations of 
chronic obstructive pulmonary disease (AECOPD), however little information is 
available on their variability during these events and on their relationships with 
objective clinical measures. This study explored changes in patients’ symptoms 
and their relationships with objective clinical measures during AECOPD. 
Methods 
A longitudinal observational study was conducted with thirty-six 
outpatients with AECOPD (24 males; 68.4±9.9 years; forced expiratory volume 
in one second (FEV1) 50.7±20.4 %predicted) recruited from the urgent care of a 
Central hospital. Patients attended to 4 assessments: until 48 hours of the urgent 
care visit (T1) and 8 days (T2), 15 days (T3) and 45 days (T4) after the hospital 
visit. Patients’ prescriptions included only pharmacological treatment and 
consisted in antibiotics (n=16; 44.4%), beta-adrenergic agonists (n=2; 5.6%), 
cholinergic antagonists (n=3; 8.3%), associations of bronchodilators with 
cholinergic antagonists (n=7; 19.4%), anti-inflammatory drugs (n=1; 2.8%), 
xanthines (n=1; 2.8%) and expectorants (n=6; 16.7%). 
Activities-related dyspnoea (modified British Medical Research Council 
questionnaire – mMRC), dyspnoea and fatigue at rest (modified Borg Scale – 
MBS), cough, sputum and wheezing symptoms (11-point numerical rating scale) 
were registered in each assessment. FEV1, using a portable spirometer, and 
quadriceps muscle strength (QMS), using a handheld dynamometer, were also 
collected. 
The number of participants presenting symptoms, the severity of 
symptoms, FEV1 and QMS were compared among T1, T2, T3 and T4 using the 
Cochran or Friedman tests, respectively. Changes in symptoms were correlated 
with changes in FEV1 and QMS using the Spearman’s correlation coefficient. 
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Results 
Dyspnoea and cough were the most reported symptoms at the onset of 
AECOPD. The number of patients with dyspnoea at rest, assessed with the MBS 
(MBS>0), decreased significantly from T1 to T4 (22 vs. 16 vs. 15 vs. 13; p=0.040) 
(table 1). No significant differences were observed in the number of patients 
presenting activities-related dyspnoea, fatigue at rest, cough, sputum and 
wheezing symptoms. During the time course of the AECOPD, participants 
presented significantly more i) activities-related dyspnoea in T1, than in T3 
(p=0.001) and T4 (p=0.028); ii) dyspnoea at rest in T1 than in T4 (p=0.016); iii) 
cough in T1 than in T2 (p=0.001), T3 (p<0.001) and T4 (p<0.001) and iii) 
wheezing in T1 than in T4 (p=0.022) (table 1).  
Table 1. Clinical variables and symptoms variability during the course of an AECOPD. 
 
AECOPD (T1) 8 days (T2) 15 days (T3) 45 days (T4) p-value 
FEV1, L 0.9 [0.7-1.4] 0.9 [0.7-1.3] 1.1 [0.7-1.6] 1.2 [0.8-1.6] 0.075 
QMS, kgf 12.2 
[9.2-20.1] 
13.9 
[10.9-18.6] 
13.2 
[11.2-21.8] 
17.8* 
[13.3-24.7] 
p<0.001 
No. patients (mMRC>0) 35 31 32 30 0.091 
mMRC 2.0 [2.0-3.0] 2.0 [2.0-2.8] 2.0 [1.0-2.0]* 1.5 [1.0-2.0]* p<0.001 
No. patients (MBS.d>0) 22 16 15 13* 0.040 
MBS - dyspnoea 3.0 [0.0-4.0] 0.0 [0.0-2.8] 0.0 [0.0-2.8] 0.0 [0.0-1.8]* p=0.001 
No. patients (MBS.f>0) 17 15 17 11 0.249 
MBS - fatigue 0.0 [0.0-3.0] 0.0 [0.0-3.0] 0.0 [0.0-3.0] 0.0 [0.0-2.0] p=0.001 
No. patients (NRS.cough>0) 24 23 21 23 0.056 
Cough 8.0 [6.0-10.0] 4.0[2.0-5.0]* 3.0 [2.0-5.0]* 2.0 [0.0-4.0]* p<0.001 
No. patients (NRS.sputum>0) 22 23 21 24 0.392 
Sputum 5.0 [2.0-7.5] 3.0 [1.5-6.0] 3.0 [2.0-4.0] 2.0 [0.5-5.0] p=0.061 
No. patients (NRS.wheezeing>0) 20 21 17 19 0.183 
Wheezing 6.0 [2.5-10.0] 4.0 [1.0-8.0] 3.0 [0.0-5.5] 2.0 [0.0-4.0]* p=0.006 
Legend: Values are shown as number or median [interquartile range]; significant difference at p<0.05; * different from T1. FEV1, forced expiratory volume in one 
second; mMRC, modified British Medical Research Council questionnaire; MBS.d, modified Borg scale – dyspnoea; MBS.f, modified Borg scale – fatigue; NRS, 
numerical rating scale; QMS, quadriceps muscle strength. 
Changes occurring between T1 and T3 in mMRC correlated inversely with 
changes in QMS (rs=-0.41; p=0.013) whilst changes in cough (rs=0.47; p=0.021) 
correlated positively with QMS. Changes in MBS – dyspnoea (rs=-0.47; p=0.004) 
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and fatigue (rs=-0.34; p=0.046) correlated inversely with changes in FEV1 (figure 
1). No further correlations were found. 
Figure 1. Correlations between changes from T1 to T3 in A) modified Borg scale – dyspnoea 
(MBS.d) and forced expiratory volume in 1 second (FEV1); B) modified Borg scale – fatigue 
(MBS.f) and FEV1; C) modified British Medical Research Council questionnaire (mMRC) and 
quadriceps muscle strength (QMS); D) Cough, assessed with the numerical scale, and QMS. 
Discussion 
Dyspnoea and cough were the most reported symptoms at the onset of 
AECOPD (Parker, Voduc, Aaron, Webb, & O'Donnell, 2005; Seemungal, 
Donaldson, Bhowmik, Jeffries, & Wedzicha, 2000). Dyspnoea was the most 
prevalent symptom. Its time-recovery matched previous reports (i.e., 6 to 30 
days) (Parker et al., 2005; Seemungal et al., 2000). Cough was the symptom 
reported with the highest severity and the first to improve after treatment initiation. 
In COPD cough is the most common symptom for which individuals seek medical 
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attention and is a cardinal symptom in upper tract infections (Morice et al., 2014), 
one of the most common causes of AECOPD. Our results support the need of 
increasing awareness about cough severity and behaviour. Recognising the 
cough pattern may aid to guide patients’ monitoring and interventions, reduce 
need for hospitalisation, recurrence of AECOPD and, consequently, costs and 
morbidity related with these events.  
Differences in wheezing were only detected 45 days after the onset of the 
exacerbation, which differs from previous reports using computerised respiratory 
sound analysis (i.e., improvements 15 days after the AECOPD) (Oliveira, 
Rodrigues, & Marques, 2018). Lack of agreement between subjective and 
objective measures have already been reported for other outcomes, such as 
cough (Crook et al., 2017), and highlights the need for incorporating both patient-
reported and clinical outcome measures in the assessment of patients with 
AECOPD.  
Similar to other studies, associations between improvements in dyspnoea 
and higher expiratory flow rates were found, possibly due to the inflammatory 
aetiology of the acute exacerbation itself (i.e., reduction in inflammation during 
recovery from the AECOPD may influence the reduction of dyspnoea and 
increase expiratory flow rates) and/or reductions in lung hyperinflation (Parker et 
al., 2005). Nevertheless, both inflammation and hyperinflation were not directly 
studied in the present research and thus interpretations should be made carefully. 
A relationship between dyspnoea and QMS was also found, as previously 
reported in stable patients with COPD, due to the “downward disease spiral” of 
increased dyspnoea, decreased physical activity and deconditioning of locomotor 
muscles (Polkey & Moxham, 2006). During AECOPD, this downward spiral may 
be even more prominent as patients severely decrease their activities.  
The positive correlation found between changes in cough severity and 
QMS was unexpected. Whilst cough severity showed significant improvements 
at day 15 of the AECOPD, QMS remained statistically unchanged during the 
same period, with 36% of the patients exhibiting decreases in their QMS. Similar 
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results have been found in hospitalised patients, where QMS decreased during 
the first 8 days of hospitalisation for AECOPD and only recovered at day 90 
(Spruit et al., 2003). Thus, although both outcomes improved during an AECOPD, 
their timing of improvement differs, which may explain the positive correlation 
found between changes at T3-T1 between these two outcomes. Studies 
describing the pattern of QMS recovery in outpatients with AECOPD are needed 
to confirm these results and aid developing timely and personalised interventions. 
Despite the novel findings in symptoms behaviour during AECOPD, this 
study has some limitations that need to be acknowledged. Treatment of 
exacerbations was not standardised, but rather prescribed according to the 
physician best judgment. Although the effects of therapies were not of interest in 
this study, it must be acknowledged that different combination of treatments might 
influence the recovery times and outcomes of individual patients. 
Characterisation of symptoms lack other important features, such as sputum 
purulence. These data can contribute to infer about the nature of the AECOPD 
(i.e., infective - viral and/or bacterial - or non-infective) and about the suitability of 
treatments prescribed. It is thus recommended to add sputum purulence to data 
collection in future study protocols.  
In sum, this study showed that: i) dyspnoea is the most representative 
symptom at the onset of an AECOPD; ii) severity of cough is the first symptom to 
improve during the course of an AECOPD, and iii) changes in symptoms were 
correlated with FEV1 and QMS, which are predictors of COPD hospitalisations 
and mortality. Our findings evidence that timely management of symptoms is 
essential for patients’ recovery and should encourage health professionals to 
perform a comprehensive evaluation of outpatients with AECOPD using both 
patients reported symptoms and objective clinical outcome measures.  
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Abstract 
Purpose: Acute exacerbations of COPD (AECOPD) are associated with 
pulmonary/systemic changes; however, quantification of those changes during 
AECOPD managed on an outpatient basis and factors influencing recovery are 
lacking. This study aimed to characterise patients’ changes during AECOPD and 
identify factors influencing their recovery.  
Methods: Body mass index, the modified British Medical Research 
Council questionnaire, number of exacerbations in the previous year, and the 
Charlson comorbidity index (independent variables) were collected within 24–48 
hours of hospital presentation (T0). Peripheral oxygen saturation (SpO2), forced 
expiratory volume in one second, percentage predicted (FEV1%predicted), 
maximum inspiratory pressure, quadriceps muscle strength, 5 times sit-to-stand, 
and COPD assessment test (CAT) (dependent variables) were collected at T0 
and approximately at days 8 (T1), 15 (T2), and 45 (T3) after T0.  
Results: A total of 44 outpatients with AECOPD (31♂; 68.2±9.1 years; 
51.1±20.3 FEV1%predicted) were enrolled. All variables improved overtime 
(P<0.05); however, at day 8, only SpO2 and CAT (P≤0.001) showed significant 
improvements. Changes in FEV1 were not influenced by any independent 
measure, while changes in other outcome measures were influenced by at least 
one of the independent measures. Independently of the time of data collection, 
being underweight or overweight and having increased dyspnoea, previous 
exacerbations, and severe comorbidities negatively affected patients’ outcomes. 
Conclusion: FEV1%predicted and SpO2 were not influenced by any 
independent measure and, thus, seem to be robust measures to follow-up 
outpatients with AECOPD. No single indicator was able to predict patients’ 
recovery for all measures; thus, a comprehensive assessment at the onset of the 
AECOPD is required to personalise interventions.  
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Introduction 
COPD is frequently punctuated by acute exacerbations (acute 
exacerbations of COPD [AECOPD]), which account for more than half of the 
hospitalisations in COPD (Gulati & Wells, 2017) and are the main responsible for 
patients’ clinical deterioration and increased health care costs (Anzueto, 2010). 
Globally, more than 50% of COPD-related costs are due to AECOPD (Celli & 
MacNee, 2004) and in USA, costs are estimated in $7.100 per 
patient/exacerbation (Guarascio, Ray, Finch, & Self, 2013). 
Long-term consequences of AECOPD are known, such as clinical 
important physiological and functional deteriorations (Anzueto, 2010), resulting in 
significant declines in lung function, muscle strength, and quality of life and 
increased mortality (Anzueto, 2010; Spruit et al., 2003). AECOPD are also 
responsible for significant patients’ clinical deterioration during its time course; 
however, most of the information available is on lung function and dyspnoea 
(Parker, Voduc, Aaron, Webb, & O'Donnell, 2005; Seemungal, Donaldson, 
Bhowmik, Jeffries, & Wedzicha, 2000; Seemungal et al., 1998) in hospitalised 
patients (Feliz-Rodriguez et al., 2013; Koutsokera et al., 2009; Mesquita, 
Donaria, Genz, Pitta, & Probst, 2013; Seemungal et al., 2000; Spruit et al., 2003). 
Little information is still available on more functional parameters, such as muscle 
strength, activities of daily living, and impact of the disease. Moreover, 
hospitalised patients differ from outpatients not only in their management but also 
in the disease severity (The Global Initiative for Chronic Obstructive Lung 
Disease, 2018), which may influence their pattern of recovery. Thus, 
understanding outpatients’ recovery seems crucial to timely manage and 
appropriately plan their follow-ups. 
Factors associated with the progression and prognosis of AECOPD during 
hospitalisations have already been studied and include patients’ anthropometrics, 
stage of the disease (according to dyspnoea and number of AECOPD in the 
previous year), severity of comorbidities, and acute physiological derangements 
(Singanayagam, Schembri, & Chalmers, 2013). Such information is essential to 
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design management strategies and discharge plans during hospital stay. 
However, more than 80% of AECOPD are managed on an outpatient basis (The 
Global Initiative for Chronic Obstructive Lung Disease, 2018) and knowledge on 
factors influencing the time course of AECOPD managed in this setting is scarce. 
This unawareness impairs the standardisation, optimisation, and personalisation 
of the treatment and ultimately contributes to the existing high rate of AECOPD 
relapses (Adams, Melo, Luther, & Anzueto, 2000). 
This study aimed to characterise patients’ lung function, oxygen saturation, 
muscles strength, impact of the disease, and functionality during the time course 
of AECOPD managed on an outpatient basis. Additionally, it was aimed to identify 
the factors influencing this recovery period. 
Methods 
Study design and participants 
A longitudinal observational study was conducted in non-hospitalised 
patients with AECOPD recruited from the urgent care of a Central Hospital. 
Inclusion criteria were the diagnosis of an AECOPD according to the GOLD 
criteria (The Global Initiative for Chronic Obstructive Lung Disease, 2018). 
Exclusion criteria were hospitalisation (defined as the need to be admitted as an 
inpatient at the respiratory or intensive care unit for further assessment/treatment 
after consultation with the urgency clinician); patients requiring emergency 
intubation and/or mechanical ventilation; and patients with compromised 
neurological status or hemodynamic instability or presence of severe co-existing 
respiratory, neurological (e.g., Parkinson’s disease), cardiac (e.g., uncontrolled 
symptomatic heart failure), musculoskeletal (e.g., kyphoscoliosis), or signs of 
psychiatric impairments. Eligible patients were identified by clinicians and 
contacted by the researchers to schedule an appointment within 48 hours of the 
hospital visit. 
Approval was obtained from the ethics committee of the Centro Hospitalar 
do Baixo Vouga (13NOV’1514:40065682) and from the National Data Protection 
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Committee (8828/2016). Written informed consent was obtained before data 
collection. 
Sample size 
In order to test the time effect (four measurements) over quantitative 
variables, a sample size estimation was performed to detect moderate effect 
sizes (f=0.25) as significant, with 80% power, 5% significance level. The minimum 
sample size estimated was 35 participants. In health-related longitudinal studies, 
dropout rates are of approximately 20%–45% (Bildt et al., 2001; Soyseth, 
Johnsen, & Kongerud, 2008); thus, 44 participants with AECOPD were aimed to 
be recruited. 
Data collection 
Patients were asked to attend to the following four assessment sessions: 
within 48 hours of the urgent care visit (T0, exacerbation onset) and 
approximately 8 days (T1, during exacerbation), 15 days (T2, following 
exacerbation),7 and 45 days after the hospital visit (T3, at stability 
postexacerbation). Data were collected at the urgent care, in the facilities of the 
University of Aveiro, or at patients’ home. 
Sociodemographic (age and gender), anthropometric (height, weight, and 
body mass index [BMI]), and general clinical (smoking habits, number of 
exacerbations in the previous year, medication, comorbidities, and dyspnoea) 
data were first collected. The severity of comorbid diseases was recorded and 
scored according to the Charlson comorbidity index (CCI) (Charlson, Pompei, 
Ales, & MacKenzie, 1987). Dyspnoea was assessed with the modified British 
Medical Research Council (mMRC) questionnaire (Doherty et al., 2006). 
In each data collection moment, peripheral oxygen saturation (SpO2), 
collected with a pulse oximeter (Pulsox 300i; Konica Minolta, Tokyo, Japan), lung 
function, respiratory muscle strength, quadriceps muscle strength (QMS), impact 
of the disease, and functionality were collected by a physiotherapist following the 
described standardised order. 
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Impact of the disease was measured with the COPD assessment test 
(CAT), a disease-specific questionnaire with eight items (i.e., cough, sputum, 
chest tightness, breathlessness going up hills/stairs, activity limitations at home, 
confidence leaving home, sleep, and energy) (Jones et al., 2009). 
Lung function was assessed with a portable spirometer (MicroLab 3535; 
CareFusion, Kent, UK) (Miller et al., 2005), and respiratory muscle strength was 
measured at the mouth as maximum inspiratory pressure (PImax) using an 
electronic pressure transducer (MicroRPM; Micromedical, Kent, UK) according to 
the American Thoracic Society, & European Respiratory Society (2002) 
guidelines. 
QMS was measured as quadriceps peak torque during an isometric 
contraction of the quadriceps of the dominant side with a handheld dynamometer 
(microFET2; Hoggan Health, Salt Lake City, Utah) (Troosters et al., 2010). The 
best of three acceptable and reproducible manoeuvres was considered for 
analysis. Quadriceps peak torque was calculated in the percentage of predicted 
(QMS% predicted) (Bohannon, 1997). 
Functionality was assessed with the 5 times sit-to-stand test (5STS). A 
straight-backed armless chair with a hard seat stabilised against a wall was used, 
and the protocol of Jones et al. (2013) was followed. The best of three acceptable 
and reproducible manoeuvres was considered for analysis. 
Statistical analysis 
All statistical analyses were performed using IBM SPSS Statistics 24.0 
(IBM Corporation, Armonk, NY, USA), and plots were created using GraphPad 
Prism 5.01 (GraphPad Software, Inc., La Jolla, CA, USA). The level of 
significance was set at 0.05. 
Descriptive statistics was used to describe the sample. The evolution of 
each dependent variable during AECOPD and the identification of variables that 
could influence the evolution of the dependent variables were analysed with 
generalised estimating equation’ (GEE) models with a gama link function and 
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independent correlation structure. This method is an extension of generalised 
linear models to longitudinal data permitting the inclusion of time-dependent 
variables and the analysis of incomplete data (without imputing missing data), 
common in longitudinal health studies (Ma, Mazumdar, & Memtsoudis, 2012). 
To explore the influence of time independently, a first analysis was 
performed using SpO2, FEV1 percentage predicted (FEV1%predicted), PImax, 
QMS% predicted, CAT, and 5STS as dependent variables and time as the only 
independent variable. Then, to identify variables that could influence the evolution 
of the dependent variables, BMI (i.e., underweight <18.50, normal weight <24.99, 
and overweight ≥25.00) (World Health Organization, 2006), number of 
exacerbations in the previous year (i.e., 0–1 and ≥2) (The Global Initiative for 
Chronic Obstructive Lung Disease, 2018), comorbidities (mild: CCI ≤2, moderate: 
CCI ≤4, and severe: CCI≥5) (Charlson, Pompei, Ales, & MacKenzie, 1987), and 
dyspnoea (mild: mMRC<2 and severe: mMRC≥2) (The Global Initiative for 
Chronic Obstructive Lung Disease, 2018) were included as independent 
variables. A clinical criterion was used to select the dependent and independent 
variables included in the models (variables commonly reported and associated 
with the response to treatments in COPD and with AECOPD in the literature) 
(Guerra, Gaveikaite, Bianchi, & Puhan, 2017; Singanayagam et al., 2013; Spruit 
et al., 2015; Viniol & Vogelmeier, 2018). 
Results 
Participants 
Seventy-eight non-hospitalised patients with AECOPD were referred for 
possible inclusion in the study. Of whom, 34 patients were excluded because at 
T0 they had a pulmonary function and clinical history incompatible with a 
diagnosis of COPD (n=22), did not meet the definition for AECOPD (n=1), 
presented lung neoplasia (n=2) and severe heart failure (n=1), were unable to 
comply with testing (n=3), and showed decline to participate in the study (n=5). 
Forty-four non-hospitalised patients with AECOPD (31♂; 68.18±9.09 years; 
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51.11±20.27 FEV1% predicted) were invited and agreed to participate in the 
study. Participants’ characteristics are summarised in Table 1. 
Table 1. Sample characterisation. 
Characteristics Patients with 
AECOPD 
(n=44) 
Age, years 68.18±9.09 
Gender (male), n(%) 31 (70.5) 
BMI (kg/m)2 25.86±4.83 
Smoking status, n(%) 
Current 
Former 
Never 
8 (18.2) 
22 (50.0) 
14 (31.8) 
Packs/year 45.00 [22.00-67.25] 
Exacerbations (previous year), n(%) 
0 
1 
≥2 
8 (18.2) 
11 (25.0) 
25 (56.8) 
FEV1, L 1.22±0.51 
FEV1, %predicted 51.11±20.27 
FEV1/FVC, % 50.47±13.64 
GOLD stages, n(%) 
A 6 (13.6) 
B 5 (11.4) 
C 5 (11.4) 
D 26 (59.1) 
Medication, n(%) 
Antibiotics 28 (65.1) 
Bronchodilators 
SABA 9 (20.9) 
SAMA 6 (14.0) 
SABA/SAMA combination 6 (14.0) 
LABA 5 (11.6) 
LAMA 22 (51.2) 
LABA/LAMA combination 5 (11.6) 
ICS 7 (16.3) 
ICS/LABA combination 27 (62.8) 
Xanthines 16 (37.2) 
LTRA 4 (9.3) 
Expectorants 20 (46.5) 
Oral Corticosteroids 9 (20.9) 
CCI 
Mild 6 (14) 
Moderate 25 (57) 
Severe 13 (29) 
mMRC 1 [0.5-2.0] 
Notes: Values are presented as mean±SD (for normal distributed variables), or median (interquartile range) (for non-normal distributed variables) at T0, unless 
otherwise stated. FEV1, at stability – T3; FVC, at stability – T3. 
Abbreviations: AECOPD, acute exacerbations of COPD; BMI, body mass index; CCI, Charlson comorbidity index; ICS, Inhaled corticosteroid; LABA, long-acting 
beta-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; SABA, short-acting beta-agonist; SAMA, short-acting muscarinic 
antagonist; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, Modified British Medical Research Council questionnaire; FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity. 
 158 
Time course of AECOPD 
The variation of each variable within the time course of the AECOPD is 
found in Figure 1. At day 8, only SpO2 and CAT (P≤0.001) have shown significant 
improvements. At day 15, FEV1%predicted (P=0.007) and 5STS (P<0.001) had 
improved from the onset of the AECOPD and at day 45, all variables presented 
significant improvements (P<0.05). A detailed description of the variables 
analysed per moment of data collection is found in Tables S1 and S2. 
 
Figure 1. Changes in (A) peripheral oxygen saturation (SpO2, %), (B) FEV1%predicted, (C) PImax 
(cmH2O), (D) QMS%predicted, (E) CAT, and (F) 5STS test (seconds). 
Note: *Significantly different from T0 (P<0.05).  
Abbreviations: CAT, COPD assessment test; PImax, maximum inspiratory pressure; 
QMS%predicted, quadriceps muscle strength percentage predicted; 5STS, 5 times sit-to-stand 
test. 
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Factors influencing recovery from AECOPD 
Complete results of the independent variables’ (i.e., BMI, number of 
exacerbations in the past year, CCI, and mMRC) effects in each of the dependent 
variables (i.e., SpO2, FEV1%predicted, PImax, QMS%predicted, CAT, and 5STS) 
are found in Table S3. 
Peripheral oxygen saturation 
No significant interactions were found between the independent variables 
and SpO2 (P>0.05). However, patients presenting two or more AECOPD had 
mean values of SpO2 lower than those with one or no AECOPD (mean difference 
-1.56%±0.53%; P=0.003) independently of the moment of data collection. Other 
independent variables were not found to significantly affect SpO2 (P>0.05) 
(Figure S1). 
FEV1%predicted 
No significant interactions were found between the independent variables 
and FEV1%predicted (P>0.05). However, underweight patients presented lower 
FEV1%predicted than overweight (mean difference -18.98%±4.49% predicted) 
and normal weight (mean difference -17.84%±4.15% predicted) patients, 
independently of the moment of data collection (P<0.001). Other independent 
variables were not found to significantly affect FEV1%predicted (P>0.05) (Figure 
S2). 
PImax 
Significant interactions between time and number of exacerbations in the 
previous year (P=0.007), comorbidities (P=0.025), and dyspnoea (P=0.012) were 
found to affect changes in PImax during AECOPD. Other independent variables 
were not found to significantly affect PImax (P>0.05) (Figure S3). 
QMS%predicted 
Significant interactions between time and number of exacerbations in the 
previous year (P=0.035) and comorbidities (P=0.020) were found to affect 
changes in QMS%predicted during AECOPD. Additionally, QMS% predicted was 
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lower in more dyspnoeic patients (mMRC≥2) than in less dyspnoeic patients 
(mMRC<2; mean difference -24.27%±11.74% predicted; P=0.011), 
independently of the moment of data collection. Other independent variables 
were not found to significantly affect QMS%predicted (P>0.05) (Figure S4). 
CAT 
Significant interactions between time and BMI (P=0.039) were found to 
affect changes in CAT during AECOPD. Additionally, CAT scores were higher in 
overweight patients (BMI ≥25) than in patients with normal BMI (mean difference 
4.59±1.77; P=0.042) and in more dyspnoeic patients (mMRC ≥2; mean difference 
7.98±1.84; P<0.001), independently of the moment of data collection. Other 
independent variables were not found to significantly affect CAT (P>0.05) (Figure 
S5). 
5STS 
Significant interactions between time and BMI (P=0.008), comorbidities 
(P=0.001), and dyspnoea (P=0.003) were found to affect changes in 5STS during 
AECOPD. Additionally, patients with severe comorbidities took longer to 
complete the 5STS than those with mild (mean difference 2.72±1.35) and 
moderate (mean difference 2.73±1.14) comorbidities in the CCI independently of 
the moment of data collection (P=0.013). Other independent variables were not 
found to significantly affect 5STS (P<0.05) (Figure S6). 
Discussion 
This study added important findings on the time course of AECOPD 
managed on an outpatient basis, namely: 1) SpO2 and CAT improve after 7 days 
of the onset of an AECOPD, FEV1%predicted and 5STS improve after 15 days, 
and muscle strength improve after 45 days of the AECOPD; 2) changes in SpO2 
and FEV1%predicted are not influenced by BMI, dyspnoea, previous AECOPD, 
or comorbidities; however, changes in other outcome measures were influenced 
by at least one independent variable; and 3) independently of the time of data 
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collection, low/high BMI, increased dyspnoea, previous exacerbations, and 
severe comorbidities significantly affect patients’ outcomes during AECOPD. 
Most burdensome symptoms and limitations perceived by each patient 
improved in the first week (difference of approximately five points in CAT), 
exceeding the minimal clinical important difference (MCID) of two points (Jones 
et al., 2012; Kon et al., 2014), and minor improvements were observed in the 
following weeks. These results matched those previously reported in hospitalised 
patients (Feliz-Rodriguez et al., 2013; Garcia-Sidro et al., 2015), in which major 
improvements have been obtained during the first 5 days of hospital admission 
(Feliz-Rodriguez et al., 2013). Improvements in CAT exceeding the MCID (from 
-3 to -10 (Kon et al., 2014; Miravitlles et al., 2013)) have been shown, with higher 
magnitudes observed in more severe exacerbations and in hospitalised patients 
(Feliz-Rodriguez et al., 2013). Assessment of CAT, especially in the first week 
following the AECOPD, is important, and different MCID might be needed for 
hospitalised and non-hospitalised patients with AECOPD. Additionally, a negative 
effect of overweight in CAT has been found, mimicking previous studies 
conducted in inpatients (Feliz-Rodriguez et al., 2013). These results shown that, 
independently of the setting of treatment, an excess of weight significantly impairs 
patients’ improvements in their health status. 
The use of SpO2 and lung function to monitor patients with AECOPD have 
been controversial, as these measures have shown poor reliability and/or 
sensitivity to change (Al Rajeh & Hurst, 2016; Vestbo et al., 2013). Several 
studies have used SpO2 as an outcome measure; however, the changes reported 
vary widely (Eaton et al., 2009; Parker et al., 2005; Torres-Sanchez et al., 2016) 
and, in the absence of an MCID for this parameter, it is not clear whether these 
changes are clinically significant, especially in patients not presenting hypoxemia 
at baseline assessment. Lung function measurements during AECOPD are not 
currently recommended by the GOLD (Vestbo et al., 2013); however, they are 
widely used (Mesquita et al., 2013; Parker et al., 2005; Seemungal et al., 2000). 
Results previously obtained are not homogeneous with some authors reporting 
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improvements in lung function, namely FEV1 (Parker et al., 2005; Seemungal et 
al., 2000), and others finding no improvements after an AECOPD (Mesquita et 
al., 2013), which impairs conclusions regarding its usefulness and 
responsiveness during exacerbations. Using the minimal detectable difference 
recommended by the European Respiratory Society (i.e., increment of 9% in 
FEV1%predicted) (Quanjer et al., 1993), important improvements in FEV1 were 
only achieved at T3 (mean difference 9.3% from T0), meaning that, at stability, 
most patients may have achieved full recovery. These results should nonetheless 
be interpreted with caution as the minimal detectable difference used has only 
been established for bronchodilator responsiveness in stable patients with COPD 
(Quanjer et al., 1993). Nevertheless, our study showed that both SpO2 and lung 
function are outcomes that can be simply obtained and seem not to be influenced 
by independent variables. Future studies are needed to further assess their 
adequacy to be used in monitoring AECOPD and establish their MCID. 
Changes in muscle strength measures, such as PImax and 
QMS%predicted, were only significant after 45 days of AECOPD, and the pattern 
of their recovery was influenced by several independent measures, i.e., 
dyspnoea, previous exacerbations, and comorbidities. Recovery of physical 
parameters is often impaired during AECOPD and may never fully recover 
(Anzueto, 2010). In hospitalised patients, decreases in muscle strength occur 
even during the course of AECOPD (Spruit et al., 2003), which was not observed 
in this study, possibly because patients continued to perform their daily activities 
at home, even if at a slower pace. The inclusion of strengthening exercises in 
hospitalised patients during AECOPD has been recommended to further 
enhance their recovery (Spruit et al., 2003). This addition may be equally valid 
and fruitful in outpatients, since it may fasten patients’ functional recovery to 
perform their daily and job-related activities. 
Generally, more dyspnoeic patients, under-/overweight, with more 
exacerbations/year and more comorbidities, recovered slower, except for QMS 
and 5TST. These findings may be justified by the fact that these more fragile 
163 
patients presented poorer values at baseline and, thus, had more room for 
improvement. In the 5STS test, at T0 the overall sample completed the test in 
<10 seconds, leaving them a marginal room for progress (Bernabeu-Mora et al., 
2016; Jones et al., 2013). This suggests that the 5STS presents a ceiling effect 
and may not be the most adequate outcome measure to monitor functionality in 
more functional patients but may be suitable for more severe and older patients. 
Independently of the time of data collection, underweight patients 
presented more airway obstruction; overweight patients presented higher 
impacts of the disease; dyspnoeic patients presented lower QMS; frequent 
exacerbators presented lower oxygenation values; and patients with more 
comorbidities performed worse in 5STS. It is known that all of these parameters 
are potential predictors of COPD trajectory (Guerra et al., 2017), and thus, it was 
expected that they would also play a role during the recovery of AECOPD. 
Nevertheless, it was not possible to find one single independent variable that 
influenced and differentiated improvements in all outcome measures. These 
results further highlight the multidimensional and systemic component of 
AECOPD and the importance of studying the role of emerging biomarkers (Wan, 
2018; Wang et al., 2016), together with clinical variables, to predict the trajectory 
of COPD, and specifically AECOPD. 
Limitations 
This study has some limitations that must be acknowledged. First, as 
effects of therapies were not of interest in this study, all patients were treated 
according to clinicians’ best judgment. However, it must be acknowledged that 
different combinations of treatments might have influenced the outcomes of 
individual patients. Second, although a sample calculation has been computed to 
test the time effects in the dependent variables studied, the study was not 
powered for its secondary analysis (i.e., identify the factors influencing this 
recovery from AECOPD), resulting in a possible small sample size for this 
analysis. Consequently, patients’ distribution among categories of independent 
variables (e.g., BMI – underweight, normal weight, and overweight) were not 
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homogeneous, which could have affected the results observed. Additionally, 
other variables that are known to influence COPD trajectory and that could also 
play a role in the time course of AECOPD, such as forced vital capacity, 
medication, and nature of previous exacerbations, could not been integrated in 
the models developed. Increasing the number of independent variables would 
have augmented the risk of having correlations among the variables and, thus, 
decreased the robustness and the accuracy of the models. Further studies, 
powered for a high number of variables, should clarify the role of the clinical 
variables explored and consider their potential interaction with other 
demographic, chemical, and biological variables to better understand the time 
course of AECOPD managed on an outpatient basis. Although this was not the 
main objective of the present article, our exploratory results are valuable, as they 
contributed to unravel the most promising variables to assess in clinical practice 
and may be used to compute appropriate sample sizes in future research. Third, 
most outcome measures used depend on patients’ motivation and evaluator 
expertise. To minimise these influences, a trained physiotherapist conducted all 
data collection and only variations of less than 20% between the two better results 
(except for lung function and inspiratory muscle strength, where the European 
Respiratory Society and American Thoracic Society guidelines (2002; Miller et 
al., 2005) were followed) in each measurement were considered for analysis. 
Finally, patient’s stable state prior to the exacerbation was not assessed and, 
thus, it is not known if patients returned or not to their baseline status. Still, 
information of the course of exacerbations managed on an outpatient basis is still 
provided and may be useful to personalise interventions in this population. 
Conclusion 
During an AECOPD managed on an outpatient basis, SpO2 and CAT 
improve after 7 days of the onset, FEV1%predicted and 5STS improve after 15 
days, and muscle strength measures improved only after 45 days of the 
AECOPD. FEV1%predicted and SpO2 recovery are not influenced by 
independent patients’ characteristics, such as BMI, dyspnoea, previous 
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AECOPD, or comorbidities and, thus, may be potentially useful to monitor 
AECOPD recovery. Low/high BMI, increased dyspnoea, previous exacerbations, 
and severe comorbidities significantly affect patients’ outcomes during AECOPD. 
No single indicator was able to predict patients’ recovery for all measures 
assessed; thus, a comprehensive assessment at the onset of the AECOPD is 
needed to personalise interventions to outpatients with AECOPD. 
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General discussion 
This research work has focused on two main areas of increasing research 
and clinical interest in AECOPD: i) the adequacy of outcome measures used to 
assess outpatients with AECOPD and ii) the time course of AECOPD treated on 
an outpatient-basis. Although discussion of these areas has been presented in 
each study, an overall discussion, aiming at providing a comprehensive 
perspective, is followed. 
Outcome measures in outpatients with AECOPD 
The Systematic review, developed during the course of this research, 
provides a comprehensive overview of the measurement properties of the 
outcome measures most used in pulmonary rehabilitation during AECOPD and 
that can be easily applied in outpatients’ settings. Twenty-three PROMs and 18 
clinical outcome measures were identified; however, measurement properties 
could only be synthesised for 22 PROMs and 7 clinical outcome measures. The 
methodological quality to assess measurement properties of most studies was 
poor, and the results obtained were indeterminate. These results clarify that whilst 
a large number of outcome measures are available to assess patients with 
AECOPD in outpatients’ settings, investigation of their measurement properties 
have not been adequately adressed. Thus, the use of those measures may 
compromise the validity and applicability of the results achieved after pulmonary 
rehabilitation and contribute to the conflicting results found in the literature 
(Puhan, Gimeno-Santos, Cates, & Troosters, 2016; Wedzicha et al., 2017; 
Wilson et al., 2018) regarding the effects of pulmonary rehabilitation during 
AECOPD. This Systematic review further contributed to answer to a research 
question raised by the official American Thoracic Society/ European Respiratory 
Society statement: research questions in COPD (Celli et al., 2015), by identifying 
the CAT and SpO2 as the outcome measures exhibiting the most appropriate 
measurement properties to assess patients with AECOPD. It also evidenced 
critical knowledge gaps that need to be bridged to further clarify the role of 
pulmonary rehabilitation in outpatients with AECOPD. It is of special importance 
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to establish the measurement properties (i.e., reliability, validity and 
responsiveness) of commonly used outcome measures (e.g., MBS, mMRC, FEV1 
and six-minute walking test) using robust methodologies, such as the COSMIN 
standards (Terwee et al., 2012). In order to address this gap in the literature, the 
empirical Studies, developed during the course of this research, concerning 
measurement properties (Studies I and II), followed this international 
methodology. 
Studies I and II explored the measurement properties of respiratory 
outcome measures to assess patients with AECOPD. A measure should reflect 
the construct that one intends to measure (i.e., validity) and remain unchanged 
for as long as the clinical state of the patient remains stable (i.e., reliability), to 
confidently be used as an outcome measure (Mokkink, Prinsen, Bouter, Vet, & 
Terwee, 2016). Thus, before being recommended as an outcome measure for 
AECOPD, the validity and reliability of computerised respiratory sounds were 
explored in stable patients with COPD in Study I. 
Although discreetly, the number of inspiratory crackles recorded from the 
posterior chest was the respiratory sound parameter that correlated the most with 
the patient’s severity of airway obstruction, represented by the FEV1%predicted. 
FEV1 mainly expresses obstruction in larger airways (McNulty & Usmani, 2014), 
whilst COPD pathogenesis primarily targets small airways (The Global Initiative 
for Chronic Obstructive Lung Disease, 2019). In contrast, crackles are an 
acoustic phenomenon that, when heard over distal lung regions, are associated 
with inflammation or oedema of smaller airways (Piirila & Sovijarvi, 1995). Thus, 
whilst high correlations between these outcome measures were not expected, 
the significant correlations found highlight the potential of crackles to indicate 
peripheral airway obstruction in patients with COPD. Several other studies have 
reported on the ability of lung auscultation to discriminate among patients with 
different severity grades of airway obstruction (Anderson, Aitken, Carter, 
MacLeod, & Moran, 1990; Leuppi et al., 2006; Malmberg et al., 1994; Spence, 
Bentley, Evans, & Morgan, 1992). Crackles, identified with conventional 
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auscultation, have been found to be the respiratory sounds most related with 
decreases in lung function (odds ratio of 0.995 (95% CI 0.991–0.999); p=0:039) 
of patients assessed in an emergency department (Leuppi et al., 2006). Study I, 
further highlights and establishes the clinical relevance of crackles to detect 
airway obstruction, by presenting a cut-off of 1 crackle to differentiate between 
mild-to-moderate and severe-to-very severe obstructions. Nevertheless, our 
findings differ from previous literature that has mainly found relationships 
between F50 and FEV1 (Anderson et al., 1990; Malmberg et al., 1994; Spence et 
al., 1992). The different methodologies used across studies, i.e., performing 
forced expiratory manoeuvres or using chemical substances that cause airway 
obstruction during respiratory sound recordings, might explain this incongruence 
and raise attention to the need of standardising respiratory sounds recordings to 
advance knowledge in this field. Similar to correlations found with 
FEV1%predicted, correlations with patient-reported outcomes were small or 
absent. Therefore, it seems fair to argue that computerised respiratory sounds 
should not be used isolated, but rather integrated with other clinical outcome 
measures and PROM, as they may fill the gap of assessing small airways and 
contribute towards a patient’s comprehensive evaluation. 
Regarding to reliability, results from Study I were similar but slightly lower 
than those previously reported by Jácome and Marques (2015) when exploring 
within-day reliability of computerised respiratory sounds using standardised 
respiratory flows at 0.4-0.6L/s (ICC1,3 from 0.65 to 0.99). This was expected, as it 
is known that better reliability is achieved when repeated tests are performed 
within short periods of time (Shin, Ro du, Lee, Oh, & Kim, 2012) and at target air 
flows (Vlemincx, Van Diest, & Van den Bergh, 2012). The flow, but also volume, 
dependence of respiratory sounds (Pasterkamp, Kraman, & Wodicka, 1997), has 
motivated the development of research using standardised, controlled and/or 
target air flows (Hadjileontiadis, 2018; Jácome & Marques, 2017; Malmberg, 
Pesu, & Sovijärvi, 1995; Reyes et al., 2018). This methodology is essential to 
infer about the genesis and mechanisms of respiratory sounds propagation in 
basic science research, however it may not be feasible to implement in real life 
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studies and clinical practice. The Study I of this document and the study of 
Jácome and Marques (2015) have shown that, even without flow and/or volume 
standardisation, moderate-to-excellent between days reliability exists, meaning 
that computerised respiratory sounds may be confidently used for clinical 
purposes even when respiratory flow and volume cannot be standardised. 
The Systematic review and Study I explored and described the 
measurement properties of the most used and promising respiratory outcome 
measures to assess AECOPD. Building on that knowledge, Study II pooled the 
MDD and MID for the MBS, the mMRC, FEV1 and FEV1%predicted, SpO2 and 
computerised adventitious respiratory sounds (i.e., crackles and wheezes). 
Overall, the established MDD and MID were comparable to those previously 
reported for patients with stable COPD following pharmacological treatment 
(Donohue, 2005; Jones et al., 2014; Quanjer et al., 1993; Ries, 2005). Similar 
results have been reported for health-related questionnaires, such as the CAT 
and the CCQ (Alma et al., 2018). These results suggest that the MIDs established 
for COPD following pharmacological treatments may be used interchangeably 
during stable and exacerbation periods. Thus, sparing health professionals from 
having to consider two different MIDs according to patients’ clinical state and 
increasing their applicability in clinical practice. Nevertheless, one aspect should 
be taken into consideration, that is the time needed to achieve the MID and/or 
the MDD, which was shorter in patients with AECOPD (approximately 45 days), 
than the 2 to 12 months of treatment commonly used in stable patients (Crisafulli 
& Clini, 2010; Jones et al., 2014; Ries, 2005). Due to the lack of correlation with 
the anchor chosen, MIDs could not be established for the FEV1%predicted, SpO2 
and computerised adventitious respiratory sounds. As showed in the Systematic 
review, some of these outcome measures have been extensively used to assess 
the effects of pulmonary rehabilitation and other interventions (Laue, Reierth, & 
Melbye, 2015; McCrory & Brown, 2002; Mukerji et al., 2015; Walters et al., 2014) 
in patients with AECOPD, however little is known about their measurement 
properties and interpretability in these patients. Given their great potential to be 
used at bedside of patients with AECOPD, as they are simple, non-invasive and 
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widely available, it is advisable that future studies build on knowledge from the 
results of this research and find relevant anchors to established MID for 
FEV1%predicted, SpO2 and computerised adventitious respiratory sounds. 
Time course of AECOPD treated on an outpatient-basis 
Studies III, IV and V described the time course of a variety of patient-
reported and clinical outcome measures during AECOPD treated on an 
outpatient setting. Overall, the results found matched those previously reported 
in hospitalised patients, with all outcomes improving significantly over the course 
of 45 days following an AECOPD, but exibiting different patterns of improvement 
(Feliz-Rodriguez et al., 2013; Nishimura et al., 2018; Seemungal, Donaldson, 
Bhowmik, Jeffries, & Wedzicha, 2000; The Global Initiative for Chronic 
Obstructive Lung Disease, 2019; Zhou et al., 2018). Patient reported outcome 
measures, such as the CAT, the mMRC and the numerical rating scale to assess 
cough showed statistical significant improvements after 7 to 15 days of the 
AECOPD, as well as some clinical measures, such as the SpO2, 
FEV1%predicted, 5STS and computerised inspiratory wheezes. On the other 
hand, quadriceps muscle strength, computerised inspiratory crackles and rest 
dyspnoea, assessed with the MBS, only evidenced significant improvements 
after 45 days of the acute event. No improvements were found for patients’ 
fatigue and sputum assessed with the numerical rating scale. However, when 
considering the MID established for each measure in COPD, this pattern differed 
slightly. Initial improvements in dyspnoea at rest (MBS) (i.e., -1 unit) (Jones et al., 
2014; Ries, 2005) were observed after 15 days of the AECOPD and in the 
FEV1%predicted (i.e., 9%) (Quanjer et al., 1993) only after 45 days of the 
AECOPD. Nevertheless, the CAT questionnaire (i.e., -2 units) (Kon et al., 2014) 
and the 5STS test (i.e., -1.7s) (Jones et al., 2013) still showed significant and 
clinical improvements after 15 days of the AECOPD. No comparisons could be 
established for the remaining outcome measures, due to lack of MIDs. Similar 
results can be found in the study of Koutsokera et al. (2009), where statistically 
significant improvements were observed in the FEV1%predicted at day 10 post 
AECOPD. However when we considering the MID of 9% (Quanjer et al., 1993), 
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clinically improvements were not observed during the total course of the study 
(i.e., 40 days) (Koutsokera et al., 2009). These findings reveal how vastly 
interpretations can differ if statistical or clinical significance is considered and 
should call the attention of health professionals and researchers for how these 
differences may influence decision-making in clinical practice and ultimatly affect 
patients’ treatment. Nevertheless, it is important to note that, with the exception 
of the CAT questionnaire, the MIDs used are those established for stable 
patients, as MIDs for patients with AECOPD are lacking. Considering the MID of 
the CAT, Study V found that after only 7 days of pharmacological treatment, the 
difference in CAT already exceeded in approximately 3 points the current 
established MID, supporting what has been reported in the literature (Feliz-
Rodriguez et al., 2013; Nishimura et al., 2018; Zhou et al., 2018). Overall, these 
results support the establishment of MID for outcome measures used to assess 
patients with AECOPD, but also highlight the need of revising the existing MIDs 
(Alma et al., 2018) as they may not accuretly represent the recovery process of 
patients treated on an outpatient basis. 
Considering other patient reported outcomes, such as symptoms, Study 
IV contributed to show the importance of cough during AECOPD, as this was the 
symptom reported with the highest severity and the first to improve after initiation 
of treatment. In COPD, cough is the most common symptom for which individuals 
seek medical attention and is a cardinal symptom in respiratory tract infections 
(Morice et al., 2014), one of the most common triggers of AECOPD (Wedzicha & 
Donaldson, 2003). Our results support the need of increasing awareness of 
patients, families and health professionals about cough severity and behaviour to 
guide patients’ monitoring and interventions.  
Regarding to clinical outcome measures, Studies IV and V found that, 
although some patients presented a decrease in quadriceps muscle strength, as 
observed in hospitalised patients (Spruit et al., 2003), an overall pattern of 
decrease was not observed in outpatients with AECOPD. Rather, quadriceps 
muscle strength tended to remain stable. Conversely to hospitalised patients, 
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outpatients decrease less their levels of physical activity (Donaldson, Wilkinson, 
Hurst, Perera, & Wedzicha, 2005; Esteban et al., 2016), as they tend to quickly 
return to outdoors activities (Donaldson et al., 2005) or may continue to perform 
their daily activities at home, even if at a slower pace. The inclusion of physical 
activity and exercise programmes (Spruit et al., 2003), including strengthening, 
in hospitalised patients during AECOPD has been recommended to further 
enhance patients’ recovery (Spruit et al., 2003). The results of this research work 
suggest that these additions may be equally valid and fruitful in outpatients, since 
they seem to be more predispose to physical activities. Such programmes could 
be developed using patients’ daily life activities, thus little affecting their routine, 
and may fasten patients’ functional recovery and behaviour changing towards 
physical activity in stable stages of the disease.  
Study V also showed that some clinical outcome measures, such as the 
5STS test, may not be the most adequate to monitor functionality in patients with 
AECOPD treated in an outpatient setting. This measure has been widely used in 
fragile older populations (Alcazar et al., 2018; Goldberg, Chavis, Watkins, & 
Wilson, 2012; Makizako et al., 2017) and recently it has been adapted to patients 
with stable COPD, showing to be feasible, reliable, valid and responsive (Bui, 
Nyberg, Maltais, & Saey, 2017). Nevertheless, previous studies have mainly 
enrolled patients with severe to very severe airway obstruction, which 
performance is highly reduced (i.e., mean of 13.5 to 15.4 seconds) (Crook et al., 
2017; Jones et al., 2013) when compared with patients with AECOPD with 
moderate airway obstruction and treated on an outpatient setting (i.e., mean of 
11.11 seconds). The high performance presented by outpatients with AECOPD 
leave them with a marginal room for progress and suggest a ceiling effect of the 
5STS test in this population. Recently, Morita et al. (2018) have compared 
multiple sit-to-stand tests in stable patients with COPD and reach to the 
conclusion that the 1-minute sit-to-stand test may be the best sit-to-stand test to 
evaluate subjects with COPD. This test was choosen as the best, due to its 
potential to generate high hemodynamic demands and high association with 
important clinical outcomes such as functional exercise capacity, functional 
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status, and physical activity. Sit-to-stand tests present significant advantages to 
be used in outpatients settings, since they require little space and minimal 
resources to be implemented. Thus it is advisable for future research to test the 
feasibility and measurement properties of the 1-min sit-to-stand test to be used 
as an outcome measure in outpatients with AECOPD. 
The use of both patient-reported and clinical outcome measures allowed 
to clarify the need of a comprehensive patients’ assessment at the onset of the 
AECOPD. Study V showed that low and high body mass index, increased 
dyspnoea, previous exacerbations, and severe comorbidities, assessed at the 
onset of the AECOPD, significantly affected patients’ self-reported, physical and 
functional outcomes during the recovery process, except for SpO2 and 
FEV1%predicted. Thus, whilst oximetry and lung function may be potentially 
useful to monitor AECOPD recovery, as recently reported by Fernandez-Villar et 
al. (2018), a comprehensive assessment at the onset of the AECOPD including 
patients’ body mass index, dyspnoea, previous exacerbations and comorbidities 
may be needed to develop personalised interventions. Studies III and IV also 
found significant differences in objective and self-reported perception of 
wheezing, a common symptom experience during AECOPD. Decreases in self-
reported wheezing were only perceived by patients 45 days after the onset of the 
exacerbation, whilst decreases using computerised respiratory sound analysis 
were found after 15 days of the onset. Lack of agreement between subjective and 
objective measures have already been reported for other outcomes, such as 
cough (Crooks et al., 2017), and further highlight the need for incorporating both 
patient-reported and clinical outcome measures in the assessment of patients 
with AECOPD. 
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Limitations 
The interpretation of the findings of this research work should be tempered 
considering a number of limitations. 
The first aspect that might be considered as a limitation of this research is 
the use of the COSMIN methodological recommendations in the Systematic 
Review and in Studies I and II to evaluate the quality of the outcome measures 
assessed. The COSMIN was originally developed for health-related PROM, such 
as questionnaires (Terwee et al., 2007). Therefore, the application of the 
COSMIN as a tool for guiding methodology of studies testing clinical outcome 
measures can be questioned. Nonetheless, in the absence of guidelines 
specifically designed to conduct such studies, the COSMIN is indicated as an 
adequate alternative tool (Bartels, de Groot, & Terwee, 2013). 
Secondly, flows and/or volumes were not controlled during respiratory 
sounds recordings in Studies I, II and III and it is known that respiratory sound 
acoustics depends on volume and rate of respiratory manoeuvres (Pasterkamp 
et al., 1997). However, flow and/or volume control is not current practice during 
auscultation as it requires expensive and little portable equipment (e.g., 
pneumotacographs, calibration syringes and heating elements), may be poorly 
tolerated by dyspnoeic and anxious patients and requires trained professionals. 
A previous study has demonstrated that even without airflow control, respiratory 
sounds present adequate reliability (ICC>0.70) and are almost as reliable as 
during recordings at controlled flows (Jácome & Marques, 2015). Thus, in the 
methodology of this research work it was chosen not to implement flow and/or 
volume measurements to maximise the potential of directly translating our results 
to clinical practice.  
Thirdly, the complex set up used to record computerised sounds in 
Studies I, II and III may be perceived as a limitation to their use in the clinical 
practice. Given computerised respiratory sounds potential to monitor patients 
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with AECOPD, future research should focus in developing technologies for 
acquiring high quality data at bedside with minimal setup. 
The fourth main limitation of this research work is the lack of treatment 
standardisation for AECOPD in Studies II, III, IV and V. Patients’ were treated 
according to the physician best judgment, using pharmacology as the standard 
treatment. Although the effects of therapies were not of interest in this research 
work, it must be acknowledged that different combination of treatments could 
have influenced patient’s recovery. 
Fifthly, a sample size calculation was not performed for some research 
questions explored in Studies II, IV and V, which may have resulted in a small 
sample size for the analyses conducted. Particularly in Study V, the lack of 
sample size calculation resulted in an unbalanced patients’ distribution among 
categories of the independent variables (e.g., body mass index – underweight, 
normal weight, and overweight), which could have affected the results observed.  
Finally, Studies III, IV and V lack patient’s stable state prior to the 
exacerbation, as patients were only contacted if they were diagnosed with 
AECOPD. Inclusion of such data would have allowed to conclude about patients’ 
fully recovery, or not, to their baseline status following the AECOPD and thus 
enhance the findings of this research work. 
Implications for future research and clinical practice 
From this research work, a number of implications for future research and 
clinical practice can be highlighted. 
1. There is a need to continue conducting research on the measurement 
properties of patient reported and clinical outcome measures, suitable to be used 
in outpatients with AECOPD. These measures have been identified in our 
Systematic Review but it is important that further research, using the available 
established methodologies, such as the COSMIN standards, follows. This will not 
only allow to establish comparisons among measures performance but will also 
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increase the degree of confidence in interpreting results of interventional studies 
in AECOPD.  
2. Another important avenue to pursue in future studies is to potentiate the 
use of the outcome measures identified as more adequate to monitor outpatients 
with AECOPD and their MID in clinical practice. This includes improving the 
access to promising outcome measures, such as computerised respiratory 
sounds, by developing technological solutions for their acquisition with minimal 
setup, but also disseminating of the results of this research work through 
academic, research and clinical communities. Dissemination of these results 
have been conducted throughout the timeframe of this research work by 
presenting them in scientific and clinical publications, seminars, courses and 
congresses in the respiratory field. However, further dissimination should follow 
by integrating the developed knowledge in new research studies and clinical 
settings and contexts. 
3. It is also important to personalise and optimise the length of treatment 
and timing of appropriate follow-up in outpatients with AECOPD. The information 
provided on the timing of improvement of each patient-reported and clinical 
outcome may aid health professionals to plan their follow-ups according to the 
time needed to observe effects in a specific outcome of interest, as well as to 
more accurately monitor the effects of their intervention. 
4. Much also needs to be investigated to enhance our knowledge on the 
time course of AECOPD managed on an outpatient setting and factors influencing 
patients’ recovery. This includes conducting longitudinal research with optimised 
treatment plans from patients’ stable state to recovery from AECOPD. Future 
work should also be appropriately powered for determining interactions among 
variables during the recovery of AECOPD, including other demographic, 
chemical, and biological variables that were left out of the scope of this research. 
5. Finally, more research in alternative interventions to manage outpatients 
with AECOPD is recommended. This includes further research from blind 
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randomised controlled trials defining the feasibility, effectiveness and cost-
effectiveness of the standard care (pharmacological), explored in this research 
work, against potential interventions, such as pulmonary rehabilitation, to improve 
patients’ functionality in outpatients settings.  
Summary 
The Studies conducted within the scope of this research contributed to 
clarify the adequacy of the outcome measures most currently used to assess 
patients with AECOPD treated on an outpatient basis, as well as to establish the 
time course, pattern of recovery and interactions of several outcomes and 
outcome measures during these events. This chapter presented an integrated 
discussion of the findings of the different Studies in the light of the most recent 
literature in the field, the limitations identified through the course of the reserach 
and the implications of the results achieved for future clinical and research 
practices. 
 
Chapter V 
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General conclusion 
This research work contributes with new evidence on the measurement 
properties of outcome measures used to assess patients with AECOPD treated 
on an outpatient basis and on the time course of their recovery during these 
events. It has been found that few outcome measures with sound-evidence 
measurement properties (i.e., reliability, validity and responsiveness) exist to 
assess patients with AECOPD (Systematic review). Computerised respiratory 
sounds, namely the number of crackles acquired from the posterior region, were 
found to be reliable and valid to assess patients with COPD (Study I) and minimal 
detectable and clinical differences have been established for this and other 
respiratory outcome measures (Study II). During the course of an AECOPD, 
PROMs, such as the CAT, the mMRC and the numerical rating scale to assess 
cough, significantly improved after 7 to 15 days of the AECOPD onset (Studies 
III and V), as well as some clinical measures, such as the SpO2, FEV1%predicted, 
5STS test and computerised inspiratory wheezes (Studies III and IV). On the 
other hand, quadriceps muscle strength, computerised inspiratory crackles and 
dyspnoea at rest, assessed with the MBS, only evidenced significant 
improvements after 45 days of the onset of the AECOPD (Studies III, IV and V). 
Except for SpO2 and FEV1%predicted, the recovery from an AECOPD treated on 
an outpatient basis was negatively affected by patients’ low and high body mass 
index, increased dyspnoea, previous exacerbations, and severe comorbidities 
assessed at the onset of the AECOPD (Study III). Thus, whilst oximetry and lung 
function may be potentially useful to monitor recovery from AECOPD, a 
comprehensive assessment is needed to determine patients’ progression and 
personalise interventions. Further research with standardised methodologies, 
larger samples and longitudinal pre-post exacerbation designs is warranted to 
consolidate these preliminary findings and increase the scope of knowledge on 
the time course of AECOPD treated on an outpatient basis. 
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